0001193125-16-672020.txt : 20160804 0001193125-16-672020.hdr.sgml : 20160804 20160804172004 ACCESSION NUMBER: 0001193125-16-672020 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160804 DATE AS OF CHANGE: 20160804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 161808446 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 10-Q 1 d211534d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number 001-36569

 

 

LANTHEUS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   35-2318913
(State of incorporation)  

(IRS Employer

Identification No.)

331 Treble Cove Road, North Billerica, MA   01862
(Address of principal executive offices)   (Zip Code)

(978) 671-8001

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   x  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act)    Yes  ¨    No  x

The registrant had 30,387,768 of common stock, $0.01 par value per share, issued and outstanding as of August 1, 2016.

 

 

 


Table of Contents

TABLE OF CONTENTS

 

     Page  
PART I. FINANCIAL INFORMATION   

Item 1.

 

Financial Statements (Unaudited)

     1   
 

Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2016 and 2015

     1   
 

Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2016 and 2015

     2   
 

Condensed Consolidated Balance Sheets as of June 30, 2016 and December  31, 2015

     3   
 

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and 2015

     4   
 

Notes to Unaudited Condensed Consolidated Financial Statements

     5   

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     18   

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

     31   

Item 4.

 

Controls and Procedures

     32   
PART II. OTHER INFORMATION   

Item 1.

 

Legal Proceedings

     32   

Item 1A.

 

Risk Factors

     33   

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

     35   

Item 3.

 

Defaults Upon Senior Securities

     35   

Item 4

 

Mine Safety Disclosures

     35   

Item 5

 

Other Information

     35   

Item 6.

 

Exhibits

     36   

Signatures

     37   

Exhibit Index

     38   


Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Lantheus Holdings, Inc. and subsidiaries

Condensed Consolidated Statements of Operations

(unaudited, in thousands, except share data)

 

     For the Three Months
Ended June 30,
    For the Six Months
Ended June 30,
 
     2016     2015     2016     2015  

Revenues

   $ 77,966      $ 73,314      $ 154,440      $ 148,137   

Cost of goods sold

     42,215        40,647        84,988        79,701   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     35,751        32,667        69,452        68,436   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses

        

Sales and marketing expenses

     9,843        9,229        19,150        18,301   

General and administrative expenses

     9,238        15,444        18,751        24,567   

Research and development expenses

     2,608        2,638        5,644        8,834   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     21,689        27,311        43,545        51,702   

Gain on sale of assets

     117        —          5,945        —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     14,179        5,356        31,852        16,734   

Interest expense, net

     (6,978     (13,876     (13,996     (24,499

Loss on extinguishment of debt

     —          (15,528     —          (15,528

Other income, net

     396        800        454        417   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before income taxes

     7,597        (23,248     18,310        (22,876

Provision for income taxes

     247        1,175        637        1,172   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

   $ 7,350      $ (24,423   $ 17,673      $ (24,048
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) per weighted average common share outstanding:

    

Basic and Diluted

   $ 0.24      $ (1.29   $ 0.58      $ (1.30

Weighted average common shares outstanding:

    

Basic

     30,377,562        18,898,003        30,372,901        18,489,451   

Diluted

     30,542,728        18,898,003        30,453,776        18,489,451   

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

1


Table of Contents

Lantheus Holdings, Inc. and subsidiaries

Consolidated Statements of Comprehensive Income (Loss)

(unaudited, in thousands)

 

     For the Three Months
Ended June 30,
    For the Six Months
Ended June 30,
 
     2016     2015     2016      2015  

Net income (loss)

   $ 7,350      $ (24,423   $ 17,673       $ (24,048

Foreign currency translation

     (84     (16     256         (374
  

 

 

   

 

 

   

 

 

    

 

 

 

Total comprehensive income (loss)

   $ 7,266      $ (24,439   $ 17,929       $ (24,422
  

 

 

   

 

 

   

 

 

    

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

2


Table of Contents

Lantheus Holdings, Inc. and subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited, in thousands, except share data)

 

     June 30,
2016
    December 31,
2015
 

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 54,851      $ 28,596   

Accounts receivable, net of allowance of $989 and $881

     39,457        37,293   

Inventory

     14,433        15,622   

Other current assets

     4,282        3,851   

Assets held for sale

     —         4,644   
  

 

 

   

 

 

 

Total current assets

     113,023        90,006   

Property, plant and equipment, net

     84,422        86,517   

Capitalized software development costs, net

     8,121        9,137   

Intangibles, net

     17,949        20,496   

Goodwill

     15,714        15,714   

Other long-term assets

     20,038        20,509   
  

 

 

   

 

 

 

Total assets

   $ 259,267      $ 242,379   
  

 

 

   

 

 

 

Liabilities and Stockholders’ Deficit

    

Current liabilities:

    

Current portion of long-term debt

   $ 3,650      $ 3,650   

Accounts payable

     12,778        11,657   

Accrued expenses and other liabilities

     17,664        18,502   

Liabilities held for sale

     —         1,715   
  

 

 

   

 

 

 

Total current liabilities

     34,092        35,524   

Asset retirement obligation

     8,650        8,145   

Long-term debt, net

     348,838        349,858   

Other long-term liabilities

     34,055        34,141   
  

 

 

   

 

 

 

Total liabilities

     425,635        427,668   
  

 

 

   

 

 

 

Commitments and contingencies (See Note 16)

    

Stockholders’ deficit:

    

Preferred stock ($0.01 par value, 25,000,000 shares authorized; no shares issued and outstanding)

     —         —    

Common stock ($0.01 par value, 250,000,000 shares authorized; 30,385,437 and 30,364,501 shares issued and outstanding)

     303        303   

Additional paid-in capital

     176,545        175,553   

Accumulated deficit

     (341,487     (359,160

Accumulated other comprehensive loss

     (1,729     (1,985
  

 

 

   

 

 

 

Total stockholders’ deficit

     (166,368     (185,289
  

 

 

   

 

 

 

Total liabilities and stockholders’ deficit

   $ 259,267      $ 242,379   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3


Table of Contents

Lantheus Holdings, Inc. and subsidiaries

Condensed Consolidated Statements of Cash Flows

(unaudited, in thousands)

 

     For the Six Months
Ended June 30,
 
     2016     2015  

Cash flows from operating activities

    

Net income (loss)

   $ 17,673      $ (24,048

Adjustments to reconcile net loss to cash flow from operating activities

    

Depreciation and amortization

     9,358        12,573   

Provision for excess and obsolete inventory

     818        467   

Stock-based compensation

     992        933   

Loss on extinguishment of debt

     —          15,528  

Gain on sale of assets

     (5,945     —     

Other

     118        1,457   

Increase (decrease) in cash from operating assets and liabilities

    

Accounts receivable

     (2,009     4,258   

Inventory

     525        (474

Other current assets

     393        (368

Accounts payable

     1,474        108   

Accrued expenses and other liabilities

     (1,982     (6,715
  

 

 

   

 

 

 

Cash provided by operating activities

     21,415        3,719   
  

 

 

   

 

 

 

Cash flows from investing activities

    

Proceeds from sale of assets

     9,000        —     

Capital expenditures

     (2,388     (6,112

Redemption of certificate of deposit - restricted

     74        —     
  

 

 

   

 

 

 

Cash provided by (used in) investing activities

     6,686        (6,112
  

 

 

   

 

 

 

Cash flows from financing activities

    

Proceeds from issuance of common stock in initial public offering

     —         73,539  

Payments for initial public offering costs

     —         (5,255 )

Proceeds from issuance of long-term debt

     —         360,438  

Payments on long-term debt

     (1,861     —    

Payments on senior notes

     —         (400,000

Payment for call premium on senior notes

     —         (9,752

Payments on line of credit

     —         (8,000

Payments for offering costs

     —         (563

Payments on note payable

     —         (37

Deferred financing costs

     (11     (5,315
  

 

 

   

 

 

 

Cash (used in) provided by financing activities

     (1,872     5,055   
  

 

 

   

 

 

 

Effect of foreign exchange rate on cash

     26        (201
  

 

 

   

 

 

 

Increase in cash and cash equivalents

     26,255        2,461   

Cash and cash equivalents, beginning of period

     28,596        19,739   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 54,851      $ 22,200   
  

 

 

   

 

 

 

Supplemental disclosure of cash flow information

    

Interest paid

   $ 12,790      $ 27,741   

Income taxes paid

   $ 273      $ 73   

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4


Table of Contents

Lantheus Holdings, Inc. and subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

Unless the context otherwise requires, references to the “Company” and “Lantheus” refer to Lantheus Holdings, Inc. and its direct and indirect subsidiaries, references to “Holdings” refer to Lantheus Holdings, Inc. and not to any of its subsidiaries, and references to “LMI” refer to Lantheus Medical Imaging, Inc., the direct subsidiary of Holdings. Solely for convenience, we refer to trademarks, service marks and trade names without the TM, SM and ® symbols. Those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks, service marks and trade names.

1. Business Overview

Overview

Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation.

The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers, and technologists working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks and group purchasing organizations. The Company sells its products globally and has operations in the United States, Canada, Puerto Rico and Australia and distribution relationships in Europe, Asia Pacific and Latin America.

The Company’s portfolio of 10 commercial products is diversified across a range of imaging modalities. The Company’s imaging agents and products include the following:

 

    DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.

 

    TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.

 

    Xenon Xe 133 Gas, or Xenon, is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.

 

    Neurolite is an injectable, technetium-labeled imaging agent used with Single Photon Emission Computed Tomography, or SPECT, technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.

 

    Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with SPECT technology in myocardial perfusion imaging, or MPI, procedures that assess blood flow distribution to the heart.

In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through commercial radiopharmacies owned or controlled by third parties. In Puerto Rico and Australia, the Company owns three radiopharmacies and sells its own radiopharmaceuticals, as well as others, directly to end users. In Canada, Europe, Asia Pacific and Latin America, the Company utilizes distributor relationships to market, sell and distribute its products.

Basis of Consolidation and Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

 

5


Table of Contents

In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s financial statements for interim periods in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this quarterly report should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes for the year ended December 31, 2015 included in the Company’s Form 10-K filed with the SEC on March 2, 2016. The Company’s accounting policies are described in the “Notes to Consolidated Financial Statements” in the Form 10-K and updated, as necessary, in this quarterly report. There were no changes to the Company’s accounting policies since December 31, 2015. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

The Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply, which is currently approved for manufacture by a single manufacturer. The Company has technology transfer activities ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and the Company cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY.

Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company’s ability to maintain and profitably renew those contracts and relationships with those key customers and group purchasing organizations is an important aspect of the Company’s strategy.

Borrowing capacity under the $50.0 million revolving credit facility, or the Revolving Facility, is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted operating results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of June 30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $34.4 million. The Company’s $365.0 million senior secured term loan facility, or the Term Facility, contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect the Company’s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity.

Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.

 

6


Table of Contents

Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-09, Compensation – Stock Compensation (Topic 719), Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of accounting for employee share-based payment transactions, including the accounting for income tax consequences, the classification of awards as either equity or liabilities, an accounting policy election for forfeitures, statutory tax withholding requirements and certain classifications on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.

In February 2016, the FASB, issued ASU 2016-02, Leases (Topic 842), or ASU 2016-02. ASU 2016-02 supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 was issued to increase transparency and comparability among organizations by requiring lessees to recognize all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). The accounting for lessors remains largely unchanged. ASU 2016-02 retains a distinction between finance leases and operating leases. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize a lease liability and right-of-use asset. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) or ASU 2014-09. ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

Subsequent to issuing ASU 2014-09, the FASB issued the following amendments concerning the adoption and clarification of ASU 2014-09. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date, which defers the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017 with early adoption permitted as of its original effective date of December 15, 2016. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which further clarifies the implementation guidance on principal versus agent considerations. The new guidance requires either a retrospective or a modified retrospective approach to adoption. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, which clarifies the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients or ASU 2016-12, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for noncash consideration and completed contracts at transition. The Company is currently evaluating the impact these ASUs will have on our financial position, results of operations, cash flows and disclosures.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-4): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern or ASU 2014-15. ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016. Early adoption is permitted. The Company does not anticipate this ASU will have a material impact to the Company’s financial position, results of operations, cash flows and disclosures.

2. Summary of Significant Accounting Policies

Revenue Recognition

The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.

 

7


Table of Contents

Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.

Inventory

Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. There was no significant product expensed for the six months ended June 30, 2016 and 2015. At June 30, 2016 and December 31, 2015, the Company had no capitalized inventories associated with product that did not have regulatory approval.

The Company includes within current assets the amount of inventory that is estimated to be utilized within twelve months. Inventory that will be utilized after twelve months is classified within other long-term assets.

Goodwill

Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. There were no events as of June 30, 2016 and December 31, 2015 that triggered an interim impairment test of goodwill.

3. Fair Value of Financial Instruments

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015, and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points from active markets that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability.

 

(in thousands)

   Total fair
value at
June 30,
2016
     Quoted prices
in active
markets
(Level 1)
     Significant other
observable
inputs
(Level 2)
     Significant
unobservable
inputs
(Level 3)
 

Money market

   $ 2,686       $ 2,686       $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 2,686       $ 2,686       $ —         $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

(in thousands)

   Total fair
value at
December 31,
2015
     Quoted prices
in active
markets
(Level 1)
     Significant other
observable
inputs
(Level 2)
     Significant
unobservable
inputs
(Level 3)
 

Money market

   $ 1,586       $ 1,586       $ —        $ —    

Certificates of deposit—restricted

     74         —          74         —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 1,660       $ 1,586       $ 74       $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

At December 31, 2015, the Company had a $0.1 million certificate of deposit, which was collateral for a long-term lease and was included in other long-term assets on the condensed consolidated balance sheet. In January 2016, the certificate of deposit was redeemed. Certificates of deposit are classified within Level 2 of the fair value hierarchy, as these are not traded on the open market.

 

8


Table of Contents

At June 30, 2016, the Company had total cash and cash equivalents of $54.9 million, which included approximately $2.7 million of money market funds. At December 31, 2015, the Company had total cash and cash equivalents of $28.6 million, which included approximately $1.6 million of money market funds.

The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, receivables, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The estimated fair value of the Company’s Term Facility at both June 30, 2016 and December 31, 2015, approximated the carrying value because the interest rate is subject to change with market interest rates.

4. Income Taxes

The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year in addition to discrete events which impact the interim period. The Company’s effective tax rate differs from the U.S. statutory rate principally due to the rate impact of uncertain tax positions, valuation allowance changes and state taxes. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective rate is determined. The Company’s tax provision was $0.2 million and $0.6 million for the three and six months ended June 30, 2016, respectively, compared to a tax provision of $1.2 million for the three and six months ended June 30, 2015.

In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb, or BMS, in 2008, the Company obtained a tax indemnification agreement with BMS related to certain tax obligations arising prior to the acquisition of the Company, for which the Company has the primary legal obligation. The tax indemnification receivable is recognized within other noncurrent assets. The changes in the tax indemnification asset are recognized within other income (expense), net in the condensed consolidated statement of operations. In accordance with the Company’s accounting policy, the change in the tax liability and penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within the tax provision. Accordingly, as these reserves change, adjustments are included in the tax provision while the offsetting adjustment is included in other income (expense), net. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there is no net effect on earnings related to these liabilities and no net cash outflows.

During the first quarter of 2016, the Company early adopted ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes on a retrospective basis. This standard requires all deferred taxes and liabilities, and any related valuation allowances, to be classified as non-current on the balance sheet. Adoption of this standard resulted in the reclassification of $0.1 million of current deferred tax assets to noncurrent deferred tax assets and $0.2 million of current deferred tax liabilities to noncurrent deferred tax liabilities on the balance sheet at December 31, 2015.

5. Assets Held for Sale

During the fourth quarter of 2015, the Company committed to a plan to sell certain assets and liabilities associated with the Company’s international business in Canada. This event qualified for held for sale accounting and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2015. The transaction was finalized in the first quarter of 2016.

Effective January 7, 2016, the Canadian subsidiary of the Company entered into an asset purchase agreement (“Purchase Agreement”) pursuant to which it would sell substantially all of the assets of its Canadian radiopharmacies and Gludef manufacturing and distribution business to one of its existing Canadian radiopharmacy customers.

The purchase price for the asset sale was $9.0 million in cash and also included a working capital adjustment of $0.5 million. The Purchase Agreement contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the Purchase Agreement.

As part of the transaction, the Company and the buyer also entered into a customary transition services agreement and a long-term supply contract under which the Company will supply the buyer with the Company’s products on commercial terms and under which the buyer has agreed to certain product purchase commitments.

The Company did not believe the sale of certain net assets in the international business constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s financial statements and was classified as assets and liabilities held for sale as of December 31, 2015.

 

9


Table of Contents

The following table summarizes the major classes of assets and liabilities sold as of January 12, 2016 (date of the sale) and December 31, 2015:

 

(in thousands)

   January 12,
2016
     December 31,
2015
 

Current Assets:

     

Accounts receivable, net

   $ 2,620       $ 2,512   

Inventory

     730         806   

Other current assets

     15         26   
  

 

 

    

 

 

 

Total current assets

     3,365         3,344   

Non-Current Assets:

     

Property, plant and equipment, net

     760         791   

Intangibles, net

     462         480   

Other long-term assets

     28         29   
  

 

 

    

 

 

 

Total assets held for sale

   $ 4,615       $ 4,644   
  

 

 

    

 

 

 

Current Liabilities:

     

Accounts payable

   $ 435       $ 430   

Accrued expense and other liabilities

     858         1,285   
  

 

 

    

 

 

 

Total liabilities held for sale

   $ 1,293       $ 1,715   
  

 

 

    

 

 

 

The sale resulted in a pre-tax book gain of $5.9 million, which was recorded within operating income in the condensed consolidated statement of operations for the six month period ended June 30, 2016.

6. Inventory

Inventory, classified in inventory or other long-term assets, consisted of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Raw materials

   $ 7,062       $ 7,506   

Work in process

     2,712         2,407   

Finished goods

     4,659         5,709   
  

 

 

    

 

 

 

Inventory

     14,433         15,622   

Other long-term assets

     1,156         1,156   
  

 

 

    

 

 

 

Total

   $ 15,589       $ 16,778   
  

 

 

    

 

 

 

At both June 30, 2016 and December 31, 2015, inventories reported as other long-term assets included $1.2 million of raw materials.

7. Property, Plant and Equipment, net

Property, plant and equipment consisted of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Land

   $ 14,950       $ 14,950   

Buildings

     69,577         68,941   

Machinery, equipment and fixtures

     65,982         60,787   

Construction in progress

     4,882         9,099   

Accumulated depreciation

     (70,969      (67,260
  

 

 

    

 

 

 

Property, plant and equipment, net

   $ 84,422       $ 86,517   
  

 

 

    

 

 

 

 

10


Table of Contents

For the three and six month period ended June 30, 2016, depreciation expense related to property, plant and equipment was $2.2 million and $4.1 million, respectively, as compared to $2.0 million and $7.7 million for the prior year comparative periods.

Fixed assets dedicated to research and development, or R&D, activities, which were impacted by the March 2013 R&D strategic shift, have a carrying value of $3.9 million as of June 30, 2016. The Company believes these fixed assets will be utilized for either internally funded ongoing R&D activities or R&D activities funded by a strategic partner. If the Company is not successful in finding a strategic partner and there are no alternative uses for these fixed assets, then they could be subject to impairment in the future.

8. Asset Retirement Obligations

The Company considers the legal obligation to remediate its facilities upon a decommissioning of its radioactive related operations as an asset retirement obligation. The operations of the Company have radioactive production facilities at its North Billerica, Massachusetts and San Juan, Puerto Rico sites.

The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of the North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond, which itself is currently secured by an $8.8 million unfunded Standby Letter of Credit provided to the third party issuer of the bond.

The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. As of June 30, 2016, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.7 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying value of the related long-lived assets and depreciated over the asset’s useful life.

The following is a reconciliation of the Company’s asset retirement obligations for the six months ended June 30, 2016:

 

(in thousands)

      

Balance at December 31, 2015

   $ 8,145   

Net increase due to changes in estimated future cash flows

     39   

Accretion expense

     466   
  

 

 

 

Balance at June 30, 2016

   $ 8,650   
  

 

 

 

9. Intangibles, net

Intangibles, net consisted of the following:

 

     June 30, 2016  

(in thousands)

   Cost      Accumulated
amortization
     Net      Amortization
Method
 

Trademarks

   $ 13,540       $ 7,843       $ 5,697         Straight-line   

Customer relationships

     100,997         90,158         10,839         Accelerated   

Patents

     42,780         41,367         1,413         Straight-line   
  

 

 

    

 

 

    

 

 

    
   $ 157,317       $ 139,368       $ 17,949      
  

 

 

    

 

 

    

 

 

    
     December 31, 2015  

(in thousands)

   Cost      Accumulated
amortization
     Net      Amortization
Method
 

Trademarks

   $ 13,540       $ 6,934       $ 6,606         Straight-line   

Customer relationships

     100,737         88,564         12,173         Accelerated   

Patents

     42,780         41,063         1,717         Straight-line   
  

 

 

    

 

 

    

 

 

    
   $ 157,057       $ 136,561       $ 20,496      
  

 

 

    

 

 

    

 

 

    

For the three and six month period ended June 30, 2016, the Company recorded amortization expense for its intangible assets of $1.3 million and $2.6 million, respectively, as compared to $1.5 million and $3.0 million for the prior year comparative periods.

 

11


Table of Contents

Expected future amortization expense related to the intangible assets is as follows:

 

(in thousands)

      

Remainder of 2016

   $ 2,587   

2017

     3,393   

2018

     2,688   

2019

     1,836   

2020

     1,595   

2021 and thereafter

     5,850   
  

 

 

 
   $ 17,949   
  

 

 

 

10. Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities are comprised of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Compensation and benefits

   $ 9,118       $ 10,525   

Freight, distribution and operations

     3,282         2,962   

Accrued rebates, discounts and chargebacks

     2,373         2,085   

Accrued professional fees

     1,272         1,493   

Marketing expense

     725         490   

Research and development services

     298         360   

Other

     596         587   
  

 

 

    

 

 

 
   $ 17,664       $ 18,502   
  

 

 

    

 

 

 

11. Financing Arrangements

Term Facility

On June 30, 2015, the Company entered into a $365.0 million seven-year Term Facility, which was issued net of a 1.25% discount of $4.6 million. The Company has a right to request an increase of the Term Facility in an aggregate amount up to $37.5 million plus additional amounts subject to certain leverage ratios. The net proceeds of the Term Facility, together with the net proceeds of the initial public offering, or IPO, and cash on hand, were used to refinance in full the aggregate principal amount of the $400.0 million 9.750% Senior Notes (“the Notes”) and pay related premiums, interest and expenses.

The term loans under the Term Facility bear interest, with pricing based from time to time at the Company’s election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. Interest under term loans based on (i) the LIBOR rate is payable at the end of each Interest Period (as defined in our Term Facility) and (ii) the Base Rate is payable at the end of each quarter. At June 30, 2016, the Company’s interest rate under the Term Facility was 7.00%.

The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, without premium or penalty. The Company is required to make quarterly payments, which began on September 30, 2015, in an amount equal to a quarter of a percent (0.25%) per annum of the original principal amount of the Term Facility. The remaining unpaid principal amount of the Term Facility will be payable on the maturity date, or June 30, 2022.

The Term Facility will require the Company to prepay outstanding term loans, subject to certain exceptions, with:

 

    100% of the net cash proceeds of all non-ordinary course sales or other dispositions of assets (including as a result of casualty or condemnation, subject to certain exceptions); the Company may reinvest or commit to reinvest certain of those proceeds in assets useful in our business within twelve months;

 

    100% of the net cash proceeds from issuances or incurrence of debt, other than proceeds from debt permitted under the Term Facility and Revolving Facility; and

 

    50% (with two leverage-based stepdowns) of the Company’s excess cash flow.

 

12


Table of Contents

The foregoing mandatory prepayments will be applied to the scheduled installments of principal of the Term Facility as directed by LMI, or in the absence of direction, in direct order of maturity.

The Term Facility is guaranteed by the Company and Lantheus Real Estate, and obligations under the Term Facility are secured by substantially all the property and assets and all interests of the Company, LMI and Lantheus Real Estate.

The Company’s maturities of principal obligations under the Term Facility are as follows as of June 30, 2016:

 

(in thousands)

      

Remainder of 2016

   $ 1,825   

2017

     3,650   

2018

     3,650   

2019

     3,650   

2020

     3,650   

2021 and thereafter

     344,925   
  

 

 

 

Total debt

     361,350   

Unamortized debt discount

     (3,860

Unamortized debt issuance costs

     (5,002
  

 

 

 

Total

     352,488   

Less current portion

     (3,650
  

 

 

 

Total long-term debt

   $ 348,838   
  

 

 

 

Term Facility Covenants

The Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Term Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis. The financial covenants are displayed in the table below:

Term Facility Financial Covenants

 

Period

   Total Net Leverage Ratio  

Q2 2016 to Q4 2016

     6.00 to 1.00   

Q1 2017 to Q2 2017

     5.50 to 1.00   

Thereafter

     5.00 to 1.00   

The Term Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Revolving Line of Credit

At June 30, 2016, the Company has a Revolving Facility with an aggregate principal amount not to exceed $50.0 million. The loans under the Revolving Facility bear interest with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread of 2.00% or (ii) the Reference Rate (as defined in the Revolving Facility) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020.

As of June 30, 2016, the Company has an unfunded Standby Letter of Credit for up to $8.8 million. The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires in February 2017. It automatically renewed for a one year period and will continue to automatically renew for a one year period at each anniversary date, unless the Company elects not to renew in writing within 60 days prior to such expiration.

The Revolving Facility is guaranteed by Holdings and Lantheus Real Estate and is secured by a pledge of substantially all of the assets of each of the loan parties including accounts receivable, inventory and machinery and equipment. Borrowing capacity is

 

13


Table of Contents

determined by reference to a Borrowing Base, which is based on a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves. As of June 30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by an outstanding $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $34.4 million.

Revolving Line of Credit Covenants

The Revolving Facility contains a number of affirmative, negative, reporting and financial covenants, as well as a financial covenant during trigger periods in the form of a consolidated fixed charge coverage ratio of not less than 1:00:1:00. Upon an event of default, the lender has the right to declare the loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced, and the lender may, after such events of default, require the Company to make deposits with respect to any outstanding letters of credit in an amount equal to 105% of the greatest amount for which such letter of credit may be drawn.

12. Stockholders’ Equity

As of June 30, 2016, the authorized capital stock of the Company consisted of 250,000,000 shares of common stock, par value $0.01 per share, and 25,000,000 shares of preferred stock, par value $0.01 per share. The common stockholders are entitled to one vote per share and will share equally on a per share basis in any dividend declared by the Board of Directors, subject to any preferential rights of the holders of any outstanding preferred stock.

The following table presents the changes in stockholders’ deficit for the six months ended June 30, 2016:

 

     Common Stock                   Accumulated
       
     Shares      Amount      Additional
Paid-In
Capital
     Accumulated
Deficit
    Other
Comprehensive
Loss
    Total
Stockholders’
Deficit
 

Balance at December 31, 2015

     30,364,501       $ 303       $ 175,553       $ (359,160   $ (1,985   $ (185,289

Net income

     —          —          —          17,673        —         17,673   

Other comprehensive income

     —          —          —          —         256        256   

Vesting of restricted stock awards

     20,936         —          —          —         —         —    

Stock-based compensation

     —          —          992         —         —         992   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at June 30, 2016

     30,385,437       $ 303       $ 176,545       $ (341,487   $ (1,729   $ (166,368
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

13. Stock-Based Compensation

As of June 24, 2015, the Company adopted the 2015 Equity Incentive Plan, (the “2015 Plan”).

The Company’s employees are eligible to receive awards under the 2015 Plan. The 2015 Plan is administered by the Board of Directors and permits the granting of stock options, stock appreciation rights, or SARs, restricted stock, restricted stock units and dividend equivalent rights (“DERs”) to employees, officers, directors and consultants of the Company. The Board of Directors may, at its sole discretion, grant DERs with respect to any award and such DER is treated as a separate award. The number of shares authorized for issuance under the 2015 Plan increased to 4,555,277 on April 26, 2016. Option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Time based option awards vest based on time, typically four years, and performance based option awards vest based on the performance criteria specified in the grant. All option awards have a ten-year contractual term. The Company recognizes compensation costs for its time based awards on a straight-line basis equal to the vesting period. The compensation cost for performance based awards is recognized on a graded vesting basis, based on the probability of achieving the performance targets over the requisite service period for the entire award. The fair value of each option award is estimated on the date of grant using a Black-Scholes valuation model. Expected volatilities are based on the historic volatility of a selected peer group. Expected dividends represent the dividends expected to be issued at the date of grant. The expected term of options represents the period of time that options granted are expected to be outstanding. The risk-free interest rate assumption is the U.S. Treasury rate at the date of the grant which most closely resembles the expected life of the options.

 

14


Table of Contents

Stock-based compensation expense for both time based and performance based stock options and restricted stock awards were recognized in the condensed consolidated statements of operations as follows:

 

     Three Months
Ended
June 30,
     Six Months
Ended
June 30,
 

(in thousands)

   2016      2015      2016      2015  

Cost of goods sold

   $ 73       $ 52       $ 139       $ 51   

General and administrative

     345         465         578         679   

Sales and marketing

     80         79         128         115   

Research and development

     87         60         147         88   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total stock-based compensation expense

   $ 585       $ 656       $ 992       $ 933   
  

 

 

    

 

 

    

 

 

    

 

 

 

14. Net Income (Loss) Per Share

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 

(in thousands, except share and per share amounts)

   2016      2015      2016      2015  

Net income (loss)

   $ 7,350       $ (24,423    $ 17,673       $ (24,048
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic weighted average common shares outstanding

     30,377,562         18,898,003         30,372,901         18,489,451   

Effect of dilutive restricted stock awards

     165,166         —           80,875         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted weighted average common shares outstanding

     30,542,728         18,898,003         30,453,776         18,489,451   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic and diluted income (loss) per weighted average common share outstanding

   $ 0.24       $ (1.29    $ 0.58       $ (1.30
  

 

 

    

 

 

    

 

 

    

 

 

 

The weighted average number of common shares for the three and six months ended June 30, 2016 did not include 2,183,075 options and unvested restricted stock for each period because of their antidilutive effect, as compared to the three and six months ended June 30, 2015, which did not include 2,153,827 options and unvested restricted stock for each period.

15. Other Income, net

 

     Three Months
Ended
June 30,
     Six Months
Ended
June 30,
 

(in thousands)

   2016      2015      2016      2015  

Foreign currency gains (losses)

   $ 256       $ 18       $ 19       $ (360

Tax indemnification income

     140         781         436         777   

Other income (expense)

     —           1         (1      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total other income, net

   $ 396       $ 800       $ 454       $ 417   
  

 

 

    

 

 

    

 

 

    

 

 

 

16. Legal Proceedings and Contingencies

From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect

 

15


Table of Contents

its financial condition or results of operations. As of June 30, 2016, the Company had no material ongoing litigation in which the Company was a defendant or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

On December 16, 2010, LMI filed suit against one of its insurance carriers seeking to recover business interruption losses associated with the NRU reactor shutdown and the ensuing global Moly supply shortage. The claim is the result of the shutdown of the NRU reactor in Chalk River, Ontario. The NRU reactor was off-line from May 2009 until August 2010. The defendant answered the complaint on January 21, 2011, denying substantially all of the allegations, presenting certain defenses and requesting dismissal of the case with costs and disbursements. Discovery, including international discovery and related motion practice, has been on-going for more than three years. The defendant filed a motion for summary judgment on July 14, 2014. The Company filed a memorandum of law in opposition to defendant’s motion for summary judgment on August 25, 2014. The defendant filed a reply memorandum of law in further support of its motion for summary judgment on September 15, 2014. Expert witness discovery was completed on October 31, 2014. On March 25, 2015, the United States District Court for the Southern District of New York granted defendant’s motion for summary judgment. On September 4, 2015, the Company filed an appeal of the District Court decision with the United States Court of Appeals for the Second Circuit. On December 4, 2015, the defendant filed an answer brief to the Company’s appeal, and on December 18, 2015, the Company filed a reply brief to the defendant’s answer. On April 21, 2016, the United States Court of Appeals for the Second Circuit heard oral arguments of the Company and the defendant in connection with the Company’s appeal. On May 25, 2016, the United States Court of Appeals for the Second Circuit issued a Summary Order affirming the judgment of the United States District Court which granted the defendant’s motion for summary judgment. The Company considers this matter closed.

17. Related Party Transactions

Avista, the Company’s majority shareholder, provided certain advisory services to the Company pursuant to an advisory services and monitoring agreement. The Company was required to pay an annual fee of $1.0 million and other reasonable and customary advisory fees, as applicable, paid on a quarterly basis. The initial term of the agreement was seven years. On June 25, 2015, the Company exercised its right to terminate its advisory services and monitoring agreement with Avista. In connection with such termination, the Company has paid Avista Capital Holdings, L.P. an aggregate termination fee of $6.5 million, which was included in general and administrative expenses in the condensed consolidated statement of operations during the quarter ended June 30, 2015. During the three and six months ended June 30, 2016, the Company did not incur any costs associated with this agreement as compared to $6.8 million and $7.0 million, respectively, for the prior year comparative periods. At June 30, 2016 and December 31, 2015, there were no amounts outstanding.

In the first quarter of 2016, the Company entered into a services agreement with INC Research, LLC, or INC, to provide pharmacovigilance services. Avista and certain of its affiliates are principal owners of both INC and the Company. The agreement has a term of three years. During the three and six months ended June 30, 2016, the Company incurred costs associated with this agreement of approximately $0.3 million and $0.5 million, respectively. At June 30, 2016, $0.1 million was included in accrued expenses and other liabilities.

The Company purchases inventory supplies from VWR Scientific, or VWR. Avista and certain of its affiliates are principal owners of both VWR and the Company. During each of the three and six months ended June 30, 2016, the Company made purchases of $0.1 million and $0.2 million respectively, as compared to $44,000 and $0.1 million for the prior year comparative periods. At June 30, 2016 and December 31, 2015, $6,000 and $10,000, respectively, was included in accounts payable and accrued expenses.

18. Segment Information

The Company reports two operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacturing, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. The U.S. segment comprises 83.5% and 84.2% of consolidated revenues for the three and six months ended June 30, 2016 as compared to 79.6% and 80.4% for the prior year comparative periods.

 

16


Table of Contents

Selected information for each business segment are as follows (in thousands):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2016      2015      2016      2015  

Revenues

           

U.S.

   $ 72,244       $ 64,689       $ 143,014       $ 130,477   

International

     12,832         14,936         24,373         29,092   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue, including inter-segment

     85,076         79,625         167,387         159,569   

Less inter-segment revenue

     (7,110      (6,311      (12,947      (11,432
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 77,966       $ 73,314       $ 154,440       $ 148,137   
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues from external customers

           

U.S.

   $ 65,134       $ 58,378       $ 130,067       $ 119,045   

International

     12,832         14,936         24,373         29,092   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 77,966       $ 73,314       $ 154,440       $ 148,137   
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating income

           

U.S.

   $ 15,931       $ 3,442       $ 29,335       $ 16,121   

International

     (1,443      2,059         2,691         585   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating income, including inter-segment

     14,488         5,501         32,026         16,706   

Inter-segment operating (loss) income

     (309      (145      (174      28   
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating income

     14,179         5,356         31,852         16,734   

Interest expense, net

     (6,978      (13,876      (13,996      (24,499

Loss on extinguishment of debt

     —           (15,528      —           (15,528

Other income, net

     396         800         454         417   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

   $ 7,597       $ (23,248    $ 18,310       $ (22,876
  

 

 

    

 

 

    

 

 

    

 

 

 

 

17


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

Some of the statements contained in this quarterly report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, including, in particular, statements about our plans, strategies, prospects and industry estimates are subject to risks and uncertainties. These statements identify prospective information and include words such as “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “should,” “could,” “predicts,” “targets,” “hopes” and similar expressions. Examples of forward-looking statements include, but are not limited to, statements we make regarding: (i) our outlook and expectations including, without limitation, in connection with continued market expansion and penetration for our commercial products, particularly DEFINITY in the face of increased competition; (ii) our outlook and expectations in connection with future performance of Xenon in the face of increased competition; (iii) our outlook and expectations related to products manufactured at JHS and Pharmalucence and global isotope supply; (iv) our outlook and expectations related to our engagement of strategic partners to assist in developing and potentially commercializing development candidates; and (v) our liquidity, including our belief that our existing cash, cash equivalents, anticipated revenues and availability under our Revolving Facility, are sufficient to fund our existing operating expenses, capital expenditures and liquidity requirements for at least the next twelve months. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this prospectus may not in fact occur. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions and the following:

 

    our ability to continue to increase segment penetration for DEFINITY in suboptimal echocardiograms and the increased segment competition from other echocardiography contrast agents, including Optison from GE Healthcare and Lumason from Bracco Diagnostics Inc., or Bracco;

 

    risks associated with revenues and unit volumes for Xenon in pulmonary studies with increased segment competition resulting from Mallinckrodt’s recent re-launch of their Xenon product;

 

    our dependence on key customers and group purchasing organization arrangements for our medical imaging products, and our ability to maintain and profitably renew our contracts and relationships with those key customers and group purchasing organizations;

 

    our dependence upon third parties for the manufacture and supply of a substantial portion of our products, including for DEFINITY at JHS;

 

    risks associated with the technology transfer programs to secure production of our products at alternate contract manufacturer sites, including for DEFINITY at Pharmalucence where activities have been significantly delayed;

 

    risks associated with the manufacturing and distribution of our products and the regulatory requirements related thereto;

 

    the instability of the global Molybdenum-99, or Moly, supply;

 

    the dependence of certain of our customers upon third party healthcare payors and the uncertainty of third party coverage and reimbursement rates;

 

    uncertainties regarding the impact of U.S. healthcare reform on our business, including related reimbursements for our current and potential future products;

 

    our being subject to extensive government regulation and our potential inability to comply with those regulations;

 

    potential liability associated with our marketing and sales practices;

 

    the occurrence of any side effects with our products;

 

    our exposure to potential product liability claims and environmental liability;

 

    risks associated with our lead agent in development, flurpiridaz F 18, including our ability to:

 

    attract strategic partners to successfully complete the Phase 3 clinical program and possibly commercialize the agent;

 

    obtain Food and Drug Administration, or FDA, approval; and

 

    gain post-approval market acceptance and adequate reimbursement;

 

18


Table of Contents
    risks associated with being able to negotiate in a timely manner relationships with potential strategic partners to advance our other development programs on acceptable terms, or at all;

 

    the extensive costs, time and uncertainty associated with new product development, including further product development relying on external development partners, all against an evolving diagnostic landscape;

 

    our inability to protect our intellectual property and the risk of claims that we have infringed on the intellectual property of others;

 

    risks associated with prevailing economic conditions and financial, business and other factors beyond our control;

 

    risks associated with our international operations;

 

    our inability to adequately protect our facilities, equipment and technology infrastructure;

 

    our inability to hire or retain skilled employees and key personnel;

 

    risks related to our outstanding indebtedness and our ability to satisfy those obligations;

 

    costs and other risks associated with the Sarbanes-Oxley Act and the Dodd-Frank Act; and

 

    risks related to the ownership of our common stock.

Factors that could cause or contribute to such differences include, but are not limited to, those that are discussed in other documents we file with the Securities and Exchange Commission. Any forward-looking statement made by us in this quarterly report speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

The following discussion and analysis of our financial condition and results of operations should be read together with the condensed consolidated financial statements and the related notes included in Item 1 of this Quarterly Report on Form 10-Q as well as the other factors described in “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Overview

We are a global leader in the development, manufacture and commercialization of innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Our agents are routinely used to diagnose coronary artery disease, congestive heart failure, pulmonary issues, stroke and other diseases. Clinicians use our imaging agents and products across a range of imaging modalities, including echocardiography and nuclear imaging. We believe that the resulting improved diagnostic information enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs for payers and the entire healthcare system.

Our commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. We sell our products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks and group purchasing organizations.

We sell our products globally and have operations in the United States, Puerto Rico, Canada and Australia and third-party distribution relationships in Europe, Asia Pacific and Latin America.

Our Products

Our principal products include the following:

DEFINITY is an ultrasound contrast agent used in ultrasound exams of the heart, also known as echocardiography exams. DEFINITY contains perflutren-containing lipid microspheres and is indicated in the United States for use in patients with suboptimal echocardiograms to assist in imaging the left ventricular chamber and left endocardial border of the heart in ultrasound procedures. We launched DEFINITY in 2001, and its last issued patent in the United States will currently expire in 2021 and in numerous foreign jurisdictions in 2019. We also have an active next generation development program for this agent.

 

19


Table of Contents

TechneLite is a technetium generator which provides the essential nuclear material used by radiopharmacies to radiolabel Cardiolite, Neurolite and other technetium-based radiopharmaceuticals used in nuclear medicine procedures. TechneLite uses Moly as its main active ingredient.

Xenon is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow. Xenon is manufactured by third parties and packaged by us and in certain circumstances finished by us.

Sales of our contrast agent, DEFINITY, are made in the United States and Canada through our sales team of approximately 80 employees. In the United States, our nuclear imaging products, including TechneLite, Xenon, Cardiolite and Neurolite, are primarily distributed through commercial radiopharmacies, the majority of which are controlled by or associated with Cardinal, UPPI, GE Healthcare and Triad. A small portion of our nuclear imaging product sales in the United States are made through our direct sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical capabilities. Outside the United States, we own two radiopharmacies in Australia and one in Puerto Rico. On January 12, 2016, we sold our Canadian radiopharmacies to Isologic and entered into a long-term supply agreement with Isologic under which we will supply Isologic with certain of our products on commercial terms, including certain product purchase commitments by Isologic. The agreement expires on January 12, 2021 and may be terminated upon the occurrence of specified events, including a material breach by the other party, bankruptcy by either party and certain force majeure events. We also maintain our own direct sales forces in these markets so we can control the importation, marketing, distribution and sale of our imaging agents in these regions. In Europe, Asia Pacific and Latin America, we rely on third party distributors to market, sell and distribute our nuclear imaging and contrast agent products, either on a country-by-country basis or on a multicountry regional basis.

The following table sets forth our revenue derived from our principal products:

 

     Three Months Ended June 30,     Six Months Ended June 30,  

(in thousands)

   2016      %     2015      %     2016      %     2015      %  

DEFINITY

   $ 33,474         42.9   $ 28,428         38.8   $ 64,896         42.0   $ 54,094         36.5

TechneLite

     25,252         32.4        17,362         23.7        50,088         32.4        38,221         25.8   

Xenon

     6,774         8.7        12,048         16.4        14,948         9.7        25,243         17.0   

Other

     12,466         16.0        15,476         21.1        24,508         15.9        30,579         20.7   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Revenues

   $ 77,966         100.0   $ 73,314         100.0   $ 154,440         100.0   $ 148,137         100.0
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Key Factors Affecting Our Results

Our business and financial performance have been, and continue to be, affected by the following:

Growth of DEFINITY

We believe the market opportunity for our contrast agent, DEFINITY, remains significant. DEFINITY is currently our fastest growing and highest margin commercial product. We believe that DEFINITY sales will continue to grow and that DEFINITY will constitute a greater share of our overall product mix. As we better educate the physician and healthcare provider community about the benefits and risks of this product, we believe we will experience further penetration of suboptimal echocardiograms.

The future growth of our DEFINITY sales will be dependent on our ability to continue to increase segment penetration for DEFINITY in suboptimal echocardiograms and, as discussed below in “—Inventory Supply,” on the ability of JHS, and, if approved Pharmalucence, to continue to manufacture and release DEFINITY on a timely and consistent basis. See “Part 1 – Item 1A. Risk Factors—The growth of our business is substantially dependent on increased market penetration for the appropriate use of DEFINITY in suboptimal echocardiograms” of our annual report on Form 10-K for the fiscal year ended December 31, 2015.

There are three echocardiography contrast agents approved by the FDA for sale in the U.S.—DEFINITY which as of December 2015 had an approximately 78% segment share, Optison, and Lumason, which was approved by the FDA in October 2014. Lumason is known as SonoVue outside of the U.S. and is already approved for sale in Europe and certain Asian markets, including China, Japan and Korea. While we believe that additional promotion in the U.S. echocardiography segment will help raise awareness around the value that echocardiography contrast brings and potentially increase the overall contrast penetration rate, if Bracco successfully grows the use of Lumason in the U.S. without otherwise increasing the overall usage of ultrasound contrast agents, our own growth expectations for DEFINITY revenue, gross profit and gross margin may have to be adjusted.

 

20


Table of Contents

Competition for Xenon

Xenon gas for lung ventilation diagnosis is our third largest product by revenue. Historically, several companies, including Mallinckrodt, sold packaged Xenon as a pulmonary imaging agent in the U.S., but from 2010 through the first quarter of 2016 we have been the only supplier of this imaging agent in the U.S. In March 2016, Mallinckrodt received regulatory approval from the FDA to again sell packaged Xenon in the U.S. and has begun to do so. Depending upon the pricing, extent of availability and market penetration of Mallinckrodt’s offering, we believe we are at risk for volume loss and price erosion from those customers that are not subject to price or volume commitments with us. In order to increase the predictability of our Xenon business, we have entered into Xenon supply agreements at committed volumes and substantially reduced prices with previously non-contracted customers. These steps have resulted in predictable Xenon unit volumes in 2016, but with sales at substantially lower revenue and gross margin contributions as compared to 2015. See “Part II—Item 1A. Risk Factors —We face potential supply and demand challenges for Xenon.”

Inventory Supply

Our products consist of contrast imaging agents and radiopharmaceuticals (including technetium generators). We obtain a substantial portion of our imaging agents from third party suppliers. JHS is currently our sole source manufacturer of DEFINITY, Neurolite and evacuation vials, an ancillary component for our TechneLite generators, and we have ongoing technology transfer activities at JHS for our Cardiolite product supply. In the meantime, our Cardiolite product supply is approved for manufacture by a single manufacturer. Until JHS is approved by certain foreign regulatory authorities to manufacture certain of our products, we will face continued limitations on where we can sell those products outside of the United States.

In addition to JHS, we are also currently working to secure additional alternative suppliers for our key products as part of our ongoing supply chain diversification strategy. Our technology transfer activities with Pharmalucence to manufacture and supply DEFINITY are ongoing, but such activities have been further delayed and we cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY. See “Part I – Item IA. Risk Factors – Our dependence upon third parties for the manufacture and supply of a substantial portion of our products could prevent us from delivering our products to our customers in the required quantities, within the required timeframes, or at all, which could result in order cancellations and decreased revenues” of our annual report on Form 10-K for the fiscal year ended December 31, 2015.

Radiopharmaceuticals are decaying radioisotopes with half-lives ranging from a few hours to several days. These products cannot be kept in inventory because of their limited useful lives and are subject to just-in-time manufacturing, processing and distribution, which takes place at our North Billerica, Massachusetts facility.

Global Isotope Supply

Currently, an important supplier of Moly and Xenon is Nordion, which relies on the NRU reactor in Chalk River, Ontario. For Moly and Xenon, we have supply agreements with Nordion that expire on October 31, 2016. We also have Moly supply agreements with NTP of South Africa, ANSTO of Australia, and IRE of Belgium, each running through December 31, 2017 and a Xenon supply agreement with IRE which runs through June 30, 2019 subject to extensions.

We believe we are well-positioned with our current supply partners to have a secure supply of Moly, including low-enriched uranium, or LEU, Moly, when the NRU reactor transitions in October 2016 from providing regular supply of medical isotopes to providing only an emergency back-up supply of HEU based medical isotopes through March 2018. ANSTO has under construction, in cooperation with NTP, a new Moly processing facility that ANSTO believes will expand its production capacity by approximately 2.5 times, with expanded commercial production planned to start in the latter part of 2016. In addition, IRE recently received approval from its regulator to expand its production capability by up to 50% of its former capacity. The new ANSTO and IRE production capacity is expected to replace the NRU’s current routine production.

We are also now receiving bulk unprocessed Xenon from IRE which we are processing and finishing for our customers. We believe we are well-positioned to supply Xenon to our customers after the NRU reactor transitions in October 2016 from providing regular supply of bulk Xenon to providing only an emergency back-up supply of bulk Xenon through March 2018.

Demand for TechneLite

We believe there has been a decline in the MPI study market because of industry-wide cost containment initiatives that have resulted in a transition of where imaging procedures are performed, from free-standing imaging centers to the hospital setting. While the total number of patient studies has not returned to pre-shortage levels, the total MPI market was essentially flat for the period 2011 through 2015.

 

21


Table of Contents

In November 2015, CMS announced the 2016 final Medicare payment rules for hospital outpatient settings. Under the final rules, each technetium dose produced from a generator for a diagnostic procedure in a hospital outpatient setting is reimbursed by Medicare at a higher rate if that technetium dose is produced from a generator containing Moly sourced from at least 95 percent LEU. In January 2013, we began to offer a TechneLite generator which contains Moly sourced from at least 95 percent LEU and which satisfies the requirements for reimbursement under this incentive program. Although demand for LEU generators appears to be growing, we do not know when, or if, this incremental reimbursement for LEU Moly generators will result in a material increase in our generator sales.

Research and Development Expenses

To remain a leader in the marketplace, we have historically made substantial investments in new product development. As a result, the positive contributions of those internally funded R&D programs have been a key factor in our historical results and success. In March 2013, we began to implement a strategic shift in how we fund our important R&D programs. We have reduced our internal R&D resources while at the same time we are seeking to engage strategic partners to assist us in the further development and commercialization of our important agents in development, including flurpiridaz F 18, 18F LMI 1195 and LMI 1174. As a result of this shift, we are seeking strategic partners to assist us with the further development and possible commercialization of flurpiridaz F18. For our other two important agents in development, 18F LMI 1195 and LMI 1174, we are also seeking to engage strategic partners to assist us with the ongoing development activities relating to these agents.

Segments

We report our results of operations in two operating segments: United States and International. We generate a greater proportion of our revenue and net income in the United States segment, which consists of all regions of the United States with the exception of Puerto Rico.

Executive Overview

Our results in the three and six months ended June 30, 2016 reflect the following:

 

    increased revenues and segment penetration for DEFINITY in the suboptimal echocardiogram segment as a result of our sales efforts and sustained availability of product supply;

 

    increased revenues for TechneLite, mainly the result of contracts with significant customers;

 

    decreased revenues for Xenon, mainly the result of lower selling prices;

 

    $5.9 million gain on the sale of our Canadian radiopharmacies;

 

    lower international revenues as a result of the sale of our Canadian radiopharmacies and unfavorable exchange rates;

 

    decreased depreciation over the prior year period associated with the scheduled decommissioning of certain long-lived assets in the prior year,

 

    decreased interest expense due to the refinancing of long-term debt in connection with the IPO,

 

    decreased general and administrative expenses due to a $6.5 million payment for the termination of our advisory services and monitoring agreement with Avista in the prior year; and

 

    decrease of $15.5 million loss on extinguishment of debt costs related to the redemption of LMI’s outstanding Notes in the prior year.

 

22


Table of Contents

Results of Operations

 

     For the Three Months
Ended June 30,
     For the Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

Revenues

   $ 77,966       $ 73,314       $ 154,440       $ 148,137   

Cost of goods sold

     42,215         40,647         84,988         79,701   
  

 

 

    

 

 

    

 

 

    

 

 

 

Gross profit

     35,751         32,667         69,452         68,436   
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating expenses

           

Sales and marketing expenses

     9,843         9,229         19,150         18,301   

General and administrative expenses

     9,238         15,444         18,751         24,567   

Research and development expenses

     2,608         2,638         5,644         8,834   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

     21,689         27,311         43,545         51,702   

Gain on sale of assets

     117         —           5,945         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating income

     14,179         5,356         31,852         16,734   

Interest expense, net

     (6,978      (13,876      (13,996      (24,499

Loss on extinguishment of debt

     —           (15,528      —           (15,528

Other income, net

     396         800         454         417   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

     7,597         (23,248      18,310         (22,876

Provision for income taxes

     247         1,175         637         1,172   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income (loss)

   $ 7,350       $ (24,423    $ 17,673       $ (24,048
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues

Revenues are summarized as follows:

 

     Three Months
Ended June 30,
     Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

United States

           

DEFINITY

   $ 32,698       $ 27,828       $ 63,491       $ 53,010   

TechneLite

     21,643         14,637         43,376         32,810   

Xenon

     6,773         12,038         14,945         25,224   

Other

     4,020         3,875         8,255         8,001   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total U.S. revenues

   $ 65,134       $ 58,378       $ 130,067       $ 119,045   
  

 

 

    

 

 

    

 

 

    

 

 

 

International

           

DEFINITY

   $ 776       $ 600       $ 1,405       $ 1,084   

TechneLite

     3,609         2,725         6,712         5,411   

Xenon

     1         10         3         19   

Other

     8,446         11,601         16,253         22,578   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total International revenues

   $ 12,832       $ 14,936       $ 24,373       $ 29,092   
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues

   $ 77,966       $ 73,314       $ 154,440       $ 148,137   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues increased $4.7 million, or 6.3%, to $78.0 million in the three months ended June 30, 2016, as compared to $73.3 million in the three months ended June 30, 2015. U.S. segment revenue increased $6.8 million, or 11.6%, to $65.1 million in the three months ended June 30, 2016, as compared to $58.4 million in the prior year period. The International segment revenues decreased $2.1 million, or 14.1%, to $12.8 million in the three months ended June 30, 2016, as compared to $14.9 million in the prior year period.

Total revenues increased $6.3 million, or 4.3%, to $154.4 million in the six months ended June 30, 2016, as compared to $148.1 million in the six months ended June 30, 2015. U.S. segment revenue increased $11.0 million, or 9.3%, to $130.1 million in the six months ended June 30, 2016, as compared to $119.0 million in the prior year period. The International segment revenues decreased $4.7 million, or 16.2%, to $24.4 million in the six months ended June 30, 2016, as compared to $29.1 million in the prior year period.

The increase in U.S. segment revenues for the three and six months ended June 30, 2016, as compared to the prior year periods is primarily due to a $7.0 million and $10.6 million increase, respectively, in TechneLite revenues as a result of contracts with customers that increased unit volumes and a $4.9 million and $10.5 million, respectively, increase in DEFINITY revenues as a result of higher unit volumes. Offsetting these increases was a $5.3 million and $10.3 million, respectively, decrease in Xenon revenues over the prior year periods primarily as a result of contracts with significant customers that reduced unit pricing in exchange for committed volume purchases.

 

23


Table of Contents

The decrease in the International segment revenues for the three and six months ended June 30, 2016, as compared to the prior year period is primarily a result of the decrease in revenues in Canada attributable to the sale of the Canadian radiopharmacies and $0.2 million and $1.0 million of unfavorable foreign exchange, respectively.

Rebates and Allowances

Estimates for rebates and allowances represent our estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenue and the establishment of a liability which is included in accrued expenses. These rebates result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs, administrative fees of group purchasing organizations, royalties and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third party’s buying patterns and the resulting applicable contractual rebate or commission rate(s) to be earned over a contractual period.

An analysis of the amount of, and change in, reserves is summarized as follows:

 

(in thousands)

   Rebates      Allowances      Total  

Balance, as of December 31, 2015

   $ 2,303       $ 38       $ 2,341   

Current provisions relating to revenues in current year

     3,495         120         3,615   

Adjustments relating to prior years’ estimate

     (66      —          (66

Payments/credits relating to revenues in current year

     (2,154      (94      (2,248

Payments/credits relating to revenues in prior years

     (1,205      (60      (1,265
  

 

 

    

 

 

    

 

 

 

Balance, as of June 30, 2016

   $ 2,373       $ 4       $ 2,377   
  

 

 

    

 

 

    

 

 

 

Accrued sales rebates were approximately $2.4 million and $2.3 million at June 30, 2016 and December 31, 2015, respectively.

Costs of Goods Sold

Cost of goods sold consists of manufacturing, distribution, intangible asset amortization and other costs related to our commercial products. In addition, it includes the write-off of excess and obsolete inventory.

Cost of goods sold is summarized as follows:

 

     Three Months
Ended June 30,
     Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

United States

   $ 32,448       $ 27,568       $ 65,658       $ 54,430   

International

     9,767         13,079         19,330         25,271   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Cost of Goods Sold

   $ 42,215       $ 40,647       $ 84,988       $ 79,701   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total cost of goods sold increased $1.6 million, or 3.9%, to $42.2 million in the three months ended June 30, 2016, as compared to $40.6 million in the three months ended June 30, 2015. U.S. segment cost of goods sold increased approximately $4.9 million, or 17.8%, to $32.4 million in the three months ended June 30, 2016, as compared to $27.6 million in the prior year period. For the three months ended June 30, 2016, the International segment cost of goods sold decreased $3.3 million, or 25.3%, to $9.8 million, as compared to $13.1 million in the prior year period.

Total cost of goods sold increased $5.3 million, or 6.6%, to $85.0 million in the six months ended June 30, 2016, as compared to $79.7 million in the six months ended June 30, 2015. U.S. segment cost of goods sold increased approximately $11.2 million, or 20.6%, to $65.7 million in the six months ended June 30, 2016, as compared to $54.4 million in the prior year period. For the six months ended June 30, 2016, the International segment cost of goods sold decreased $5.9 million, or 23.5%, to $19.3 million, as compared to $25.3 million in the prior year period.

The increase in the U.S. segment cost of goods sold for the three months ended June 30, 2016 over the prior year period is primarily due to a $4.8 million increase in TechneLite cost of goods sold due to higher sales unit volume and an increase of $1.1 million in Xenon cost of goods sold due to higher material costs.

 

24


Table of Contents

The increase in the U.S. segment cost of goods sold for the six months ended June 30, 2016 over the prior year period is primarily due to a $9.5 million increase in TechneLite cost of goods sold due to higher sales unit volume and an increase of $2.4 million in Xenon cost of goods sold due to higher material costs.

The decrease in the International segment cost of goods sold in the three and six months ended June 30, 2016, as compared to the prior year periods, is primarily due to lower manufacturing costs for certain products as a result of the sale of our Canadian radiopharmacies in the first quarter of 2016.

Gross Profit

 

     Three Months
Ended June 30,
     Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

United States

   $ 32,686       $ 30,810       $ 64,409       $ 64,615   

International

     3,065         1,857         5,043         3,821   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Gross Profit

   $ 35,751       $ 32,667       $ 69,452       $ 68,436   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total gross profit increased $3.1 million, or 9.4%, to $35.8 million in the three months ended June 30, 2016, as compared to $32.7 million in the three months ended June 30, 2015. U.S. segment gross profit increased $1.9 million, or 6.1%, to $32.7 million in the three months ended June 30, 2016, as compared to $30.8 million in the prior year period. For the three months ended June 30, 2016, the International segment gross profit increased $1.2 million, or 65.1%, to $3.1 million, as compared to $1.9 million in the prior year period.

Total gross profit increased $1.0 million, or 1.5%, to $69.5 million in the six months ended June 30, 2016, as compared to $68.4 million in the six months ended June 30, 2015. U.S. segment gross profit decreased $0.2 million, or 0.3%, to $64.4 million in the six months ended June 30, 2016, as compared to $64.6 million in the prior year period. For the six months ended June 30, 2016, the International segment gross profit increased $1.2 million, or 32.0%, to $5.0 million, as compared to $3.8 million in the prior year period.

The increase in the U.S. segment gross profit for the three months ended June 30, 2016 over the prior year period is primarily due to an increase in sales unit volume of DEFINITY and TechneLite, which is partially offset by a decrease in Xenon gross profit as a result of the combination of lower selling prices and higher material costs.

The decrease in the U.S. segment gross profit for the six months ended June 30, 2016 over the prior year period is primarily due to a decrease in Xenon gross profit as a result of the combination of lower selling prices and higher material costs, which was offset by increases in DEFINITY and TechneLite gross profit due to higher sales unit volume.

The increase in the International segment gross profit for the three months ended June 30, 2016 over the prior year period is primarily due to lower Thallium cost of goods per unit, lower manufacturing costs for certain products as a result of the sale of our Canadian radiopharmacies and increased operational efficiencies as a result of the shutdown of one of our Puerto Rican radiopharmacies in the third quarter of 2015.

The increase in the International segment gross profit for the six months ended June 30, 2016 over the prior year period is primarily due to lower Thallium cost of goods per unit, lower manufacturing costs for certain products as a result of the sale of our Canadian radiopharmacies and increased operational efficiencies as a result of the shutdown of one of our Puerto Rican radiopharmacies in the third quarter of 2015. These increases were partially offset by a $0.6 million unfavorable foreign exchange.

Sales and Marketing

 

     Three Months
Ended June 30,
     Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

United States

   $ 8,576       $ 8,284       $ 16,881       $ 16,352   

International

     1,267         945         2,269         1,949   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Sales and Marketing

   $ 9,843       $ 9,229       $ 19,150       $ 18,301   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

25


Table of Contents

Sales and marketing expenses consist primarily of salaries and other related costs for personnel in field sales, marketing, business development and customer service functions. Other costs in sales and marketing expenses include the development and printing of advertising and promotional material, professional services, market research and sales meetings.

Total sales and marketing expenses increased $0.6 million, or 6.7%, to $9.8 million in the three months ended June 30, 2016, as compared to $9.2 million in the three months ended June 30, 2015. In the U.S. segment, sales and marketing expense increased $0.3 million or 3.5% to $8.6 million in the three months ended June 30, 2016, as compared to $8.3 million in the prior year period. In the International segment, sales and marketing expense increased $0.3 million, or 34.1%, to $1.3 million in the three months ended June 30, 2016, as compared to $0.9 million in the prior year period.

Total sales and marketing expenses increased $0.8 million, or 4.6%, to $19.2 million in the six months ended June 30, 2016, as compared to $18.3 million in the six months ended June 30, 2015. In the U.S. segment, sales and marketing expense increased $0.5 million, or 3.2%, to $16.9 million in the six months ended June 30, 2016, as compared to $16.4 million in the prior year period. In the International segment, sales and marketing expense increased $0.3 million, or 16.4%, to $2.3 million in the six months ended June 30, 2016, as compared to $1.9 million in the prior year period.

The increase in the U.S. segment sales and marketing expenses for the three months ended June 30, 2016 over the prior year period is primarily due to the timing of sales force meetings, training and travel.

The increase in the U.S. segment sales and marketing expenses for the six months ended June 30, 2016 over the prior year period is primarily due to higher employee related expense driven by incentive compensation, as well as the timing of sales force meetings, training and travel, partially offset by the timing of advertising and promotional activities.

The increase in the International segment sales and marketing expenses for the three and six months ended June 30, 2016 over the prior year period is primarily due to increased employee related expenses for the International commercial team.

General and Administrative

 

     Three Months
Ended June 30,
     Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

United States

   $ 8,781       $ 14,893       $ 17,935       $ 23,633   

International

     457         551         816         934   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total General and Administrative

   $ 9,238       $ 15,444       $ 18,751       $ 24,567   
  

 

 

    

 

 

    

 

 

    

 

 

 

General and administrative expenses consist of salaries and other related costs for personnel in executive, finance, legal, information technology and human resource functions. Other costs included in general and administrative expenses are professional fees for information technology services, external legal fees, consulting and accounting services, as well as bad debt expense, certain facility and insurance costs, including director and officer liability insurance.

Total general and administrative expenses decreased $6.2 million, or 40.2%, to $9.2 million in the three months ended June 30, 2016, as compared to $15.4 million in the three months ended June 30, 2015. In the U.S. segment, general and administrative expense decreased $6.1 million, or 41.0%, to $8.8 million in the three months ended June 30, 2016, as compared to $14.9 million in the prior year period. In the International segment, general and administrative expense decreased $0.1 million, or 17.1% to $0.5 million in the three months ended June 30, 2016, as compared to $0.6 million in the prior year period.

Total general and administrative expenses decreased $5.8 million, or 23.7%, to $18.8 million in the six months ended June 30, 2016, as compared to $24.6 million in the six months ended June 30, 2015. In the U.S. segment, general and administrative expense decreased $5.7 million, or 24.1%, to $17.9 million in the six months ended June 30, 2016, as compared to $23.6 million in the prior year period. In the International segment, general and administrative expense decreased $0.1 million, or 12.6%, to $0.8 million in the six months ended June 30, 2016, as compared to $0.9 million in the prior year period.

The decrease in the U.S. segment general and administrative expenses for the three and six months ended June 30, 2016 over the prior year period is primarily due to the $6.5 million termination fee incurred to terminate the advisory services and monitoring agreement with Avista in the prior year and lower employee related expenses. This was partially offset by higher amortization of capitalized software and increased insurance costs.

 

26


Table of Contents

The decrease in the International segment general and administrative expenses for the three and six months ended June 30, 2016 over the prior year period is primarily due to lower employee headcount and related expenses.

Research and Development

 

     Three Months
Ended June 30,
     Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

United States

   $ 2,434       $ 2,466       $ 5,300       $ 8,481   

International

     174         172         344         353   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Research and Development

   $ 2,608       $ 2,638       $ 5,644       $ 8,834   
  

 

 

    

 

 

    

 

 

    

 

 

 

Research and development expenses relate primarily to the development of new products to add to our portfolio and costs related to its medical affairs, medical information and regulatory functions. We do not allocate research and development expenses incurred in the United States to our International segment.

Total research and development expenses remained constant in the three months ended June 30, 2016 and 2015.

Total research and development expenses decreased $3.2 million, or 36.1%, to $5.6 million in the six months ended June 30, 2016, as compared to $8.8 million in the six months ended June 30, 2015. In the U.S. segment, research and development expense decreased $3.2 million, or 37.5%, to $5.3 million in the six months ended June 30, 2016, as compared to $8.5 million in the prior year period. In the International segment, research and development expense remained consistent.

The decrease in the U.S. segment research and development expenses for the six months ended June 30, 2016 over the prior year period is primarily due to a reduction in depreciation expense as a result of the scheduled decommissioning of certain long-lived assets associated with research and development operations, partially offset by higher pharmacovigilance expenses due to the transition to a new vendor.

Gain on Sale of Assets

Effective January 7, 2016, our Canadian subsidiary entered into an asset purchase agreement, pursuant to which it sold substantially all of the assets of our Canadian radiopharmacies and Gludef manufacturing and distribution business to one of our existing Canadian radiopharmacy customers. The purchase price for the asset sale was $9.0 million in cash, resulting in a pre-tax book gain of $5.9 million, which was recorded within operating income for the six months ended June 30, 2016.

Other Expense, Net

 

     Three Months
Ended June 30,
     Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

Interest expense

   $ (6,983    $ (13,882    $ (14,007    $ (24,512

Interest income

     5         6         11         13   

Loss on extinguishment of debt

     —           (15,528      —           (15,528

Other income, net

     396         800         454         417   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Other Expense, net

   $ (6,582    $ (28,604    $ (13,542    $ (39,610
  

 

 

    

 

 

    

 

 

    

 

 

 

Interest Expense

For the three and six months ended June 30, 2016, compared to the same periods in 2015, interest expense decreased by $6.9 million and $10.5 million, respectively, as a result of the June 2015 refinancing of our long-term debt at a lower principal amount with a lower interest rate.

Interest Income

For the three and six months ended June 30, 2016, compared to the same periods in 2015, interest income remained consistent.

 

27


Table of Contents

Extinguishment of Debt

For the three and six months ended June 30, 2015, we incurred a $15.5 million loss on extinguishment of debt related to the redemption of LMI’s Notes.

Other Income, net

For the three month period ended June 30, 2016, compared to the same period in 2015, other income decreased by $0.4 million, primarily due to a $0.6 million decrease in tax indemnification income, which was partially offset by a $0.2 million increase in foreign currency gains.

For the six months ended June 30, 2016, compared to the same period in 2015, other income remained consistent.

Provision for Income Taxes

 

     Three Months
Ended June 30,
     Six Months
Ended June 30,
 

(in thousands)

   2016      2015      2016      2015  

Provision for income taxes

   $ 247       $ 1,175       $ 637       $ 1,172   

Considering our history of losses, we continue to maintain a valuation allowance against substantially all of our net deferred tax assets. Our provision for income taxes results primarily from reversals of uncertain tax positions as statutes lapse or are settled during the year, offset by taxes due in certain foreign jurisdictions where we generate taxable income, as well as interest and penalties associated with uncertain tax positions. For the six months ended June 30, 2016 and 2015, our effective tax rate was 3.5% and 5.1%, respectively. The $0.9 million and $0.5 million decrease in the tax provision for the three months and six months ended June 30, 2016, as compared to the same periods in 2015, was primarily due to changes in our uncertain tax positions relating to state tax nexus.

Liquidity and Capital Resources

Cash Flows

The following table provides information regarding our cash flows:

 

     Six Months Ended June 30,  

(in thousands)

   2016      2015      $ Change  

Cash provided by (used in):

        

Operating activities

   $ 21,415       $ 3,719       $ 17,696   

Investing activities

   $ 6,686       $ (6,112    $ 12,798   

Financing activities

   $ (1,872    $ 5,055       $ (6,927

Net Cash Provided by Operating Activities

Cash provided from operating activities of $21.4 million in the first six months of 2016 was driven primarily by net income of $17.7 million plus $9.4 million of depreciation and amortization less the gain on sale of assets of $5.9 million. These net sources of cash were partially offset by a net increase in working capital. Our working capital increase during the first six months of 2016 was driven primarily by higher accounts receivable and lower accrued expenses and other liabilities, partially offset by higher accounts payable.

Cash provided by operating activities of $3.7 million in the first six months of 2015 was driven primarily by $12.6 million of depreciation and amortization and $15.5 million on the loss on extinguishment of debt, as well as a net increase in working capital. Our net working capital increased during the first six months of 2015 due to lower accrued expenses and liabilities from the payment of interest on our Notes through the redemption date (July 30, 2015) partially offset by lower accounts receivable due to improved cash collections. These sources of cash were partially offset by a net loss of $24.0 million.

Net Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities during the six months ended June 30, 2016 was primarily due to cash proceeds of $9.0 million received for the sale of assets from our Canadian radiopharmacies, which was offset by $2.4 million for the purchase of capital expenditures

 

28


Table of Contents

Net cash used in investing activities during the six month ended June 30, 2015 was $6.1 million for the purchase of capital expenditures.

Net Cash (Used in) Provided by Financing Activities

Net cash used in financing activities during the six months ended June 30, 2016 was $1.9 million primarily for our quarterly Term Facility payments.

During the six months ended June 30, 2015, our financing activities provided a source of cash of $5.1 million as a result of generating $423.4 million from the net proceeds of the Term Facility together with the net proceeds from the IPO. The net proceeds generated from the Term Facility and the IPO were used to repay in full the aggregate principal amount of the $400.0 million Notes, pay related premiums and expenses and pay down the $8.0 million of outstanding borrowings under the Revolving Facility, which totaled $417.8 million.

External Sources of Liquidity

On June 30, 2015, we completed our initial public offering, entered into a new $365.0 million seven-year Term Facility and amended and restated our Revolving Facility that has a borrowing capacity of $50.0 million. The net proceeds of the Term Facility and the initial public offering together with available cash were used to repay in full the aggregate principal amount of the $400.0 million Notes, and pay related premiums, interest and expenses and pay down $8.0 million of borrowings under the Revolving Facility.

We have the right to request an increase of the Term Facility in an aggregate amount up to $37.5 million plus additional amounts subject to certain leverage ratios. The term loans under the Term Facility bear interest, with pricing based from time to time at our election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. Interest under term loans based on (i) the LIBOR rate is payable at the end of each interest period (as defined in our Term Facility) and (ii) the Base Rate is payable at the end of each quarter. At June 30, 2016, our interest rate under the Term Facility was 7.00%. Our Term Facility is guaranteed by the Lantheus Holdings and Lantheus Real Estate, and obligations under the Term Facility are secured by substantially all the property and assets and all interests of Lantheus Holdings, LMI and Lantheus Real Estate.

Our Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect our ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, we may be limited in utilizing our net Borrowing Base availability as a source of liquidity. Our Term Facility requires us to be in quarterly compliance, measured on a trailing four quarter basis. The financial covenants are displayed in the table below:

Term Facility Financial Covenants

 

Period

   Total Net Leverage Ratio  

Q2 2016 to Q4 2016

     6.00 to 1.00   

Q1 2017 to Q2 2017

     5.50 to 1.00   

Thereafter

     5.00 to 1.00   

The Term Facility contains usual and customary restrictions on the ability of us and our subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with our affiliates.

As of June 30, 2016, we had an unfunded Standby Letter of Credit of $8.8 million. The unfunded Standby Letter of Credit requires annual fees, payable quarterly, which, subsequent to the amendment, is set at LIBOR plus a spread of 2.00% and expires in February 2017. It automatically renewed for a one year period and will continue to automatically renew for a one year period at each anniversary date, unless we elect not to renew in writing within 60 days prior to such expiration.

Our Revolving Facility is secured by a pledge of substantially all of our assets, including accounts receivable, inventory and machinery and equipment, and is guaranteed by each of Lantheus Holdings and Lantheus Real Estate. Borrowing capacity is

 

29


Table of Contents

determined by reference to the Borrowing Base, which is based on (i) a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus (ii) any reserves. As of June 30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by an outstanding $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net borrowing base availability of approximately $34.4 million.

The loans under our Revolving Facility bear interest with pricing based from time to time at our election at (i) LIBOR plus a spread of 2.00% or (ii) the Reference Rate (as defined in our Revolving Facility) plus a spread of 1.00%. Our Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020.

Our Revolving Facility contains affirmative and negative covenants, as well as restrictions on the ability of LMI, us and our subsidiaries to: (i) incur additional indebtedness or issue preferred stock; (ii) repay subordinated indebtedness prior to its stated maturity; (iii) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (iv) make certain investments; (v) sell certain assets; (vi) create liens; (vii) consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; and (viii) enter into certain transactions with our affiliates. Our Revolving Facility also contains customary default provisions as well as cash dominion provisions which allow the lender to sweep our accounts during the period (x) certain specified events of default are continuing under our Revolving Facility or (y) excess availability under our Revolving Facility falls below (i) the greater of $7.5 million or 15% of the then-current Line Cap (as defined in the Revolving Facility) for a period of more than five consecutive Business Days or (ii) $5.0 million. During a covenant trigger period, we are required to comply with a consolidated fixed charge coverage ratio of not less than 1:00: 1:00. The fixed charge coverage ratio is calculated on a consolidated basis for us for a trailing four-fiscal quarter period basis, as (i) annualized EBITDA (as defined in the Revolving Facility) minus capital expenditures minus certain restricted payments divided by (ii) interest expense plus taxes paid or payable in cash plus certain restricted payments made in cash plus scheduled principal payments paid or payable in cash.

Our ability to fund our future capital needs will be affected by our ability to continue to generate cash from operations and may be affected by our ability to access the capital markets, money markets, or other sources of funding, as well as the capacity and terms of our financing arrangements.

We may from time to time repurchase or otherwise retire our debt and take other steps to reduce our debt or otherwise improve our balance sheet. These actions may include open market repurchases of any notes outstanding, prepayments of our term loans or other retirements or refinancing of outstanding debt, privately negotiated transactions or otherwise. The amount of debt that may be repurchased or otherwise retired, if any, would be decided at the sole discretion of our Board of Directors and will depend on market conditions, trading levels of our debt from time to time, our cash position and other considerations.

Funding Requirements

Our future capital requirements will depend on many factors, including:

 

    our ability to have product manufactured and released from JHS and other manufacturing sites in a timely manner in the future;

 

    the pricing environment and the level of product sales of our currently marketed products, particularly DEFINITY and any additional products that we may market in the future;

 

    revenue mix shifts and associated volume and selling price changes that could result from contractual status changes with key customers and additional competition;

 

    the costs of further commercialization of our existing products, particularly in international markets, including product marketing, sales and distribution and whether we obtain local partners to help share such commercialization costs;

 

    the costs of investing in our facilities, equipment and technology infrastructure;

 

    the costs and timing of establishing manufacturing and supply arrangements for commercial supplies of our products;

 

    the extent to which we acquire or invest in products, businesses and technologies;

 

    the extent to which we choose to establish collaboration, co- promotion, distribution or other similar arrangements for our marketed products;

 

    the legal costs relating to maintaining, expanding and enforcing our intellectual property portfolio, pursuing insurance or other claims and defending against product liability, regulatory compliance or other claims; and

 

    the cost of interest on any additional borrowings which we may incur under our financing arrangements.

 

30


Table of Contents

Until we successfully become dual sourced for our principal products, we are vulnerable to future supply shortages. Disruption in the financial performance could also occur if we experience significant adverse changes in customer mix, broad economic downturns, adverse industry or company conditions or catastrophic external events. If we experience one or more of these events in the future, we may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

If our capital resources become insufficient to meet our future capital requirements, we would need to finance our cash needs through public or private equity offerings, assets securitizations, debt financings, sale-leasebacks or other financing or strategic alternatives, to the extent such transactions are permissible under the covenants of the agreements governing our senior secured credit facilities. Additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all. If any of these transactions require an amendment or waiver under the covenants in the agreements governing our senior secured credit facilities, which could result in additional expenses associated with obtaining the amendment or waiver, we will seek to obtain such a waiver to remain in compliance with those covenants. However, we cannot be assured that such an amendment or waiver would be granted, or that additional capital will be available on acceptable terms, if at all.

At June 30, 2016, our only current committed external source of funds is our borrowing availability under our Revolving Facility. We had $54.9 million of cash and cash equivalents at June 30, 2016. Availability under our Revolving Facility is calculated by reference to the Borrowing Base. If we are not successful in achieving our forecasted results, our accounts receivable and inventory could be negatively affected, reducing the Borrowing Base and limiting our borrowing availability. Our new Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect our ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, we may be limited in utilizing our net Borrowing Base availability as a source of liquidity.

Based on our current operating plans, we believe that our existing cash and cash equivalents, results of operations and availability under our Revolving Facility will be sufficient to continue to fund our liquidity requirements for at least the next twelve months.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial position and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition and related allowances, inventory, impairments of long-lived assets including intangible assets, impairments of goodwill, income taxes including the valuation allowance for deferred tax assets. Actual results may differ materially from these estimates under different assumptions and conditions. In addition, our reported financial condition and results of operations could vary due to a change in the application of a particular accounting standard.

There have been no material changes to our critical accounting policies or in the underlying accounting assumptions and estimates used in such policies as of June 30, 2016. For further information, refer to our summary of significant accounting policies and estimates in our annual report on Form 10-K filed for the fiscal year ended December 31, 2015.

Off-Balance Sheet Arrangements

We are required to provide the U.S. Nuclear Regulatory Commission, or NRC, and Massachusetts Department of Public Health financial assurance demonstrating our ability to fund the decommissioning of our North Billerica, Massachusetts production facility upon closure, though we do not intend to close the facility. We have provided this financial assurance in the form of a $28.2 million surety bond and an $8.8 million letter of credit.

Since inception, we have not engaged in any other off-balance sheet arrangements, including structured finance, special purpose entities or variable interest entities.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in interest rates and foreign currency exchange rates. We do not hold or issue financial instruments to reduce these risks or for trading purposes.

 

31


Table of Contents

Interest Rate Risk

As a result of our new Term Facility, we have substantial variable rate debt. Fluctuations in interest rates may affect our business, financial condition, results of operations and cash flows. As of June 30, 2016, we had $361.4 million outstanding under our Term Facility with a variable interest rate that only varies to the extent LIBOR exceeds one percent.

Furthermore, we are subject to interest rate risk in connection with the Revolving Facility, which is variable rate indebtedness. Interest rate changes could increase the amount of our interest payments and thus negatively impact our future earnings and cash flows. As of June 30, 2016, there was an $8.8 million unfunded Standby Letter of Credit and $0.1 million accrued interest, which reduced availability to $34.4 million on the Revolving Facility. Any increase in the interest rate under the Revolving Facility may have a negative impact on our future earnings to the extent we have outstanding borrowings under the Revolving Facility. The effect of a 100 basis points adverse change in market interest rates, in excess of minimum floors, on our interest expense would be approximately $1.8 million in the six months ended June 30, 2016.

Historically, we have not used derivative financial instruments or other financial instruments to hedge such economic exposures.

Foreign Currency Risk

We face exposure to movements in foreign currency exchange rates whenever we, or any of our subsidiaries, enter into transactions with third parties that are denominated in currencies other than ours, or that subsidiary’s, functional currency. Intercompany transactions between entities that use different functional currencies also expose us to foreign currency risk.

During the six months ended June 30, 2016 and 2015, the net impact of foreign currency changes on transactions was a gain of $19,000 and a loss $0.4 million, respectively. Historically, we have not used derivative financial instruments or other financial instruments to hedge these economic exposures.

A portion of our earnings is generated by our foreign subsidiaries, whose functional currencies are other than the U.S. Dollar. Our earnings could be materially impacted by movements in foreign currency exchange rates upon the translation of the earnings of those subsidiaries into the U.S. Dollar. The Canadian Dollar presents the primary currency risk on our earnings. The cost of goods for our products that are manufactured in the United States and are sold in currencies other than the U.S. Dollar by our foreign subsidiaries are also affected by foreign currency exchange rate movements. Our cost of goods would have increased by $1.2 million if the U.S. Dollar had been stronger by 10% when compared to the actual rates used during the six months ended June 30, 2016.

If the U.S. Dollar had been uniformly stronger by 10%, compared to the actual average exchange rates, our revenues would have decreased by $1.5 million and our net income would have decreased by $1.2 million for the six months ended June 30, 2016.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) or 15d-15(e) promulgated under the Exchange Act. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control Over Financial Reporting

There have been no changes during the quarter ended June 30, 2016 in our internal control over financial reporting (as defined in Rule 13a-15(f) promulgated under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations.

 

32


Table of Contents

On December 16, 2010, LMI filed suit against one of its insurance carriers seeking to recover business interruption losses associated with the NRU reactor shutdown and the ensuing global Moly supply shortage. The claim is the result of the shutdown of the NRU reactor in Chalk River, Ontario. The NRU reactor was off-line from May 2009 until August 2010. The defendant answered the complaint on January 21, 2011, denying substantially all of the allegations, presenting certain defenses and requesting dismissal of the case with costs and disbursements. Discovery, including international discovery and related motion practice, has been on-going for more than three years. The defendant filed a motion for summary judgment on July 14, 2014. The Company filed a memorandum of law in opposition to defendant’s motion for summary judgment on August 25, 2014. The defendant filed a reply memorandum of law in further support of its motion for summary judgment on September 15, 2014. Expert witness discovery was completed on October 31, 2014. On March 25, 2015, the United States District Court for the Southern District of New York granted defendant’s motion for summary judgment. On September 4, 2015, the Company filed an appeal of the District Court decision with the United States Court of Appeals for the Second Circuit. On December 4, 2015, the defendant filed an answer brief to the Company’s appeal, and on December 18, 2015, the Company filed a reply brief to the defendant’s answer. On April 21, 2016, the United States Court of Appeals for the Second Circuit heard oral arguments of the Company and defendant in connection with the Company’s appeal. On May 25, 2016, the United States Court of Appeals for the Second Circuit issued a Summary Order affirming the judgment of the United States District Court which granted the defendant’s motion for summary judgment. The Company considers this matter now closed.

Except as noted above, as of June 30, 2016, the Company had no material ongoing litigation in which the Company was a defendant or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

Item 1A. Risk Factors

There have been no material changes in the risk factors set forth in our Form 10-K for the fiscal year ended December 31, 2015 except as set forth below. For further information, refer to “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Our dependence upon third parties for the manufacture and supply of a substantial portion of our products could prevent us from delivering our products to our customers in the required quantities, within the required timeframes, or at all, which could result in order cancellations and decreased revenues.

We obtain a substantial portion of our products from third party manufacturers and suppliers. We rely on JHS as our sole source manufacturer of DEFINITY, Neurolite and evacuation vials. We currently have additional ongoing technology transfer activities at JHS for our Cardiolite products and at Pharmalucence for DEFINITY, but we can give no assurances as to when each technology transfer will be completed and when we will actually receive supply of Cardiolite from JHS or DEFINITY from Pharmalucence. Currently, our DEFINITY, Neurolite, evacuation vial, saline and Cardiolite product supply is approved for manufacture by a single manufacturer. In addition, we have no manufacturer for Ablavar.

Currently, we believe that we will have sufficient supply of DEFINITY, Neurolite and evacuation vials from JHS to meet expected demand and sufficient supply of saline from our sole manufacturer. We also believe that we will have sufficient Cardiolite product supply from our current supplier and from JHS to meet expected demand when the technology transfer process is completed and we have obtained regulatory approval for this manufacturing site. However, we can give no assurances that JHS or our other manufacturing partners will be able to manufacture and distribute our products in a high quality and timely manner and in sufficient quantities to allow us to avoid product stock-outs and shortfalls. Currently, regulatory authorities in certain countries have not yet approved JHS as a manufacturer of our products. Accordingly, until those regulatory approvals have been obtained, our international business, results of operations, financial condition and cash flows will continue to be adversely affected.

Our manufacturing agreement for Ablavar has terminated. We have no current plans to initiate technology transfer activities for Ablavar. Our existing Ablavar inventory will expire in the third quarter of 2016, and we will have no further Ablavar inventory that we will be able to sell unless and until we engage in Ablavar technology transfer activities in the future with a new manufacturing partner.

In addition to the products described above, for reasons of quality assurance or cost-effectiveness, we purchase certain components and raw materials from sole suppliers (including, for example, the lead casing for our TechneLite generators, the evacuation vials for our TechneLite generators manufactured by JHS and the lipid blend material used in the processing of

 

33


Table of Contents

DEFINITY). Because we do not control the actual production of many of the products we sell and many of the raw materials and components that make up the products we sell, we may be subject to delays caused by interruption in production based on events and conditions outside of our control. At our North Billerica, Massachusetts facility, we manufacture TechneLite on a relatively new, highly automated production line, as well as Thallium and Gallium using our older cyclotron technology and Xenon using our hot cell infrastructure. As with all manufacturing facilities, equipment and infrastructure age and become subject to increasing maintenance and repair. If we or one of our manufacturing partners experiences an event, including a labor dispute, natural disaster, fire, power outage, machinery breakdown, security problem, failure to meet regulatory requirements, product quality issue, technology transfer issue or other issue, we may be unable to manufacture the relevant products at previous levels or on the forecasted schedule, if at all. Due to the stringent regulations and requirements of the governing regulatory authorities regarding the manufacture of our products, we may not be able to quickly restart manufacturing at a third party or our own facility or establish additional or replacement sources for certain products, components or materials.

In addition to our existing manufacturing relationships, we are also pursuing new manufacturing relationships to establish and secure additional or alternative suppliers for our commercial products. Our technology transfer activities are ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and we cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY. We cannot assure you that any of our additional supply activities will be successful, or that before those new manufacturers or sources of product are fully functional and qualified, that we will be able to avoid or mitigate interim supply shortages. In addition, we cannot assure you that our existing manufacturers or suppliers or any new manufacturers or suppliers can adequately maintain either their financial health or regulatory compliance to allow continued production and supply. A reduction or interruption in manufacturing, or an inability to secure alternative sources of raw materials or components, could eventually have a material adverse effect on our business, results of operations, financial condition and cash flows.

We face potential supply and demand challenges for Xenon.

Historically, Nordion has been our sole supplier, and a principal supplier on a global basis, of Xenon, which is captured as a by-product of the Moly production process. In January 2015, we entered into a strategic agreement with IRE for the supply of Xenon. We are now receiving bulk unprocessed Xenon from IRE, which we are processing and finishing for our customers. We believe we will have a sufficient supply of Xenon for our customers after the NRU reactor transitions in October 2016 from providing regular supply of bulk Xenon to providing only an emergency back-up supply of bulk Xenon through March 2018. However, until we can qualify an additional source of bulk unprocessed Xenon, after the Nordion transition we will rely on IRE as a sole source provider. For the year ended December 31, 2015, Xenon represented approximately 17% of our revenues.

Historically, several companies, including Mallinckrodt, sold packaged Xenon as a pulmonary imaging agent in the U.S., but starting in 2010 we have been the only supplier of this imaging agent in the U.S. In March 2016, Mallinckrodt received regulatory approval from the FDA to again sell packaged Xenon in the U.S. and has begun to do so. Depending upon the pricing, extent of availability and market penetration of Mallinckrodt’s offering, we believe we are at risk for volume loss and price erosion from those customers that are not subject to price or volume commitments with us.

In addition to Mallinckrodt again selling packaged Xenon in the U.S., if there is an increase in the use of other imaging modalities in place of packaged Xenon, our current sales volumes would decrease, which could have a negative effect on our business, results of operations, financial condition and cash flows.

Xenon is frequently administered as part of a ventilation scan to evaluate pulmonary function prior to a perfusion scan with microaggregated albumin, or MAA, a technetium-based radiopharmaceutical used to evaluate blood flow to the lungs. Currently, Draxis is the sole supplier of MAA on a global basis. In 2014, Draxis announced substantial price increases for MAA. The increased price of MAA, or difficulties in obtaining MAA, could decrease the frequency in which MAA is used for lung perfusion evaluation, in turn, decreasing the frequency that Xenon is used for pulmonary function evaluation, resulting in a negative effect on our business, results of operations, financial condition and cash flows.

We face significant competition in our business and may not be able to compete effectively.

The market for diagnostic medical imaging agents is highly competitive and continually evolving. Our principal competitors in existing diagnostic modalities include large, global companies with substantial financial, manufacturing, sales and marketing and logistics resources that are more diversified than ours, such as GE Healthcare, Bracco, Mallinckrodt, Bayer and Draxis, as well as other competitors. We cannot anticipate their actions in the same or competing diagnostic modalities, such as significant price reductions on products that are comparable to our own, development or introduction of new products that are more cost-effective or have superior performance than our current products, the introduction of generic versions when our proprietary products lose their patent protection or the new entry into a generic market in which we are already a participant. In addition, distributors of our products

 

34


Table of Contents

could attempt to shift end-users to competing diagnostic modalities and products. Our current or future products could be rendered obsolete or uneconomical as a result of these activities. Our failure to compete effectively could cause us to lose market share to our competitors and have a material adverse effect on our business, results of operations, financial condition and cash flows.

In October 2014, Bracco received FDA approval in the United States for its echocardiography agent, Lumason (known as SonoVue outside of the U.S.), which is already approved for sale in Europe and certain Asian markets, including China, Japan and Korea. Bracco now has one of three FDA-approved echocardiography contrast agents in the United States, together with GE Healthcare’s Optison and our DEFINITY. If Bracco successfully grows the use of Lumason in the United States without otherwise increasing the overall usage of ultrasound contrast agents, our current and future sales volume could suffer, which would have a material adverse effect on our business, results of operations, financial condition and cash flows.

Xenon for lung ventilation diagnosis is our third largest product by revenue. Historically, several companies, including Mallinckrodt, sold packaged Xenon as a pulmonary imaging agent in the U.S., but starting in 2010 we have been the only supplier of this imaging agent in the U.S. In March 2016, Mallinckrodt received regulatory approval from the FDA to again sell packaged Xenon in the U.S. and has begun to do so. Depending upon the pricing, extent of availability and market penetration of Mallinckrodt’s offering, we believe we are at risk of volume loss and price erosion from those customers that are not subject to price or volume commitments with us.

We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability.

As of December 31, 2015, we had federal income tax loss carryforwards of $175.5 million, which will begin to expire in 2031 and will completely expire in 2034. We have had significant financial losses in previous years and as a result we currently maintain a full valuation allowance for our net deferred tax assets including our federal and state tax loss carryforwards. We may be limited in our ability to use these tax loss carryforwards to reduce our future U.S. federal income tax liabilities if we were to experience an “ownership change” as specified in Section 382 of the Internal Revenue Code including if we were to issue a certain amount of equity securities, certain of our Stockholders were to sell shares of our common stock, or we were to enter into certain strategic transactions.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Unregistered Sales of Equity Securities

None.

Issuer Purchase of Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

 

35


Table of Contents

Item 6. Exhibits

 

         

INCORPORATED BY REFERENCE

EXHIBIT
NUMBER

  

DESCRIPTION OF EXHIBITS

  

FORM

  

FILE
NUMBER

  

EXHIBIT

  

FILING

DATE

  10.1    Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan    8-K    001-36569    10.1    April 28, 2016
  31.1*    Certification of the Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            
  31.2*    Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            
  32.1*    Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002.            
101.INS*    XBRL Instance Document            
101.SCH*    XBRL Taxonomy Extension Schema Document            
101.CAL*    XBRL Taxonomy Extension Calculation Linkbase Document            
101.DEF*    XBRL Taxonomy Extension Definition Linkbase Document            
101.LAB*    XBRL Taxonomy Extension Label Linkbase Document            
101.PRE*    XBRL Taxonomy Extension Presentation Linkbase Document            

 

* Filed herewith

 

36


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

LANTHEUS HOLDINGS, INC.
By:   /s/ MARY ANNE HEINO
Name:   Mary Anne Heino
Title:   President and Chief Executive Officer
Date:   August 4, 2016
LANTHEUS HOLDINGS, INC.
By:   /s/ JOHN CROWLEY
Name:   John Crowley
Title:   Chief Financial Officer
Date:   August 4, 2016

 

37


Table of Contents

EXHIBIT INDEX

 

         

INCORPORATED BY REFERENCE

 

EXHIBIT
NUMBER

  

DESCRIPTION OF EXHIBITS

  

FORM

    

FILE
NUMBER

    

EXHIBIT

    

FILING

DATE

 
  10.1    Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan      8-K         001-36569         10.1         April 28, 2016   
  31.1*    Certification of the Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            
  31.2*    Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            
  32.1*    Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002.            
101.INS*    XBRL Instance Document            
101.SCH*    XBRL Taxonomy Extension Schema Document            
101.CAL*    XBRL Taxonomy Extension Calculation Linkbase Document            
101.DEF*    XBRL Taxonomy Extension Definition Linkbase Document            
101.LAB*    XBRL Taxonomy Extension Label Linkbase Document            
101.PRE*    XBRL Taxonomy Extension Presentation Linkbase Document            

 

* Filed herewith

 

38

EX-31.1 2 d211534dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mary Anne Heino, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Lantheus Holdings, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 4, 2016

 

/s/ MARY ANNE HEINO
Name:   Mary Anne Heino
Title:   President and Chief Executive Officer
EX-31.2 3 d211534dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Crowley, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Lantheus Holdings, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 4, 2016

 

/s/ JOHN CROWLEY
Name:   John Crowley
Title:   Chief Financial Officer
EX-32.1 4 d211534dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned hereby certifies that to his knowledge the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016 of Lantheus Holdings, Inc. (the “Company”) filed with the Securities and Exchange Commission on the date hereof fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 4, 2016

 

/s/ MARY ANNE HEINO
Name:   Mary Anne Heino
Title:   President and Chief Executive Officer

Dated: August 4, 2016

 

/s/ JOHN CROWLEY
Name:   John Crowley
Title:   Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 lnth-20160630.xml XBRL INSTANCE DOCUMENT 30387768 4555277 22200000 4600000 365000000 0.0125 0.09750 400000000 725000 9118000 157317000 0.01 70969000 30385437 30385437 259267000 2688000 3393000 113023000 8121000 250000000 176545000 989000 54851000 1836000 8650000 39457000 303000 2587000 12778000 5850000 1595000 1272000 17664000 -1729000 7062000 0.01 25000000 348838000 139368000 3650000 4282000 0 14433000 1156000 425635000 259267000 17949000 15714000 34055000 34092000 596000 4659000 20038000 2712000 84422000 -166368000 -341487000 0 10 3282000 1200000 2373000 298000 15589000 3 26700000 1 2686000 2686000 6000 100000 43300000 34400000 50000000 8800000 50000000 0.0700 0.50 2686000 2686000 2700000 4882000 69577000 14950000 65982000 3900000 3860000 361350000 365000000 344925000 348838000 352488000 3650000 3650000 3650000 3650000 1825000 3650000 5002000 100997000 90158000 10839000 42780000 41367000 1413000 13540000 7843000 5697000 0 1000000 176545000 303000 30385437 -1729000 -341487000 19739000 490000 10525000 157057000 0.01 67260000 30364501 30364501 242379000 90006000 9137000 250000000 175553000 881000 28596000 8145000 37293000 303000 11657000 1493000 18502000 -1985000 4644000 7506000 0.01 25000000 349858000 136561000 3650000 3851000 0 15622000 1156000 427668000 242379000 20496000 15714000 34141000 35524000 587000 5709000 1715000 20509000 2407000 86517000 -185289000 -359160000 0 2962000 1200000 2085000 360000 16778000 74000 74000 1586000 1586000 10000 26000 806000 430000 791000 29000 4644000 3344000 2512000 480000 1715000 1285000 200000 100000 1660000 74000 1586000 100000 1600000 9099000 68941000 14950000 60787000 100737000 88564000 12173000 42780000 41063000 1717000 13540000 6934000 6606000 0 175553000 303000 30364501 -1985000 -359160000 15000 730000 435000 760000 28000 4615000 3365000 2620000 462000 1293000 858000 1 6500000 0.0550 2461000 -1.30 24567000 -201000 12573000 7700000 -24422000 3000000 79701000 -360000 9752000 148137000 27741000 417000 -6715000 68436000 368000 -22876000 -6112000 5315000 467000 -4258000 -15528000 108000 -24048000 474000 16734000 5055000 6112000 73000 -374000 1172000 3719000 -1457000 -24499000 18489451 400000000 73539000 18489451 8834000 360438000 563000 18301000 8000000 933000 37000 5255000 777000 0 51702000 0.804 2153827 -11432000 28000 159569000 16706000 29092000 585000 130477000 16121000 37500000 51000 679000 88000 115000 7000000 29092000 119045000 100000 LANTHEUS HOLDINGS, INC. 39000 10-Q 0001521036 466000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>11.&#xA0;Financing Arrangements</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Term Facility</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On June&#xA0;30, 2015, the Company entered into a $365.0 million seven-year Term Facility, which was issued net of a 1.25% discount of $4.6 million. The Company has a right to request an increase of the Term Facility in an aggregate amount up to $37.5&#xA0;million plus additional amounts subject to certain leverage ratios. The net proceeds of the Term Facility, together with the net proceeds of the initial public offering, or IPO, and cash on hand, were used to refinance in full the aggregate principal amount of the $400.0 million 9.750% Senior Notes (&#x201C;the Notes&#x201D;) and pay related premiums, interest and expenses.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The term loans under the Term Facility bear interest, with pricing based from time to time at the Company&#x2019;s election at (i)&#xA0;LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii)&#xA0;the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. Interest under term loans based on (i)&#xA0;the LIBOR rate is payable at the end of each Interest Period (as defined in our Term Facility) and (ii)&#xA0;the Base Rate is payable at the end of each quarter. At June&#xA0;30, 2016, the Company&#x2019;s interest rate under the Term Facility was 7.00%.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, without premium or penalty. The Company is required to make quarterly payments, which began on September&#xA0;30, 2015, in an amount equal to a quarter of a percent (0.25%) per annum of the original principal amount of the Term Facility.&#xA0;The remaining unpaid principal amount of the Term Facility will be payable on the maturity date, or June&#xA0;30, 2022.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Term Facility will require the Company to prepay outstanding term loans, subject to certain exceptions, with:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">100% of the net cash proceeds of all non-ordinary course sales or other dispositions of assets (including as a result of casualty or condemnation, subject to certain exceptions); the Company may reinvest or commit to reinvest certain of those proceeds in assets useful in our business within twelve months;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">100% of the net cash proceeds from issuances or incurrence of debt, other than proceeds from debt permitted under the Term Facility and Revolving Facility; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">50% (with two leverage-based stepdowns) of the Company&#x2019;s excess cash flow.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The foregoing mandatory prepayments will be applied to the scheduled installments of principal of the Term Facility as directed by LMI, or in the absence of direction, in direct order of maturity.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Term Facility is guaranteed by the Company and Lantheus Real Estate, and obligations under the Term Facility are secured by substantially all the property and assets and all interests of the Company, LMI and Lantheus Real Estate.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s maturities of principal obligations under the Term Facility are as follows as of June&#xA0;30, 2016:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Remainder of 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,825</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2021 and thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">344,925</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total debt</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">361,350</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unamortized debt discount</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,860</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unamortized debt issuance costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,002</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">352,488</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less current portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,650</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total long-term debt</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">348,838</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Term Facility Covenants</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Term Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis. The financial covenants are displayed in the table below:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 24pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center"><b>Term Facility Financial Covenants</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 22.65pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>Period</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"> <b>Total&#xA0;Net&#xA0;Leverage&#xA0;Ratio</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Q2 2016 to Q4 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.00&#xA0;to&#xA0;1.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Q1 2017 to Q2 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.50 to 1.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.00 to 1.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Term Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i)&#xA0;incur additional indebtedness (ii)&#xA0;create liens; (iii)&#xA0;consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv)&#xA0;sell certain assets; (v)&#xA0;pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi)&#xA0;make certain investments; (vii)&#xA0;repay subordinated indebtedness prior to stated maturity; and (viii)&#xA0;enter into certain transactions with its affiliates.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Revolving Line of Credit</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> At June&#xA0;30, 2016, the Company has a Revolving Facility with an aggregate principal amount not to exceed $50.0&#xA0;million. The loans under the Revolving Facility bear interest with pricing based from time to time at the election of LMI at (i)&#xA0;LIBOR plus a spread of 2.00% or (ii)&#xA0;the Reference Rate (as defined in the Revolving Facility) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June&#xA0;30, 2020.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> As of June&#xA0;30, 2016, the Company has an unfunded Standby Letter of Credit for up to $8.8 million. The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires in February 2017. It automatically renewed for a one year period and will continue to automatically renew for a one year period at each anniversary date, unless the Company elects not to renew in writing within 60 days prior to such expiration.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Revolving Facility is guaranteed by Holdings and Lantheus Real Estate and is secured by a pledge of substantially all of the assets of each of the loan parties including accounts receivable, inventory and machinery and equipment. Borrowing capacity is determined by reference to a Borrowing Base, which is based on a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves. As of June&#xA0;30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by an outstanding $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $34.4 million.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Revolving Line of Credit Covenants</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Revolving Facility contains a number of affirmative, negative, reporting and financial covenants, as well as a financial covenant during trigger periods in the form of a consolidated fixed charge coverage ratio of not less than 1:00:1:00. Upon an event of default, the lender has the right to declare the loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced, and the lender may, after such events of default, require the Company to make deposits with respect to any outstanding letters of credit in an amount equal to 105% of the greatest amount for which such letter of credit may be drawn.</p> </div> 992000 2016-06-30 26255000 0.58 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 30px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Basis of Consolidation and Presentation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company&#x2019;s financial statements for interim periods in accordance with U.S.&#xA0;GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S.&#xA0;GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this quarterly report should be read in conjunction with the Company&#x2019;s consolidated financial statements and the accompanying notes for the year ended December&#xA0;31, 2015 included in the Company&#x2019;s Form 10-K filed with the SEC on March&#xA0;2, 2016. The Company&#x2019;s accounting policies are described in the &#x201C;Notes to Consolidated Financial Statements&#x201D; in the Form 10-K and updated, as necessary, in this quarterly report. There were no changes to the Company&#x2019;s accounting policies since December&#xA0;31, 2015. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S.&#xA0;GAAP. The results of operations for the three and six months ended June&#xA0;30, 2016 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply, which is currently approved for manufacture by a single manufacturer. The Company has technology transfer activities ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and the Company cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company&#x2019;s ability to maintain and profitably renew those contracts and relationships with those key customers and group purchasing organizations is an important aspect of the Company&#x2019;s strategy.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Borrowing capacity under the $50.0 million revolving credit facility, or the Revolving Facility, is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted operating results, the Company&#x2019;s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company&#x2019;s borrowing capacity. As of June 30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $34.4 million. The Company&#x2019;s $365.0 million senior secured term loan facility, or the Term Facility, contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect the Company&#x2019;s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Based on the Company&#x2019;s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company&#x2019;s liquidity requirements for at least the next twelve months.</p> </div> One vote per share 2016 false --12-31 18751000 26000 9358000 4100000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>13.&#xA0;Stock-Based Compensation</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> As of June&#xA0;24, 2015, the Company adopted the 2015 Equity Incentive Plan, (the &#x201C;2015 Plan&#x201D;).</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s employees are eligible to receive awards under the 2015 Plan. The 2015 Plan is administered by the Board of Directors and permits the granting of stock options, stock appreciation rights, or SARs, restricted stock, restricted stock units and dividend equivalent rights (&#x201C;DERs&#x201D;) to employees, officers, directors and consultants of the Company. The Board of Directors may, at its sole discretion, grant DERs with respect to any award and such DER is treated as a separate award. The number of shares authorized for issuance under the 2015 Plan increased to 4,555,277 on April&#xA0;26, 2016. Option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company&#x2019;s common stock at the date of grant. Time based option awards vest based on time, typically four years, and performance based option awards vest based on the performance criteria specified in the grant. All option awards have a ten-year contractual term. The Company recognizes compensation costs for its time based awards on a straight-line basis equal to the vesting period. The compensation cost for performance based awards is recognized on a graded vesting basis, based on the probability of achieving the performance targets over the requisite service period for the entire award. The fair value of each option award is estimated on the date of grant using a Black-Scholes valuation model. Expected volatilities are based on the historic volatility of a selected peer group. Expected dividends represent the dividends expected to be issued at the date of grant. The expected term of options represents the period of time that options granted are expected to be outstanding. The risk-free interest rate assumption is the U.S. Treasury rate at the date of the grant which most closely resembles the expected life of the options.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Stock-based compensation expense for both time based and performance based stock options and restricted stock awards were recognized in the condensed consolidated statements of operations as follows:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months<br /> Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six Months<br /> Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cost of goods sold</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">73</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">52</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">139</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">51</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> General and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">345</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">465</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">578</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">679</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Sales and marketing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">128</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">115</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">87</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">147</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total stock-based compensation expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">585</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">656</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">933</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> Q2 17929000 Non-accelerated Filer 2600000 84988000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>3.&#xA0;Fair Value of Financial Instruments</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The tables below present information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of June&#xA0;30, 2016 and December&#xA0;31, 2015, and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level&#xA0;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level&#xA0;2 inputs utilize data points from active markets that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level&#xA0;3 inputs utilize unobservable data points for the asset or liability.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="54%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 48.6pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total&#xA0;fair<br /> value at<br /> June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices<br /> in active<br /> markets<br /> (Level&#xA0;1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable<br /> inputs<br /> (Level&#xA0;2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable<br /> inputs<br /> (Level&#xA0;3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Money market</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,686</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,686</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,686</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,686</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 48.6pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total fair<br /> value at<br /> December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices<br /> in active<br /> markets<br /> (Level&#xA0;1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable<br /> inputs<br /> (Level&#xA0;2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable<br /> inputs<br /> (Level&#xA0;3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Money market</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Certificates of deposit&#x2014;restricted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,660</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> At December&#xA0;31, 2015, the Company had a $0.1&#xA0;million certificate of deposit, which was collateral for a long-term lease and was included in other long-term assets on the condensed consolidated balance sheet. In January 2016, the certificate of deposit was redeemed. Certificates of deposit are classified within Level&#xA0;2 of the fair value hierarchy, as these are not traded on the open market.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> At June&#xA0;30, 2016, the Company had total cash and cash equivalents of $54.9&#xA0;million, which included approximately $2.7&#xA0;million of money market funds. At December&#xA0;31, 2015, the Company had total cash and cash equivalents of $28.6&#xA0;million, which included approximately $1.6 million of money market funds.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The estimated fair values of the Company&#x2019;s financial instruments, including its cash and cash equivalents, receivables, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The estimated fair value of the Company&#x2019;s Term Facility at both June&#xA0;30, 2016 and December&#xA0;31, 2015, approximated the carrying value because the interest rate is subject to change with market interest rates.</p> </div> 19000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Goodwill</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October&#xA0;31 of each year. There were no events as of June&#xA0;30, 2016 and December&#xA0;31, 2015 that triggered an interim impairment test of goodwill.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>14.&#xA0;Net Income (Loss) Per Share</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> June 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six Months Ended<br /> June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 175.4pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands, except share and per share amounts)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income (loss)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,350</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(24,423</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(24,048</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted average common shares outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,377,562</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,898,003</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,372,901</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,489,451</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Effect of dilutive restricted stock awards</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">165,166</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80,875</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Diluted weighted average common shares outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,542,728</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,898,003</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,453,776</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,489,451</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic and diluted income (loss) per weighted average common share outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.24</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.29</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.58</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.30</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The weighted average number of common shares for the three and six months ended June&#xA0;30, 2016 did not include 2,183,075 options and unvested restricted stock for each period because of their antidilutive effect, as compared to the three and six months ended June 30, 2015, which did not include 2,153,827 options and unvested restricted stock for each period.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>8. Asset Retirement Obligations</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company considers the legal obligation to remediate its facilities upon a decommissioning of its radioactive related operations as an asset retirement obligation. The operations of the Company have radioactive production facilities at its North Billerica, Massachusetts and San Juan, Puerto Rico sites.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company&#x2019;s ability to fund the decommissioning of the North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond, which itself is currently secured by an $8.8 million unfunded Standby Letter of Credit provided to the third party issuer of the bond.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. As of June&#xA0;30, 2016, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.7 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying value of the related long-lived assets and depreciated over the asset&#x2019;s useful life.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The following is a reconciliation of the Company&#x2019;s asset retirement obligations for the six months ended June&#xA0;30, 2016:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 48.6pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,145</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net increase due to changes in estimated future cash flows</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">39</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accretion expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">466</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at June&#xA0;30, 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 154440000 12790000 74000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>6.&#xA0;Inventory</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Inventory, classified in inventory or other long-term assets, consisted of the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,062</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,506</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Work in process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,712</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,407</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,659</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,709</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Inventory</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,433</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,622</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other long-term assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,156</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,156</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,589</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,778</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> At both June&#xA0;30, 2016 and December&#xA0;31, 2015, inventories reported as other long-term assets included $1.2&#xA0;million of raw materials.</p> </div> 454000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The tables below present information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of June&#xA0;30, 2016 and December&#xA0;31, 2015,&#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="54%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 48.6pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total&#xA0;fair<br /> value at<br /> June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices<br /> in active<br /> markets<br /> (Level&#xA0;1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable<br /> inputs<br /> (Level&#xA0;2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable<br /> inputs<br /> (Level&#xA0;3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Money market</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,686</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,686</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,686</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,686</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 48.6pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total fair<br /> value at<br /> December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;prices<br /> in active<br /> markets<br /> (Level&#xA0;1)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;other<br /> observable<br /> inputs<br /> (Level&#xA0;2)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant<br /> unobservable<br /> inputs<br /> (Level&#xA0;3)</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Money market</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Certificates of deposit&#x2014;restricted</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,660</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,586</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> -1982000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>9.&#xA0;Intangibles, net</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Intangibles, net consisted of the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>June&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortization<br /> Method</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Trademarks</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,540</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,843</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,697</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">Straight-line</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100,997</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">90,158</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,839</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Accelerated</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">42,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,367</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Straight-line</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">157,317</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">139,368</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortization<br /> Method</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Trademarks</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,540</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,934</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,606</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">Straight-line</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100,737</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">88,564</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,173</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Accelerated</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">42,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,063</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,717</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Straight-line</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">157,057</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">136,561</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,496</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> For the three and six month period ended June&#xA0;30, 2016, the Company recorded amortization expense for its intangible assets of $1.3 million and $2.6&#xA0;million, respectively, as compared to $1.5 million and $3.0&#xA0;million for the prior year comparative periods.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Expected future amortization expense related to the intangible assets is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Remainder of 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,587</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,393</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,688</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,836</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,595</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2021 and thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,850</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>7.&#xA0;Property, Plant and Equipment, net</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Property, plant and equipment consisted of the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Land</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,950</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,950</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Buildings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69,577</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68,941</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Machinery, equipment and fixtures</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,982</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">60,787</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Construction in progress</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,882</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,099</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accumulated depreciation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(70,969</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(67,260</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property, plant and equipment, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">84,422</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">86,517</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> For the three and six month period ended June&#xA0;30, 2016, depreciation expense related to property, plant and equipment was $2.2 million and $4.1&#xA0;million, respectively, as compared to $2.0 million and $7.7&#xA0;million for the prior year comparative periods.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Fixed assets dedicated to research and development, or R&amp;D, activities, which were impacted by the March 2013 R&amp;D strategic shift, have a carrying value of $3.9 million as of June&#xA0;30, 2016. The Company believes these fixed assets will be utilized for either internally funded ongoing R&amp;D activities or R&amp;D activities funded by a strategic partner. If the Company is not successful in finding a strategic partner and there are no alternative uses for these fixed assets, then they could be subject to impairment in the future.</p> </div> 5945000 69452000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>4.&#xA0;Income Taxes</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year in addition to discrete events which impact the interim period. The Company&#x2019;s effective tax rate differs from the U.S. statutory rate principally due to the rate impact of uncertain tax positions, valuation allowance changes and state taxes. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective rate is determined. The Company&#x2019;s tax provision was $0.2&#xA0;million and $0.6 million for the three and six months ended June&#xA0;30, 2016, respectively, compared to a tax provision of $1.2&#xA0;million for the three and six months ended June&#xA0;30, 2015.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In connection with the Company&#x2019;s acquisition of the medical imaging business from Bristol-Myers Squibb, or BMS, in 2008, the Company obtained a tax indemnification agreement with BMS related to certain tax obligations arising prior to the acquisition of the Company, for which the Company has the primary legal obligation. The tax indemnification receivable is recognized within other noncurrent assets. The changes in the tax indemnification asset are recognized within other income (expense), net in the condensed consolidated statement of operations. In accordance with the Company&#x2019;s accounting policy, the change in the tax liability and penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within the tax provision. Accordingly, as these reserves change, adjustments are included in the tax provision while the offsetting adjustment is included in other income (expense), net. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there is no net effect on earnings related to these liabilities and no net cash outflows.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> During the first quarter of 2016, the Company early adopted ASU No. 2015-17, <i>Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</i> on a retrospective basis.&#xA0;This standard requires all deferred taxes and liabilities, and any related valuation allowances, to be classified as non-current on the balance sheet.&#xA0;Adoption of this standard resulted in the reclassification of $0.1 million of current deferred tax assets to noncurrent deferred tax assets and $0.2 million of current deferred tax liabilities to noncurrent deferred tax liabilities on the balance sheet at December 31, 2015.</p> </div> -393000 256000 18310000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Inventory</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. There was no significant product expensed for the six months ended June&#xA0;30, 2016 and 2015. At June&#xA0;30, 2016 and December&#xA0;31, 2015, the Company had no capitalized inventories associated with product that did not have regulatory approval.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company includes within current assets the amount of inventory that is estimated to be utilized within twelve months. Inventory that will be utilized after twelve months is classified within other long-term assets.</p> </div> 6686000 11000 818000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Property, plant and equipment consisted of the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Land</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,950</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,950</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Buildings</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">69,577</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">68,941</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Machinery, equipment and fixtures</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,982</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">60,787</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Construction in progress</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,882</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,099</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accumulated depreciation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(70,969</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(67,260</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property, plant and equipment, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">84,422</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">86,517</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 2009000 9000000 1474000 17673000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 30px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Recent Accounting Pronouncements</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In March 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-09,&#xA0;<i>Compensation &#x2013; Stock Compensation (Topic 719), Improvements to Employee Share-Based Payment Accounting</i>.&#xA0;ASU 2016-09 simplifies several aspects of accounting for employee share-based payment transactions, including the accounting for income tax consequences, the classification of awards as either equity or liabilities, an accounting policy election for forfeitures, statutory tax withholding requirements and certain classifications on the statement of cash flows.&#xA0;ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods.&#xA0;Early adoption is permitted.&#xA0;The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In February 2016, the FASB, issued ASU 2016-02,&#xA0;<i>Leases (Topic 842)</i>, or ASU 2016-02. ASU 2016-02 supersedes the existing guidance for lease accounting,&#xA0;<i>Leases (Topic 840)</i>. ASU 2016-02 was issued to increase transparency and comparability among organizations by requiring lessees to recognize all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). The accounting for lessors remains largely unchanged. ASU 2016-02 retains a distinction between finance leases and operating leases. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize a lease liability and right-of-use asset. ASU 2016-02 is effective for fiscal years beginning after December&#xA0;15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In May 2014, the FASB issued ASU 2014-09,&#xA0;<i>Revenue from Contracts with Customers (Topic 606</i>) or ASU 2014-09. ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Subsequent to issuing ASU 2014-09, the FASB issued the following amendments concerning the adoption and clarification of ASU 2014-09.&#xA0;In August 2015, the FASB issued ASU 2015-14,&#xA0;<i>Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date</i>, which defers the effective date of ASU 2014-09 to annual reporting periods beginning after December&#xA0;15, 2017 with early adoption permitted as of its original effective date of December&#xA0;15, 2016. In March 2016, the FASB issued ASU 2016-08,&#xA0;<i>Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net),</i>&#xA0;which further clarifies the implementation guidance on principal versus agent considerations. The new guidance requires either a retrospective or a modified retrospective approach to adoption. In April 2016, the FASB issued ASU 2016-10,&#xA0;<i>Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing</i>, which clarifies the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas.&#xA0;In May 2016, the FASB issued ASU 2016-12,&#xA0;<i>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&#xA0;</i>or ASU 2016-12, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for noncash consideration and completed contracts at transition.&#xA0;The Company is currently evaluating the impact these ASUs will have on our financial position, results of operations, cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In August 2014, the FASB issued ASU 2014-15,&#xA0;<i>Presentation of Financial Statements-Going Concern (Subtopic 205-4): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</i>&#xA0;or ASU 2014-15. ASU 2014-15 provides guidance on management&#x2019;s responsibility in evaluating whether there is substantial doubt about a company&#x2019;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December&#xA0;15, 2016. Early adoption is permitted. The Company does not anticipate this ASU will have a material impact to the Company&#x2019;s financial position, results of operations, cash flows and disclosures.</p> </div> -525000 31852000 -1872000 2388000 273000 256000 637000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>16.&#xA0;Legal Proceedings and Contingencies</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. As of June&#xA0;30, 2016, the Company had no material ongoing litigation in which the Company was a defendant or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On December&#xA0;16, 2010, LMI filed suit against one of its insurance carriers seeking to recover business interruption losses associated with the NRU reactor shutdown and the ensuing global Moly supply shortage. The claim is the result of the shutdown of the NRU reactor in Chalk River, Ontario. The NRU reactor was off-line from May 2009 until August 2010. The defendant answered the complaint on January&#xA0;21, 2011, denying substantially all of the allegations, presenting certain defenses and requesting dismissal of the case with costs and disbursements. Discovery, including international discovery and related motion practice, has been on-going for more than three years. The defendant filed a motion for summary judgment on July&#xA0;14, 2014. The Company filed a memorandum of law in opposition to defendant&#x2019;s motion for summary judgment on August&#xA0;25, 2014. The defendant filed a reply memorandum of law in further support of its motion for summary judgment on September&#xA0;15, 2014. Expert witness discovery was completed on October&#xA0;31, 2014. On March&#xA0;25, 2015, the United States District Court for the Southern District of New York granted defendant&#x2019;s motion for summary judgment. On September&#xA0;4, 2015, the Company filed an appeal of the District Court decision with the United States Court of Appeals for the Second Circuit. On December&#xA0;4, 2015, the defendant filed an answer brief to the Company&#x2019;s appeal, and on December&#xA0;18, 2015, the Company filed a reply brief to the defendant&#x2019;s answer. On April&#xA0;21, 2016, the United States Court of Appeals for the Second Circuit heard oral arguments of the Company and the defendant in connection with the Company&#x2019;s appeal. On May 25, 2016, the United States Court of Appeals for the Second Circuit issued a Summary Order affirming the judgment of the United States District Court which granted the defendant&#x2019;s motion for summary judgment.&#xA0;The Company considers this matter closed.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>1.&#xA0;Business Overview</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Overview</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company&#x2019;s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers, and technologists working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks and group purchasing organizations. The Company sells its products globally and has operations in the United States, Canada, Puerto Rico and Australia and distribution relationships in Europe, Asia Pacific and Latin America.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s portfolio of 10 commercial products is diversified across a range of imaging modalities. The Company&#x2019;s imaging agents and products include the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Xenon Xe 133 Gas, or Xenon, is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Neurolite is an injectable, technetium-labeled imaging agent used with Single Photon Emission Computed Tomography, or SPECT, technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%">&#xA0;</td> <td valign="top" width="2%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with SPECT technology in myocardial perfusion imaging, or MPI, procedures that assess blood flow distribution to the heart.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company&#x2019;s radiopharmaceutical products are primarily distributed through commercial radiopharmacies owned or controlled by third parties. In Puerto Rico and Australia, the Company owns three radiopharmacies and sells its own radiopharmaceuticals, as well as others, directly to end users. In Canada, Europe, Asia Pacific and Latin America, the Company utilizes distributor relationships to market, sell and distribute its products.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 30px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Basis of Consolidation and Presentation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company&#x2019;s financial statements for interim periods in accordance with U.S.&#xA0;GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S.&#xA0;GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this quarterly report should be read in conjunction with the Company&#x2019;s consolidated financial statements and the accompanying notes for the year ended December&#xA0;31, 2015 included in the Company&#x2019;s Form 10-K filed with the SEC on March&#xA0;2, 2016. The Company&#x2019;s accounting policies are described in the &#x201C;Notes to Consolidated Financial Statements&#x201D; in the Form 10-K and updated, as necessary, in this quarterly report. There were no changes to the Company&#x2019;s accounting policies since December&#xA0;31, 2015. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S.&#xA0;GAAP. The results of operations for the three and six months ended June&#xA0;30, 2016 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply, which is currently approved for manufacture by a single manufacturer. The Company has technology transfer activities ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and the Company cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company&#x2019;s ability to maintain and profitably renew those contracts and relationships with those key customers and group purchasing organizations is an important aspect of the Company&#x2019;s strategy.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Borrowing capacity under the $50.0 million revolving credit facility, or the Revolving Facility, is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted operating results, the Company&#x2019;s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company&#x2019;s borrowing capacity. As of June 30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $34.4 million. The Company&#x2019;s $365.0 million senior secured term loan facility, or the Term Facility, contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect the Company&#x2019;s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Based on the Company&#x2019;s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company&#x2019;s liquidity requirements for at least the next twelve months.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 30px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The preparation of condensed consolidated financial statements in conformity with U.S.&#xA0;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company&#x2019;s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 30px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Recent Accounting Pronouncements</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In March 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-09,&#xA0;<i>Compensation &#x2013; Stock Compensation (Topic 719), Improvements to Employee Share-Based Payment Accounting</i>.&#xA0;ASU 2016-09 simplifies several aspects of accounting for employee share-based payment transactions, including the accounting for income tax consequences, the classification of awards as either equity or liabilities, an accounting policy election for forfeitures, statutory tax withholding requirements and certain classifications on the statement of cash flows.&#xA0;ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods.&#xA0;Early adoption is permitted.&#xA0;The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In February 2016, the FASB, issued ASU 2016-02,&#xA0;<i>Leases (Topic 842)</i>, or ASU 2016-02. ASU 2016-02 supersedes the existing guidance for lease accounting,&#xA0;<i>Leases (Topic 840)</i>. ASU 2016-02 was issued to increase transparency and comparability among organizations by requiring lessees to recognize all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). The accounting for lessors remains largely unchanged. ASU 2016-02 retains a distinction between finance leases and operating leases. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize a lease liability and right-of-use asset. ASU 2016-02 is effective for fiscal years beginning after December&#xA0;15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In May 2014, the FASB issued ASU 2014-09,&#xA0;<i>Revenue from Contracts with Customers (Topic 606</i>) or ASU 2014-09. ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Subsequent to issuing ASU 2014-09, the FASB issued the following amendments concerning the adoption and clarification of ASU 2014-09.&#xA0;In August 2015, the FASB issued ASU 2015-14,&#xA0;<i>Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date</i>, which defers the effective date of ASU 2014-09 to annual reporting periods beginning after December&#xA0;15, 2017 with early adoption permitted as of its original effective date of December&#xA0;15, 2016. In March 2016, the FASB issued ASU 2016-08,&#xA0;<i>Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net),</i>&#xA0;which further clarifies the implementation guidance on principal versus agent considerations. The new guidance requires either a retrospective or a modified retrospective approach to adoption. In April 2016, the FASB issued ASU 2016-10,&#xA0;<i>Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing</i>, which clarifies the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas.&#xA0;In May 2016, the FASB issued ASU 2016-12,&#xA0;<i>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&#xA0;</i>or ASU 2016-12, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for noncash consideration and completed contracts at transition.&#xA0;The Company is currently evaluating the impact these ASUs will have on our financial position, results of operations, cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In August 2014, the FASB issued ASU 2014-15,&#xA0;<i>Presentation of Financial Statements-Going Concern (Subtopic 205-4): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</i>&#xA0;or ASU 2014-15. ASU 2014-15 provides guidance on management&#x2019;s responsibility in evaluating whether there is substantial doubt about a company&#x2019;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December&#xA0;15, 2016. Early adoption is permitted. The Company does not anticipate this ASU will have a material impact to the Company&#x2019;s financial position, results of operations, cash flows and disclosures.</p> </div> 21415000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>15.&#xA0;Other Income, net</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months<br /> Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six Months<br /> Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency gains (losses)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(360</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Tax indemnification income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">140</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">781</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">436</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">777</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other income (expense)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total other income, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">396</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">454</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">417</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> -118000 -13996000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>12.&#xA0;Stockholders&#x2019; Equity</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> As of June&#xA0;30, 2016, the authorized capital stock of the Company consisted of 250,000,000 shares of common stock, par value $0.01 per share, and 25,000,000&#xA0;shares of preferred stock, par value $0.01 per share. The common stockholders are entitled to one vote per share and will share equally on a per share basis in any dividend declared by the Board of Directors, subject to any preferential rights of the holders of any outstanding preferred stock.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table presents the changes in stockholders&#x2019; deficit for the six months ended June&#xA0;30, 2016:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="47%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Common Stock</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Accumulated<br /></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amount</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Additional<br /> Paid-In<br /> Capital</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Deficit</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Other<br /> Comprehensive<br /> Loss</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Stockholders&#x2019;<br /> Deficit</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,364,501</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">175,553</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(359,160</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,985</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(185,289</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other comprehensive income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Vesting of restricted stock awards</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,936</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Stock-based compensation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at June&#xA0;30, 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,385,437</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">176,545</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(341,487</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,729</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(166,368</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 30px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The preparation of condensed consolidated financial statements in conformity with U.S.&#xA0;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company&#x2019;s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> <div> <br class="Apple-interchange-newline" /> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months<br /> Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six Months<br /> Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Foreign currency gains (losses)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">18</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(360</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Tax indemnification income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">140</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">781</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">436</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">777</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other income (expense)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total other income, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">396</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">454</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">417</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 30453776 P10Y <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> June 30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six Months Ended<br /> June 30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 175.4pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands, except share and per share amounts)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income (loss)</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,350</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(24,423</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(24,048</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic weighted average common shares outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,377,562</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,898,003</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,372,901</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,489,451</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Effect of dilutive restricted stock awards</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">165,166</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80,875</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Diluted weighted average common shares outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,542,728</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,898,003</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,453,776</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18,489,451</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Basic and diluted income (loss) per weighted average common share outstanding</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.24</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.29</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.58</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.30</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Stock-based compensation expense for both time based and performance based stock options and restricted stock awards were recognized in the condensed consolidated statements of operations as follows:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;Months<br /> Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six Months<br /> Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Cost of goods sold</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">73</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">52</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">139</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">51</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> General and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">345</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">465</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">578</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">679</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Sales and marketing</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">128</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">115</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">87</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">60</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">147</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">88</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total stock-based compensation expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">585</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">656</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">933</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The following is a reconciliation of the Company&#x2019;s asset retirement obligations for the six months ended June&#xA0;30, 2016:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 48.6pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,145</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net increase due to changes in estimated future cash flows</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">39</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accretion expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">466</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at June&#xA0;30, 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Intangibles, net consisted of the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>June&#xA0;30, 2016</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortization<br /> Method</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Trademarks</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,540</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,843</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,697</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">Straight-line</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100,997</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">90,158</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,839</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Accelerated</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">42,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,367</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Straight-line</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">157,317</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">139,368</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> amortization</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortization<br /> Method</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Trademarks</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,540</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,934</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,606</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right"><font style="WHITE-SPACE: nowrap">Straight-line</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Customer relationships</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100,737</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">88,564</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,173</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Accelerated</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Patents</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">42,780</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">41,063</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,717</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">Straight-line</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">157,057</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">136,561</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,496</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company&#x2019;s maturities of principal obligations under the Term Facility are as follows as of June&#xA0;30, 2016:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Remainder of 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,825</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,650</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2021 and thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">344,925</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total debt</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">361,350</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unamortized debt discount</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,860</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Unamortized debt issuance costs</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(5,002</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">352,488</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less current portion</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,650</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total long-term debt</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">348,838</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 30372901 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>2.&#xA0;Summary of Significant Accounting Policies</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Revenue Recognition</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement&#x2019;s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i)&#xA0;vendor-specific objective evidence of fair value; (ii)&#xA0;third-party evidence of selling price; and (iii)&#xA0;best estimate of selling price. The best estimate of selling price reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Inventory</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. There was no significant product expensed for the six months ended June&#xA0;30, 2016 and 2015. At June&#xA0;30, 2016 and December&#xA0;31, 2015, the Company had no capitalized inventories associated with product that did not have regulatory approval.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company includes within current assets the amount of inventory that is estimated to be utilized within twelve months. Inventory that will be utilized after twelve months is classified within other long-term assets.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Goodwill</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October&#xA0;31 of each year. There were no events as of June&#xA0;30, 2016 and December&#xA0;31, 2015 that triggered an interim impairment test of goodwill.</p> </div> LNTH <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table presents the changes in stockholders&#x2019; deficit for the six months ended June&#xA0;30, 2016:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="47%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Common Stock</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2" align="center"> <b>Accumulated<br /></b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Amount</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Additional<br /> Paid-In<br /> Capital</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated<br /> Deficit</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Other<br /> Comprehensive<br /> Loss</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total<br /> Stockholders&#x2019;<br /> Deficit</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at December&#xA0;31, 2015</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,364,501</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">175,553</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(359,160</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,985</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(185,289</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Net income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17,673</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other comprehensive income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Vesting of restricted stock awards</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,936</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Stock-based compensation</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance at June&#xA0;30, 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,385,437</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">176,545</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(341,487</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,729</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(166,368</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 5644000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Accrued expenses and other liabilities are comprised of the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Compensation and benefits</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,118</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Freight, distribution and operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,282</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,962</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accrued rebates, discounts and chargebacks</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,373</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,085</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accrued professional fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,272</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,493</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Marketing expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">725</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">490</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development services</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">298</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">360</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">596</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">587</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,664</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,502</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>18.&#xA0;Segment Information</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company reports two operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company&#x2019;s chief operating decision maker, the President and Chief Executive Officer. The Company&#x2019;s segments derive revenues through the manufacturing, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. The U.S. segment comprises 83.5% and 84.2% of consolidated revenues for the three and six months ended June&#xA0;30, 2016 as compared to 79.6% and 80.4% for the prior year comparative periods.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Selected information for each business segment are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six Months Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Revenues</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">72,244</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">64,689</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">143,014</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">130,477</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,832</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,936</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24,373</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenue, including inter-segment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">85,076</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">79,625</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">167,387</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">159,569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less inter-segment revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(7,110</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6,311</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(12,947</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(11,432</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,966</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">73,314</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">154,440</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">148,137</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Revenues from external customers</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">65,134</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,378</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">130,067</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">119,045</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,832</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,936</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24,373</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,966</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">73,314</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">154,440</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">148,137</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Operating income</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,442</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,335</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,121</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,443</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,059</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,691</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">585</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total operating income, including inter-segment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,488</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,501</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,026</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,706</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Inter-segment operating (loss) income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(309</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(145</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(174</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,179</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,356</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,852</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,734</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Interest expense, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6,978</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(13,876</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(13,996</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(24,499</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loss on extinguishment of debt</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(15,528</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(15,528</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other income, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">396</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">454</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">417</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income (loss) before income taxes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,597</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(23,248</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,310</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(22,876</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Selected information for each business segment are as follows (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt &quot;Times New Roman&quot;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six Months Ended<br /> June&#xA0;30,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Revenues</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">72,244</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">64,689</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">143,014</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">130,477</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,832</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,936</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24,373</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total revenue, including inter-segment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">85,076</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">79,625</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">167,387</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">159,569</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Less inter-segment revenue</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(7,110</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6,311</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(12,947</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(11,432</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,966</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">73,314</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">154,440</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">148,137</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Revenues from external customers</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">65,134</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,378</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">130,067</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">119,045</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,832</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,936</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24,373</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,092</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">77,966</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">73,314</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">154,440</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">148,137</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> <b>Operating income</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> U.S.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,442</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,335</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,121</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> International</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(1,443</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,059</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,691</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">585</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total operating income, including inter-segment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,488</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,501</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">32,026</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,706</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Inter-segment operating (loss) income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(309</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(145</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(174</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Operating income</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,179</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,356</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">31,852</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">16,734</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Interest expense, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(6,978</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(13,876</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(13,996</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(24,499</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Loss on extinguishment of debt</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(15,528</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(15,528</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other income, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">396</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">800</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">454</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">417</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Income (loss) before income taxes</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,597</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(23,248</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,310</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">(22,876</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Revenue Recognition</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement&#x2019;s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i)&#xA0;vendor-specific objective evidence of fair value; (ii)&#xA0;third-party evidence of selling price; and (iii)&#xA0;best estimate of selling price. The best estimate of selling price reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Expected future amortization expense related to the intangible assets is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" colspan="2">&#xA0;</td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Remainder of 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,587</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,393</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2018</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,688</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2019</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,836</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2020</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,595</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> 2021 and thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,850</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,949</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> 19150000 992000 1861000 <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>17.&#xA0;Related Party Transactions</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Avista, the Company&#x2019;s majority shareholder, provided certain advisory services to the Company pursuant to an advisory services and monitoring agreement. The Company was required to pay an annual fee of $1.0&#xA0;million and other reasonable and customary advisory fees, as applicable, paid on a quarterly basis. The initial term of the agreement was seven years. On June&#xA0;25, 2015, the Company exercised its right to terminate its advisory services and monitoring agreement with Avista. In connection with such termination, the Company has paid Avista Capital Holdings, L.P. an aggregate termination fee of $6.5 million, which was included in general and administrative expenses in the condensed consolidated statement of operations during the quarter ended June&#xA0;30, 2015. During the three and six months ended June&#xA0;30, 2016, the Company did not incur any costs associated with this agreement as compared to $6.8&#xA0;million and $7.0 million, respectively, for the prior year comparative periods. At June 30, 2016 and December&#xA0;31, 2015, there were no amounts outstanding.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In the first quarter of 2016, the Company entered into a services agreement with INC Research, LLC, or INC, to provide pharmacovigilance services. Avista and certain of its affiliates are principal owners of both INC and the Company. The agreement has a term of three years. During the three and six months ended June 30, 2016, the Company incurred costs associated with this agreement of approximately $0.3 million and $0.5 million, respectively.&#xA0;At June 30, 2016, $0.1 million was included in accrued expenses and other liabilities.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company purchases inventory supplies from VWR Scientific, or VWR. Avista and certain of its affiliates are principal owners of both VWR and the Company. During each of the three and six months ended June&#xA0;30, 2016, the Company made purchases of $0.1 million and $0.2 million respectively, as compared to $44,000 and $0.1 million for the prior year comparative periods. At June&#xA0;30, 2016 and December&#xA0;31, 2015, $6,000 and $10,000, respectively, was included in accounts payable and accrued expenses.</p> </div> 2 500000 28200000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>5. Assets Held for Sale</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> During the fourth quarter of 2015, the Company committed to a plan to sell certain assets and liabilities associated with the Company&#x2019;s international business in Canada. This event qualified for held for sale accounting and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December&#xA0;31, 2015. The transaction was finalized in the first quarter of 2016.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Effective January&#xA0;7, 2016, the Canadian subsidiary of the Company entered into an asset purchase agreement (&#x201C;Purchase Agreement&#x201D;) pursuant to which it would sell substantially all of the assets of its Canadian radiopharmacies and Gludef manufacturing and distribution business to one of its existing Canadian radiopharmacy customers.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The purchase price for the asset sale was $9.0 million in cash and also included a working capital adjustment of $0.5 million. The Purchase Agreement contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company&#x2019;s representations, warranties and covenants in the Purchase Agreement.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> As part of the transaction, the Company and the buyer also entered into a customary transition services agreement and a long-term supply contract under which the Company will supply the buyer with the Company&#x2019;s products on commercial terms and under which the buyer has agreed to certain product purchase commitments.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company did not believe the sale of certain net assets in the international business constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company&#x2019;s financial statements and was classified as assets and liabilities held for sale as of December&#xA0;31, 2015.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table summarizes the major classes of assets and liabilities sold as of January&#xA0;12, 2016 (date of the sale) and December&#xA0;31, 2015:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>January&#xA0;12,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Current Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,620</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,512</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Inventory</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">730</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">806</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,365</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,344</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-Current Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property, plant and equipment, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">760</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">791</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Intangibles, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">462</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">480</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other long-term assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total assets held for sale</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,615</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,644</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Current Liabilities:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts payable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">435</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">430</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accrued expense and other liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">858</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,285</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total liabilities held for sale</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,293</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,715</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The sale resulted in a pre-tax book gain of $5.9 million, which was recorded within operating income in the condensed consolidated statement of operations for the six month period ended June&#xA0;30, 2016.</p> </div> 0 9000000 436000 80875 8800000 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>10.&#xA0;Accrued Expenses and Other Liabilities</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Accrued expenses and other liabilities are comprised of the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Compensation and benefits</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,118</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Freight, distribution and operations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,282</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,962</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accrued rebates, discounts and chargebacks</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,373</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,085</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accrued professional fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,272</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,493</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Marketing expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">725</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">490</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Research and development services</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">298</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">360</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">596</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">587</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,664</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,502</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table summarizes the major classes of assets and liabilities sold as of January&#xA0;12, 2016 (date of the sale) and December&#xA0;31, 2015:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>January&#xA0;12,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Current Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts receivable, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,620</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,512</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Inventory</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">730</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">806</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total current assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,365</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,344</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Non-Current Assets:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Property, plant and equipment, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">760</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">791</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Intangibles, net</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">462</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">480</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other long-term assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total assets held for sale</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,615</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,644</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Current Liabilities:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accounts payable</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">435</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">430</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Accrued expense and other liabilities</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">858</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,285</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total liabilities held for sale</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,293</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,715</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The financial covenants are displayed in the table below:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 24pt" align="center"><b>Term Facility Financial Covenants</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 22.65pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"> <b>Period</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>Total&#xA0;Net&#xA0;Leverage&#xA0;Ratio</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Q2 2016 to Q4 2016</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.00&#xA0;to&#xA0;1.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Q1 2017 to Q2 2017</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.50 to 1.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Thereafter</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5.00 to 1.00</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> </div> 1.05 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Inventory, classified in inventory or other long-term assets, consisted of the following:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 48.6pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"> <b>(in thousands)</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br /> 2016</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2015</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,062</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,506</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Work in process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,712</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,407</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,659</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,709</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Inventory</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">14,433</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15,622</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Other long-term assets</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,156</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,156</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,589</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,778</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"> &#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /> </div> -1000 0 43545000 0.842 2183075 -12947000 -174000 167387000 32026000 24373000 2691000 143014000 29335000 The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires in February 2017. 100000 2017-02-28 P1Y P60D 0.00375 The loans under the Revolving Facility bear interest with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread of 2.00% or (ii) the Reference Rate (as defined in the Revolving Facility) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020. 0.0200 0.0100 0.0200 2022-06-30 The term loans under the Term Facility bear interest, with pricing based from time to time at the Company's election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, without premium or penalty. 1.00 0.0025 1.00 0.0500 0.0600 0.0100 P4Y 139000 578000 147000 128000 500000 P3Y Accelerated Straight-line Straight-line 0 P7Y 24373000 130067000 200000 992000 20936 256000 17673000 0.0500 0.0600 0 -1.29 15444000 2000000 -24439000 1500000 40647000 18000 73314000 800000 32667000 -23248000 -15528000 -24423000 5356000 -16000 1175000 -13876000 18898003 18898003 2638000 9229000 656000 781000 1000 27311000 0.796 2153827 -6311000 -145000 79625000 5501000 14936000 2059000 64689000 3442000 52000 465000 60000 79000 6800000 14936000 58378000 44000.0 0.24 9238000 2200000 7266000 1300000 42215000 256000 77966000 396000 117000 35751000 7597000 7350000 14179000 -84000 247000 -6978000 30542728 30377562 2608000 9843000 585000 140000 165166 21689000 0.835 2183075 -7110000 -309000 85076000 14488000 12832000 -1443000 72244000 15931000 73000 345000 87000 80000 300000 0 12832000 65134000 100000 0001521036 lnth:VWRScientificMember 2016-04-01 2016-06-30 0001521036 lnth:UsSegmentMember 2016-04-01 2016-06-30 0001521036 lnth:InternationalSegmentMember 2016-04-01 2016-06-30 0001521036 us-gaap:MajorityShareholderMemberlnth:AdvisoryServicesAndMonitoringAgreementMember 2016-04-01 2016-06-30 0001521036 lnth:INCResearchLLCMemberus-gaap:MajorityShareholderMember 2016-04-01 2016-06-30 0001521036 us-gaap:SellingAndMarketingExpenseMember 2016-04-01 2016-06-30 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001521036 us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0001521036 us-gaap:OperatingSegmentsMemberlnth:UsSegmentMember 2016-04-01 2016-06-30 0001521036 us-gaap:OperatingSegmentsMemberlnth:InternationalSegmentMember 2016-04-01 2016-06-30 0001521036 us-gaap:OperatingSegmentsMember 2016-04-01 2016-06-30 0001521036 us-gaap:IntersegmentEliminationMember 2016-04-01 2016-06-30 0001521036 us-gaap:EmployeeStockOptionMemberlnth:UnvestedRestrictedStockMember 2016-04-01 2016-06-30 0001521036 us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberlnth:UsSegmentMember 2016-04-01 2016-06-30 0001521036 2016-04-01 2016-06-30 0001521036 lnth:VWRScientificMember 2015-04-01 2015-06-30 0001521036 lnth:UsSegmentMember 2015-04-01 2015-06-30 0001521036 lnth:InternationalSegmentMember 2015-04-01 2015-06-30 0001521036 us-gaap:MajorityShareholderMemberlnth:AdvisoryServicesAndMonitoringAgreementMember 2015-04-01 2015-06-30 0001521036 us-gaap:SellingAndMarketingExpenseMember 2015-04-01 2015-06-30 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001521036 us-gaap:CostOfSalesMember 2015-04-01 2015-06-30 0001521036 us-gaap:OperatingSegmentsMemberlnth:UsSegmentMember 2015-04-01 2015-06-30 0001521036 us-gaap:OperatingSegmentsMemberlnth:InternationalSegmentMember 2015-04-01 2015-06-30 0001521036 us-gaap:OperatingSegmentsMember 2015-04-01 2015-06-30 0001521036 us-gaap:IntersegmentEliminationMember 2015-04-01 2015-06-30 0001521036 us-gaap:EmployeeStockOptionMemberlnth:UnvestedRestrictedStockMember 2015-04-01 2015-06-30 0001521036 us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberlnth:UsSegmentMember 2015-04-01 2015-06-30 0001521036 2015-04-01 2015-06-30 0001521036 2015-01-01 2015-12-31 0001521036 lnth:SeniorSecuredTermLoanFacilityMemberus-gaap:ScenarioForecastMember 2016-04-01 2016-12-31 0001521036 lnth:SeniorSecuredTermLoanFacilityMemberus-gaap:ScenarioForecastMember 2016-07-01 2022-06-30 0001521036 us-gaap:RetainedEarningsMember 2016-01-01 2016-06-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-06-30 0001521036 us-gaap:CommonStockMember 2016-01-01 2016-06-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-06-30 0001521036 lnth:VWRScientificMember 2016-01-01 2016-06-30 0001521036 lnth:UsSegmentMember 2016-01-01 2016-06-30 0001521036 lnth:InternationalSegmentMember 2016-01-01 2016-06-30 0001521036 us-gaap:MajorityShareholderMemberlnth:AdvisoryServicesAndMonitoringAgreementMember 2016-01-01 2016-06-30 0001521036 us-gaap:TrademarksMember 2016-01-01 2016-06-30 0001521036 us-gaap:PatentsMember 2016-01-01 2016-06-30 0001521036 us-gaap:CustomerRelationshipsMember 2016-01-01 2016-06-30 0001521036 lnth:INCResearchLLCMemberus-gaap:MajorityShareholderMember 2016-01-01 2016-06-30 0001521036 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001521036 us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001521036 lnth:TimeBasedStockOptionsMember 2016-01-01 2016-06-30 0001521036 lnth:TermFacilityMemberlnth:DebtInstrumentVariableRateBaseReferenceRateMember 2016-01-01 2016-06-30 0001521036 lnth:TermFacilityMemberlnth:DebtInstrumentVariableRateBaseLiborMember 2016-01-01 2016-06-30 0001521036 lnth:TermFacilityMemberus-gaap:InterestRateFloorMember 2016-01-01 2016-06-30 0001521036 lnth:TermFacilityMember 2016-01-01 2016-06-30 0001521036 us-gaap:RevolvingCreditFacilityMemberlnth:DebtInstrumentVariableRateBaseLiborMember 2016-01-01 2016-06-30 0001521036 lnth:LantheusMedicalImagingMemberus-gaap:RevolvingCreditFacilityMemberlnth:DebtInstrumentVariableRateBaseReferenceRateMember 2016-01-01 2016-06-30 0001521036 lnth:LantheusMedicalImagingMemberus-gaap:RevolvingCreditFacilityMemberlnth:DebtInstrumentVariableRateBaseLiborMember 2016-01-01 2016-06-30 0001521036 lnth:LantheusMedicalImagingMemberus-gaap:RevolvingCreditFacilityMember 2016-01-01 2016-06-30 0001521036 us-gaap:RevolvingCreditFacilityMember 2016-01-01 2016-06-30 0001521036 us-gaap:OperatingSegmentsMemberlnth:UsSegmentMember 2016-01-01 2016-06-30 0001521036 us-gaap:OperatingSegmentsMemberlnth:InternationalSegmentMember 2016-01-01 2016-06-30 0001521036 us-gaap:OperatingSegmentsMember 2016-01-01 2016-06-30 0001521036 us-gaap:IntersegmentEliminationMember 2016-01-01 2016-06-30 0001521036 us-gaap:EmployeeStockOptionMemberlnth:UnvestedRestrictedStockMember 2016-01-01 2016-06-30 0001521036 us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberlnth:UsSegmentMember 2016-01-01 2016-06-30 0001521036 2016-01-01 2016-06-30 0001521036 lnth:VWRScientificMember 2015-01-01 2015-06-30 0001521036 lnth:UsSegmentMember 2015-01-01 2015-06-30 0001521036 lnth:InternationalSegmentMember 2015-01-01 2015-06-30 0001521036 us-gaap:MajorityShareholderMemberlnth:AdvisoryServicesAndMonitoringAgreementMember 2015-01-01 2015-06-30 0001521036 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-06-30 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001521036 us-gaap:CostOfSalesMember 2015-01-01 2015-06-30 0001521036 lnth:TermFacilityMember 2015-01-01 2015-06-30 0001521036 us-gaap:OperatingSegmentsMemberlnth:UsSegmentMember 2015-01-01 2015-06-30 0001521036 us-gaap:OperatingSegmentsMemberlnth:InternationalSegmentMember 2015-01-01 2015-06-30 0001521036 us-gaap:OperatingSegmentsMember 2015-01-01 2015-06-30 0001521036 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-06-30 0001521036 us-gaap:EmployeeStockOptionMemberlnth:UnvestedRestrictedStockMember 2015-01-01 2015-06-30 0001521036 us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberlnth:UsSegmentMember 2015-01-01 2015-06-30 0001521036 2015-01-01 2015-06-30 0001521036 lnth:SeniorSecuredTermLoanFacilityMemberus-gaap:ScenarioForecastMember 2017-01-01 2017-06-30 0001521036 us-gaap:MajorityShareholderMemberlnth:AdvisoryServicesAndMonitoringAgreementMember 2016-06-25 2016-06-25 0001521036 us-gaap:InsuranceSettlementMember 2010-12-16 2010-12-16 0001521036 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2016-01-12 0001521036 us-gaap:RetainedEarningsMember 2015-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001521036 us-gaap:CommonStockMember 2015-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001521036 us-gaap:MajorityShareholderMemberlnth:AdvisoryServicesAndMonitoringAgreementMember 2015-12-31 0001521036 us-gaap:TrademarksMember 2015-12-31 0001521036 us-gaap:PatentsMember 2015-12-31 0001521036 us-gaap:CustomerRelationshipsMember 2015-12-31 0001521036 lnth:MachineryEquipmentAndFixturesMember 2015-12-31 0001521036 us-gaap:LandMember 2015-12-31 0001521036 us-gaap:BuildingMember 2015-12-31 0001521036 us-gaap:ConstructionInProgressMember 2015-12-31 0001521036 us-gaap:MoneyMarketFundsMember 2015-12-31 0001521036 us-gaap:CertificatesOfDepositMember 2015-12-31 0001521036 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2015-12-31 0001521036 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember 2015-12-31 0001521036 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001521036 us-gaap:AccountingStandardsUpdate201517Member 2015-12-31 0001521036 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2015-12-31 0001521036 us-gaap:AccountsPayableAndAccruedLiabilitiesMemberlnth:VWRScientificMember 2015-12-31 0001521036 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2015-12-31 0001521036 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001521036 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember 2015-12-31 0001521036 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001521036 2015-12-31 0001521036 2014-12-31 0001521036 us-gaap:RetainedEarningsMember 2016-06-30 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0001521036 us-gaap:CommonStockMember 2016-06-30 0001521036 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0001521036 us-gaap:MajorityShareholderMemberlnth:AdvisoryServicesAndMonitoringAgreementMember 2016-06-30 0001521036 us-gaap:TrademarksMember 2016-06-30 0001521036 us-gaap:PatentsMember 2016-06-30 0001521036 us-gaap:CustomerRelationshipsMember 2016-06-30 0001521036 lnth:SeniorSecuredTermLoanFacilityMember 2016-06-30 0001521036 lnth:FixedAssetsDedicatedToResearchAndDevelopmentActivitiesMember 2016-06-30 0001521036 lnth:MachineryEquipmentAndFixturesMember 2016-06-30 0001521036 us-gaap:LandMember 2016-06-30 0001521036 us-gaap:BuildingMember 2016-06-30 0001521036 us-gaap:ConstructionInProgressMember 2016-06-30 0001521036 us-gaap:MoneyMarketFundsMember 2016-06-30 0001521036 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2016-06-30 0001521036 us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0001521036 lnth:TermFacilityMember 2016-06-30 0001521036 lnth:LantheusMedicalImagingMemberus-gaap:RevolvingCreditFacilityMember 2016-06-30 0001521036 us-gaap:RevolvingCreditFacilityMember 2016-06-30 0001521036 lnth:INCResearchLLCMemberlnth:AccruedExpensesAndOtherLiabilitiesMemberus-gaap:MajorityShareholderMember 2016-06-30 0001521036 us-gaap:AccountsPayableAndAccruedLiabilitiesMemberlnth:VWRScientificMember 2016-06-30 0001521036 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2016-06-30 0001521036 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0001521036 2016-06-30 0001521036 us-gaap:SeniorNotesMember 2015-06-30 0001521036 lnth:TermFacilityMember 2015-06-30 0001521036 2015-06-30 0001521036 lnth:EquityIncentivePlan2015Member 2016-04-26 0001521036 2016-08-01 shares iso4217:USD pure iso4217:USD shares lnth:Item lnth:Lawsuits lnth:Segment EX-101.SCH 6 lnth-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated statements of Comprehensive Income (Loss) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Business Overview link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Assets Held for Sale link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Inventory link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Property, Plant and Equipment, Net link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Asset Retirement Obligations link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Intangibles, Net link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Accrued Expenses and Other Liabilities link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Financing Arrangements link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Net Income (Loss) Per Share link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Other Income, net link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Legal Proceedings and Contingencies link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Segment Information link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Business Overview (Policies) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Assets Held for Sale (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Inventory (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Property, Plant and Equipment, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Asset Retirement Obligations (Tables) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Intangibles, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Accrued Expenses and Other Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Financing Arrangements (Tables) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Net Income (Loss) Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Other Income, net (Tables) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Segment Information (Tables) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Business Overview - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Fair Value of Financial Instruments - Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Assets Held for Sale - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Assets Held for Sale - Summary of Assets and Liabilities Sold (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Inventory - Schedule of Inventory, Classified in Inventory or Other Long-term Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Inventory - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Asset Retirement Obligations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Intangibles, Net - Schedule of Intangibles, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Intangibles, Net - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Financing Arrangements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Financing Arrangements - Schedule of Maturities of Principal Obligations Under Term Facility (Detail) link:calculationLink link:presentationLink link:definitionLink 159 - Disclosure - Financing Arrangements - Schedule of Term Facility Financial Covenants (Detail) link:calculationLink link:presentationLink link:definitionLink 160 - Disclosure - Stockholder's Equity - Additional information (Detail) link:calculationLink link:presentationLink link:definitionLink 161 - Disclosure - Stockholders' Equity - Schedule of Changes in Stockholders' Deficit (Detail) link:calculationLink link:presentationLink link:definitionLink 162 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 163 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 164 - Disclosure - Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 165 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 166 - Disclosure - Other Income, Net - Schedule of Other Income, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 167 - Disclosure - Legal Proceedings and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 168 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 169 - Disclosure - Segment Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 170 - Disclosure - Segment Information - Schedule of Selected Information for Each Business Segment (Detail) link:calculationLink link:presentationLink link:definitionLink 171 - Disclosure - Financing Arrangements - Schedule of Maturities of Principal Obligations Under Term Facility (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 lnth-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 lnth-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 lnth-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 lnth-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2016
Aug. 01, 2016
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Trading Symbol LNTH  
Entity Registrant Name LANTHEUS HOLDINGS, INC.  
Entity Central Index Key 0001521036  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Common Stock, Shares Outstanding   30,387,768
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Income Statement [Abstract]        
Revenues $ 77,966 $ 73,314 $ 154,440 $ 148,137
Cost of goods sold 42,215 40,647 84,988 79,701
Gross profit 35,751 32,667 69,452 68,436
Operating expenses        
Sales and marketing expenses 9,843 9,229 19,150 18,301
General and administrative expenses 9,238 15,444 18,751 24,567
Research and development expenses 2,608 2,638 5,644 8,834
Total operating expenses 21,689 27,311 43,545 51,702
Gain on sale of assets 117   5,945  
Operating income 14,179 5,356 31,852 16,734
Interest expense, net (6,978) (13,876) (13,996) (24,499)
Loss on extinguishment of debt   (15,528)   (15,528)
Other income, net 396 800 454 417
Income (loss) before income taxes 7,597 (23,248) 18,310 (22,876)
Provision for income taxes 247 1,175 637 1,172
Net income (loss) $ 7,350 $ (24,423) $ 17,673 $ (24,048)
Net income (loss) per weighted average common share outstanding:        
Basic and Diluted $ 0.24 $ (1.29) $ 0.58 $ (1.30)
Weighted average common shares outstanding:        
Basic 30,377,562 18,898,003 30,372,901 18,489,451
Diluted 30,542,728 18,898,003 30,453,776 18,489,451
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ 7,350 $ (24,423) $ 17,673 $ (24,048)
Foreign currency translation (84) (16) 256 (374)
Total comprehensive income (loss) $ 7,266 $ (24,439) $ 17,929 $ (24,422)
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 54,851 $ 28,596
Accounts receivable, net of allowance of $989 and $881 39,457 37,293
Inventory 14,433 15,622
Other current assets 4,282 3,851
Assets held for sale   4,644
Total current assets 113,023 90,006
Property, plant and equipment, net 84,422 86,517
Capitalized software development costs, net 8,121 9,137
Intangibles, net 17,949 20,496
Goodwill 15,714 15,714
Other long-term assets 20,038 20,509
Total assets 259,267 242,379
Current liabilities:    
Current portion of long-term debt 3,650 3,650
Accounts payable 12,778 11,657
Accrued expenses and other liabilities 17,664 18,502
Liabilities held for sale   1,715
Total current liabilities 34,092 35,524
Asset retirement obligation 8,650 8,145
Long-term debt, net 348,838 349,858
Other long-term liabilities 34,055 34,141
Total liabilities 425,635 427,668
Commitments and contingencies (See Note 16)
Stockholders' deficit:    
Preferred stock ($0.01 par value, 25,000,000 shares authorized; no shares issued and outstanding)
Common stock ($0.01 par value, 250,000,000 shares authorized; 30,385,437 and 30,364,501 shares issued and outstanding) 303 303
Additional paid-in capital 176,545 175,553
Accumulated deficit (341,487) (359,160)
Accumulated other comprehensive loss (1,729) (1,985)
Total stockholders' deficit (166,368) (185,289)
Total liabilities and stockholders' deficit $ 259,267 $ 242,379
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Accounts receivable, allowance $ 989 $ 881
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 25,000,000 25,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 30,385,437 30,364,501
Common stock, shares outstanding 30,385,437 30,364,501
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash flows from operating activities    
Net income (loss) $ 17,673 $ (24,048)
Adjustments to reconcile net loss to cash flow from operating activities    
Depreciation and amortization 9,358 12,573
Provision for excess and obsolete inventory 818 467
Stock-based compensation 992 933
Loss on extinguishment of debt   15,528
Gain on sale of assets (5,945)  
Other 118 1,457
Increase (decrease) in cash from operating assets and liabilities    
Accounts receivable (2,009) 4,258
Inventory 525 (474)
Other current assets 393 (368)
Accounts payable 1,474 108
Accrued expenses and other liabilities (1,982) (6,715)
Cash provided by operating activities 21,415 3,719
Cash flows from investing activities    
Proceeds from sale of assets 9,000  
Capital expenditures (2,388) (6,112)
Redemption of certificate of deposit-restricted 74  
Cash provided by (used in) investing activities 6,686 (6,112)
Cash flows from financing activities    
Proceeds from issuance of common stock in initial public offering   73,539
Payments for initial public offering costs   (5,255)
Proceeds from issuance of long-term debt   360,438
Payments on long-term debt (1,861)  
Payments on senior notes   (400,000)
Payment for call premium on senior notes   (9,752)
Payments on line of credit   (8,000)
Payments for offering costs   (563)
Payments on note payable   (37)
Deferred financing costs (11) (5,315)
Cash (used in) provided by financing activities (1,872) 5,055
Effect of foreign exchange rate on cash 26 (201)
Increase in cash and cash equivalents 26,255 2,461
Cash and cash equivalents, beginning of period 28,596 19,739
Cash and cash equivalents, end of period 54,851 22,200
Supplemental disclosure of cash flow information    
Interest paid 12,790 27,741
Income taxes paid $ 273 $ 73
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Overview
6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Overview

1. Business Overview

Overview

Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation.

The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers, and technologists working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks and group purchasing organizations. The Company sells its products globally and has operations in the United States, Canada, Puerto Rico and Australia and distribution relationships in Europe, Asia Pacific and Latin America.

The Company’s portfolio of 10 commercial products is diversified across a range of imaging modalities. The Company’s imaging agents and products include the following:

 

    DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.

 

    TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.

 

    Xenon Xe 133 Gas, or Xenon, is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.

 

    Neurolite is an injectable, technetium-labeled imaging agent used with Single Photon Emission Computed Tomography, or SPECT, technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.

 

    Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with SPECT technology in myocardial perfusion imaging, or MPI, procedures that assess blood flow distribution to the heart.

In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through commercial radiopharmacies owned or controlled by third parties. In Puerto Rico and Australia, the Company owns three radiopharmacies and sells its own radiopharmaceuticals, as well as others, directly to end users. In Canada, Europe, Asia Pacific and Latin America, the Company utilizes distributor relationships to market, sell and distribute its products.

Basis of Consolidation and Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

 

In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s financial statements for interim periods in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this quarterly report should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes for the year ended December 31, 2015 included in the Company’s Form 10-K filed with the SEC on March 2, 2016. The Company’s accounting policies are described in the “Notes to Consolidated Financial Statements” in the Form 10-K and updated, as necessary, in this quarterly report. There were no changes to the Company’s accounting policies since December 31, 2015. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

The Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply, which is currently approved for manufacture by a single manufacturer. The Company has technology transfer activities ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and the Company cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY.

Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company’s ability to maintain and profitably renew those contracts and relationships with those key customers and group purchasing organizations is an important aspect of the Company’s strategy.

Borrowing capacity under the $50.0 million revolving credit facility, or the Revolving Facility, is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted operating results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of June 30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $34.4 million. The Company’s $365.0 million senior secured term loan facility, or the Term Facility, contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect the Company’s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity.

Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.

 

Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-09, Compensation – Stock Compensation (Topic 719), Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of accounting for employee share-based payment transactions, including the accounting for income tax consequences, the classification of awards as either equity or liabilities, an accounting policy election for forfeitures, statutory tax withholding requirements and certain classifications on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.

In February 2016, the FASB, issued ASU 2016-02, Leases (Topic 842), or ASU 2016-02. ASU 2016-02 supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 was issued to increase transparency and comparability among organizations by requiring lessees to recognize all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). The accounting for lessors remains largely unchanged. ASU 2016-02 retains a distinction between finance leases and operating leases. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize a lease liability and right-of-use asset. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) or ASU 2014-09. ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

Subsequent to issuing ASU 2014-09, the FASB issued the following amendments concerning the adoption and clarification of ASU 2014-09. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date, which defers the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017 with early adoption permitted as of its original effective date of December 15, 2016. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which further clarifies the implementation guidance on principal versus agent considerations. The new guidance requires either a retrospective or a modified retrospective approach to adoption. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, which clarifies the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients or ASU 2016-12, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for noncash consideration and completed contracts at transition. The Company is currently evaluating the impact these ASUs will have on our financial position, results of operations, cash flows and disclosures.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-4): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern or ASU 2014-15. ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016. Early adoption is permitted. The Company does not anticipate this ASU will have a material impact to the Company’s financial position, results of operations, cash flows and disclosures.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Revenue Recognition

The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.

 

Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.

Inventory

Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. There was no significant product expensed for the six months ended June 30, 2016 and 2015. At June 30, 2016 and December 31, 2015, the Company had no capitalized inventories associated with product that did not have regulatory approval.

The Company includes within current assets the amount of inventory that is estimated to be utilized within twelve months. Inventory that will be utilized after twelve months is classified within other long-term assets.

Goodwill

Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. There were no events as of June 30, 2016 and December 31, 2015 that triggered an interim impairment test of goodwill.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments
6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

3. Fair Value of Financial Instruments

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015, and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points from active markets that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability.

 

(in thousands)

   Total fair
value at
June 30,
2016
     Quoted prices
in active
markets
(Level 1)
     Significant other
observable
inputs
(Level 2)
     Significant
unobservable
inputs
(Level 3)
 

Money market

   $ 2,686       $ 2,686       $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 2,686       $ 2,686       $ —         $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

(in thousands)

   Total fair
value at
December 31,
2015
     Quoted prices
in active
markets
(Level 1)
     Significant other
observable
inputs
(Level 2)
     Significant
unobservable
inputs
(Level 3)
 

Money market

   $ 1,586       $ 1,586       $ —        $ —    

Certificates of deposit—restricted

     74         —          74         —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 1,660       $ 1,586       $ 74       $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

At December 31, 2015, the Company had a $0.1 million certificate of deposit, which was collateral for a long-term lease and was included in other long-term assets on the condensed consolidated balance sheet. In January 2016, the certificate of deposit was redeemed. Certificates of deposit are classified within Level 2 of the fair value hierarchy, as these are not traded on the open market.

 

At June 30, 2016, the Company had total cash and cash equivalents of $54.9 million, which included approximately $2.7 million of money market funds. At December 31, 2015, the Company had total cash and cash equivalents of $28.6 million, which included approximately $1.6 million of money market funds.

The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, receivables, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The estimated fair value of the Company’s Term Facility at both June 30, 2016 and December 31, 2015, approximated the carrying value because the interest rate is subject to change with market interest rates.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes
6 Months Ended
Jun. 30, 2016
Income Tax Disclosure [Abstract]  
Income Taxes

4. Income Taxes

The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year in addition to discrete events which impact the interim period. The Company’s effective tax rate differs from the U.S. statutory rate principally due to the rate impact of uncertain tax positions, valuation allowance changes and state taxes. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective rate is determined. The Company’s tax provision was $0.2 million and $0.6 million for the three and six months ended June 30, 2016, respectively, compared to a tax provision of $1.2 million for the three and six months ended June 30, 2015.

In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb, or BMS, in 2008, the Company obtained a tax indemnification agreement with BMS related to certain tax obligations arising prior to the acquisition of the Company, for which the Company has the primary legal obligation. The tax indemnification receivable is recognized within other noncurrent assets. The changes in the tax indemnification asset are recognized within other income (expense), net in the condensed consolidated statement of operations. In accordance with the Company’s accounting policy, the change in the tax liability and penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within the tax provision. Accordingly, as these reserves change, adjustments are included in the tax provision while the offsetting adjustment is included in other income (expense), net. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there is no net effect on earnings related to these liabilities and no net cash outflows.

During the first quarter of 2016, the Company early adopted ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes on a retrospective basis. This standard requires all deferred taxes and liabilities, and any related valuation allowances, to be classified as non-current on the balance sheet. Adoption of this standard resulted in the reclassification of $0.1 million of current deferred tax assets to noncurrent deferred tax assets and $0.2 million of current deferred tax liabilities to noncurrent deferred tax liabilities on the balance sheet at December 31, 2015.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Assets Held for Sale
6 Months Ended
Jun. 30, 2016
Leases [Abstract]  
Assets Held for Sale

5. Assets Held for Sale

During the fourth quarter of 2015, the Company committed to a plan to sell certain assets and liabilities associated with the Company’s international business in Canada. This event qualified for held for sale accounting and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2015. The transaction was finalized in the first quarter of 2016.

Effective January 7, 2016, the Canadian subsidiary of the Company entered into an asset purchase agreement (“Purchase Agreement”) pursuant to which it would sell substantially all of the assets of its Canadian radiopharmacies and Gludef manufacturing and distribution business to one of its existing Canadian radiopharmacy customers.

The purchase price for the asset sale was $9.0 million in cash and also included a working capital adjustment of $0.5 million. The Purchase Agreement contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the Purchase Agreement.

As part of the transaction, the Company and the buyer also entered into a customary transition services agreement and a long-term supply contract under which the Company will supply the buyer with the Company’s products on commercial terms and under which the buyer has agreed to certain product purchase commitments.

The Company did not believe the sale of certain net assets in the international business constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s financial statements and was classified as assets and liabilities held for sale as of December 31, 2015.

 

The following table summarizes the major classes of assets and liabilities sold as of January 12, 2016 (date of the sale) and December 31, 2015:

 

(in thousands)

   January 12,
2016
     December 31,
2015
 

Current Assets:

     

Accounts receivable, net

   $ 2,620       $ 2,512   

Inventory

     730         806   

Other current assets

     15         26   
  

 

 

    

 

 

 

Total current assets

     3,365         3,344   

Non-Current Assets:

     

Property, plant and equipment, net

     760         791   

Intangibles, net

     462         480   

Other long-term assets

     28         29   
  

 

 

    

 

 

 

Total assets held for sale

   $ 4,615       $ 4,644   
  

 

 

    

 

 

 

Current Liabilities:

     

Accounts payable

   $ 435       $ 430   

Accrued expense and other liabilities

     858         1,285   
  

 

 

    

 

 

 

Total liabilities held for sale

   $ 1,293       $ 1,715   
  

 

 

    

 

 

 

The sale resulted in a pre-tax book gain of $5.9 million, which was recorded within operating income in the condensed consolidated statement of operations for the six month period ended June 30, 2016.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventory
6 Months Ended
Jun. 30, 2016
Inventory Disclosure [Abstract]  
Inventory

6. Inventory

Inventory, classified in inventory or other long-term assets, consisted of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Raw materials

   $ 7,062       $ 7,506   

Work in process

     2,712         2,407   

Finished goods

     4,659         5,709   
  

 

 

    

 

 

 

Inventory

     14,433         15,622   

Other long-term assets

     1,156         1,156   
  

 

 

    

 

 

 

Total

   $ 15,589       $ 16,778   
  

 

 

    

 

 

 

At both June 30, 2016 and December 31, 2015, inventories reported as other long-term assets included $1.2 million of raw materials.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property, Plant and Equipment, Net
6 Months Ended
Jun. 30, 2016
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, Net

7. Property, Plant and Equipment, net

Property, plant and equipment consisted of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Land

   $ 14,950       $ 14,950   

Buildings

     69,577         68,941   

Machinery, equipment and fixtures

     65,982         60,787   

Construction in progress

     4,882         9,099   

Accumulated depreciation

     (70,969      (67,260
  

 

 

    

 

 

 

Property, plant and equipment, net

   $ 84,422       $ 86,517   
  

 

 

    

 

 

 

 

For the three and six month period ended June 30, 2016, depreciation expense related to property, plant and equipment was $2.2 million and $4.1 million, respectively, as compared to $2.0 million and $7.7 million for the prior year comparative periods.

Fixed assets dedicated to research and development, or R&D, activities, which were impacted by the March 2013 R&D strategic shift, have a carrying value of $3.9 million as of June 30, 2016. The Company believes these fixed assets will be utilized for either internally funded ongoing R&D activities or R&D activities funded by a strategic partner. If the Company is not successful in finding a strategic partner and there are no alternative uses for these fixed assets, then they could be subject to impairment in the future.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Asset Retirement Obligations
6 Months Ended
Jun. 30, 2016
Asset Retirement Obligation Disclosure [Abstract]  
Asset Retirement Obligations

8. Asset Retirement Obligations

The Company considers the legal obligation to remediate its facilities upon a decommissioning of its radioactive related operations as an asset retirement obligation. The operations of the Company have radioactive production facilities at its North Billerica, Massachusetts and San Juan, Puerto Rico sites.

The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of the North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond, which itself is currently secured by an $8.8 million unfunded Standby Letter of Credit provided to the third party issuer of the bond.

The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. As of June 30, 2016, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.7 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying value of the related long-lived assets and depreciated over the asset’s useful life.

The following is a reconciliation of the Company’s asset retirement obligations for the six months ended June 30, 2016:

 

(in thousands)

      

Balance at December 31, 2015

   $ 8,145   

Net increase due to changes in estimated future cash flows

     39   

Accretion expense

     466   
  

 

 

 

Balance at June 30, 2016

   $ 8,650   
  

 

 

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles, Net
6 Months Ended
Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangibles, Net

9. Intangibles, net

Intangibles, net consisted of the following:

 

     June 30, 2016  

(in thousands)

   Cost      Accumulated
amortization
     Net      Amortization
Method
 

Trademarks

   $ 13,540       $ 7,843       $ 5,697         Straight-line   

Customer relationships

     100,997         90,158         10,839         Accelerated   

Patents

     42,780         41,367         1,413         Straight-line   
  

 

 

    

 

 

    

 

 

    
   $ 157,317       $ 139,368       $ 17,949      
  

 

 

    

 

 

    

 

 

    
     December 31, 2015  

(in thousands)

   Cost      Accumulated
amortization
     Net      Amortization
Method
 

Trademarks

   $ 13,540       $ 6,934       $ 6,606         Straight-line   

Customer relationships

     100,737         88,564         12,173         Accelerated   

Patents

     42,780         41,063         1,717         Straight-line   
  

 

 

    

 

 

    

 

 

    
   $ 157,057       $ 136,561       $ 20,496      
  

 

 

    

 

 

    

 

 

    

For the three and six month period ended June 30, 2016, the Company recorded amortization expense for its intangible assets of $1.3 million and $2.6 million, respectively, as compared to $1.5 million and $3.0 million for the prior year comparative periods.

 

Expected future amortization expense related to the intangible assets is as follows:

 

(in thousands)

      

Remainder of 2016

   $ 2,587   

2017

     3,393   

2018

     2,688   

2019

     1,836   

2020

     1,595   

2021 and thereafter

     5,850   
  

 

 

 
   $ 17,949   
  

 

 

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses and Other Liabilities
6 Months Ended
Jun. 30, 2016
Text Block [Abstract]  
Accrued Expenses and Other Liabilities

10. Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities are comprised of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Compensation and benefits

   $ 9,118       $ 10,525   

Freight, distribution and operations

     3,282         2,962   

Accrued rebates, discounts and chargebacks

     2,373         2,085   

Accrued professional fees

     1,272         1,493   

Marketing expense

     725         490   

Research and development services

     298         360   

Other

     596         587   
  

 

 

    

 

 

 
   $ 17,664       $ 18,502   
  

 

 

    

 

 

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Financing Arrangements
6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]  
Financing Arrangements

11. Financing Arrangements

Term Facility

On June 30, 2015, the Company entered into a $365.0 million seven-year Term Facility, which was issued net of a 1.25% discount of $4.6 million. The Company has a right to request an increase of the Term Facility in an aggregate amount up to $37.5 million plus additional amounts subject to certain leverage ratios. The net proceeds of the Term Facility, together with the net proceeds of the initial public offering, or IPO, and cash on hand, were used to refinance in full the aggregate principal amount of the $400.0 million 9.750% Senior Notes (“the Notes”) and pay related premiums, interest and expenses.

The term loans under the Term Facility bear interest, with pricing based from time to time at the Company’s election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. Interest under term loans based on (i) the LIBOR rate is payable at the end of each Interest Period (as defined in our Term Facility) and (ii) the Base Rate is payable at the end of each quarter. At June 30, 2016, the Company’s interest rate under the Term Facility was 7.00%.

The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, without premium or penalty. The Company is required to make quarterly payments, which began on September 30, 2015, in an amount equal to a quarter of a percent (0.25%) per annum of the original principal amount of the Term Facility. The remaining unpaid principal amount of the Term Facility will be payable on the maturity date, or June 30, 2022.

The Term Facility will require the Company to prepay outstanding term loans, subject to certain exceptions, with:

 

    100% of the net cash proceeds of all non-ordinary course sales or other dispositions of assets (including as a result of casualty or condemnation, subject to certain exceptions); the Company may reinvest or commit to reinvest certain of those proceeds in assets useful in our business within twelve months;

 

    100% of the net cash proceeds from issuances or incurrence of debt, other than proceeds from debt permitted under the Term Facility and Revolving Facility; and

 

    50% (with two leverage-based stepdowns) of the Company’s excess cash flow.

 

The foregoing mandatory prepayments will be applied to the scheduled installments of principal of the Term Facility as directed by LMI, or in the absence of direction, in direct order of maturity.

The Term Facility is guaranteed by the Company and Lantheus Real Estate, and obligations under the Term Facility are secured by substantially all the property and assets and all interests of the Company, LMI and Lantheus Real Estate.

The Company’s maturities of principal obligations under the Term Facility are as follows as of June 30, 2016:

 

(in thousands)

      

Remainder of 2016

   $ 1,825   

2017

     3,650   

2018

     3,650   

2019

     3,650   

2020

     3,650   

2021 and thereafter

     344,925   
  

 

 

 

Total debt

     361,350   

Unamortized debt discount

     (3,860

Unamortized debt issuance costs

     (5,002
  

 

 

 

Total

     352,488   

Less current portion

     (3,650
  

 

 

 

Total long-term debt

   $ 348,838   
  

 

 

 

Term Facility Covenants

The Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Term Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis. The financial covenants are displayed in the table below:

Term Facility Financial Covenants

 

Period

   Total Net Leverage Ratio  

Q2 2016 to Q4 2016

     6.00 to 1.00   

Q1 2017 to Q2 2017

     5.50 to 1.00   

Thereafter

     5.00 to 1.00   

The Term Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Revolving Line of Credit

At June 30, 2016, the Company has a Revolving Facility with an aggregate principal amount not to exceed $50.0 million. The loans under the Revolving Facility bear interest with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread of 2.00% or (ii) the Reference Rate (as defined in the Revolving Facility) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020.

As of June 30, 2016, the Company has an unfunded Standby Letter of Credit for up to $8.8 million. The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires in February 2017. It automatically renewed for a one year period and will continue to automatically renew for a one year period at each anniversary date, unless the Company elects not to renew in writing within 60 days prior to such expiration.

The Revolving Facility is guaranteed by Holdings and Lantheus Real Estate and is secured by a pledge of substantially all of the assets of each of the loan parties including accounts receivable, inventory and machinery and equipment. Borrowing capacity is determined by reference to a Borrowing Base, which is based on a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves. As of June 30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by an outstanding $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $34.4 million.

Revolving Line of Credit Covenants

The Revolving Facility contains a number of affirmative, negative, reporting and financial covenants, as well as a financial covenant during trigger periods in the form of a consolidated fixed charge coverage ratio of not less than 1:00:1:00. Upon an event of default, the lender has the right to declare the loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced, and the lender may, after such events of default, require the Company to make deposits with respect to any outstanding letters of credit in an amount equal to 105% of the greatest amount for which such letter of credit may be drawn.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2016
Equity [Abstract]  
Stockholders' Equity

12. Stockholders’ Equity

As of June 30, 2016, the authorized capital stock of the Company consisted of 250,000,000 shares of common stock, par value $0.01 per share, and 25,000,000 shares of preferred stock, par value $0.01 per share. The common stockholders are entitled to one vote per share and will share equally on a per share basis in any dividend declared by the Board of Directors, subject to any preferential rights of the holders of any outstanding preferred stock.

The following table presents the changes in stockholders’ deficit for the six months ended June 30, 2016:

 

     Common Stock                   Accumulated
       
     Shares      Amount      Additional
Paid-In
Capital
     Accumulated
Deficit
    Other
Comprehensive
Loss
    Total
Stockholders’
Deficit
 

Balance at December 31, 2015

     30,364,501       $ 303       $ 175,553       $ (359,160   $ (1,985   $ (185,289

Net income

     —          —          —          17,673        —         17,673   

Other comprehensive income

     —          —          —          —         256        256   

Vesting of restricted stock awards

     20,936         —          —          —         —         —    

Stock-based compensation

     —          —          992         —         —         992   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at June 30, 2016

     30,385,437       $ 303       $ 176,545       $ (341,487   $ (1,729   $ (166,368
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation

13. Stock-Based Compensation

As of June 24, 2015, the Company adopted the 2015 Equity Incentive Plan, (the “2015 Plan”).

The Company’s employees are eligible to receive awards under the 2015 Plan. The 2015 Plan is administered by the Board of Directors and permits the granting of stock options, stock appreciation rights, or SARs, restricted stock, restricted stock units and dividend equivalent rights (“DERs”) to employees, officers, directors and consultants of the Company. The Board of Directors may, at its sole discretion, grant DERs with respect to any award and such DER is treated as a separate award. The number of shares authorized for issuance under the 2015 Plan increased to 4,555,277 on April 26, 2016. Option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Time based option awards vest based on time, typically four years, and performance based option awards vest based on the performance criteria specified in the grant. All option awards have a ten-year contractual term. The Company recognizes compensation costs for its time based awards on a straight-line basis equal to the vesting period. The compensation cost for performance based awards is recognized on a graded vesting basis, based on the probability of achieving the performance targets over the requisite service period for the entire award. The fair value of each option award is estimated on the date of grant using a Black-Scholes valuation model. Expected volatilities are based on the historic volatility of a selected peer group. Expected dividends represent the dividends expected to be issued at the date of grant. The expected term of options represents the period of time that options granted are expected to be outstanding. The risk-free interest rate assumption is the U.S. Treasury rate at the date of the grant which most closely resembles the expected life of the options.

 

Stock-based compensation expense for both time based and performance based stock options and restricted stock awards were recognized in the condensed consolidated statements of operations as follows:

 

     Three Months
Ended
June 30,
     Six Months
Ended
June 30,
 

(in thousands)

   2016      2015      2016      2015  

Cost of goods sold

   $ 73       $ 52       $ 139       $ 51   

General and administrative

     345         465         578         679   

Sales and marketing

     80         79         128         115   

Research and development

     87         60         147         88   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total stock-based compensation expense

   $ 585       $ 656       $ 992       $ 933   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share
6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share

14. Net Income (Loss) Per Share

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 

(in thousands, except share and per share amounts)

   2016      2015      2016      2015  

Net income (loss)

   $ 7,350       $ (24,423    $ 17,673       $ (24,048
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic weighted average common shares outstanding

     30,377,562         18,898,003         30,372,901         18,489,451   

Effect of dilutive restricted stock awards

     165,166         —           80,875         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted weighted average common shares outstanding

     30,542,728         18,898,003         30,453,776         18,489,451   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic and diluted income (loss) per weighted average common share outstanding

   $ 0.24       $ (1.29    $ 0.58       $ (1.30
  

 

 

    

 

 

    

 

 

    

 

 

 

The weighted average number of common shares for the three and six months ended June 30, 2016 did not include 2,183,075 options and unvested restricted stock for each period because of their antidilutive effect, as compared to the three and six months ended June 30, 2015, which did not include 2,153,827 options and unvested restricted stock for each period.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Income, net
6 Months Ended
Jun. 30, 2016
Other Income and Expenses [Abstract]  
Other Income, net

15. Other Income, net

 

     Three Months
Ended
June 30,
     Six Months
Ended
June 30,
 

(in thousands)

   2016      2015      2016      2015  

Foreign currency gains (losses)

   $ 256       $ 18       $ 19       $ (360

Tax indemnification income

     140         781         436         777   

Other income (expense)

     —           1         (1      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total other income, net

   $ 396       $ 800       $ 454       $ 417   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Legal Proceedings and Contingencies
6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings and Contingencies

16. Legal Proceedings and Contingencies

From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. As of June 30, 2016, the Company had no material ongoing litigation in which the Company was a defendant or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

On December 16, 2010, LMI filed suit against one of its insurance carriers seeking to recover business interruption losses associated with the NRU reactor shutdown and the ensuing global Moly supply shortage. The claim is the result of the shutdown of the NRU reactor in Chalk River, Ontario. The NRU reactor was off-line from May 2009 until August 2010. The defendant answered the complaint on January 21, 2011, denying substantially all of the allegations, presenting certain defenses and requesting dismissal of the case with costs and disbursements. Discovery, including international discovery and related motion practice, has been on-going for more than three years. The defendant filed a motion for summary judgment on July 14, 2014. The Company filed a memorandum of law in opposition to defendant’s motion for summary judgment on August 25, 2014. The defendant filed a reply memorandum of law in further support of its motion for summary judgment on September 15, 2014. Expert witness discovery was completed on October 31, 2014. On March 25, 2015, the United States District Court for the Southern District of New York granted defendant’s motion for summary judgment. On September 4, 2015, the Company filed an appeal of the District Court decision with the United States Court of Appeals for the Second Circuit. On December 4, 2015, the defendant filed an answer brief to the Company’s appeal, and on December 18, 2015, the Company filed a reply brief to the defendant’s answer. On April 21, 2016, the United States Court of Appeals for the Second Circuit heard oral arguments of the Company and the defendant in connection with the Company’s appeal. On May 25, 2016, the United States Court of Appeals for the Second Circuit issued a Summary Order affirming the judgment of the United States District Court which granted the defendant’s motion for summary judgment. The Company considers this matter closed.

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions
6 Months Ended
Jun. 30, 2016
Related Party Transactions [Abstract]  
Related Party Transactions

17. Related Party Transactions

Avista, the Company’s majority shareholder, provided certain advisory services to the Company pursuant to an advisory services and monitoring agreement. The Company was required to pay an annual fee of $1.0 million and other reasonable and customary advisory fees, as applicable, paid on a quarterly basis. The initial term of the agreement was seven years. On June 25, 2015, the Company exercised its right to terminate its advisory services and monitoring agreement with Avista. In connection with such termination, the Company has paid Avista Capital Holdings, L.P. an aggregate termination fee of $6.5 million, which was included in general and administrative expenses in the condensed consolidated statement of operations during the quarter ended June 30, 2015. During the three and six months ended June 30, 2016, the Company did not incur any costs associated with this agreement as compared to $6.8 million and $7.0 million, respectively, for the prior year comparative periods. At June 30, 2016 and December 31, 2015, there were no amounts outstanding.

In the first quarter of 2016, the Company entered into a services agreement with INC Research, LLC, or INC, to provide pharmacovigilance services. Avista and certain of its affiliates are principal owners of both INC and the Company. The agreement has a term of three years. During the three and six months ended June 30, 2016, the Company incurred costs associated with this agreement of approximately $0.3 million and $0.5 million, respectively. At June 30, 2016, $0.1 million was included in accrued expenses and other liabilities.

The Company purchases inventory supplies from VWR Scientific, or VWR. Avista and certain of its affiliates are principal owners of both VWR and the Company. During each of the three and six months ended June 30, 2016, the Company made purchases of $0.1 million and $0.2 million respectively, as compared to $44,000 and $0.1 million for the prior year comparative periods. At June 30, 2016 and December 31, 2015, $6,000 and $10,000, respectively, was included in accounts payable and accrued expenses.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information
6 Months Ended
Jun. 30, 2016
Segment Reporting [Abstract]  
Segment Information

18. Segment Information

The Company reports two operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacturing, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. The U.S. segment comprises 83.5% and 84.2% of consolidated revenues for the three and six months ended June 30, 2016 as compared to 79.6% and 80.4% for the prior year comparative periods.

 

Selected information for each business segment are as follows (in thousands):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2016      2015      2016      2015  

Revenues

           

U.S.

   $ 72,244       $ 64,689       $ 143,014       $ 130,477   

International

     12,832         14,936         24,373         29,092   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue, including inter-segment

     85,076         79,625         167,387         159,569   

Less inter-segment revenue

     (7,110      (6,311      (12,947      (11,432
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 77,966       $ 73,314       $ 154,440       $ 148,137   
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues from external customers

           

U.S.

   $ 65,134       $ 58,378       $ 130,067       $ 119,045   

International

     12,832         14,936         24,373         29,092   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 77,966       $ 73,314       $ 154,440       $ 148,137   
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating income

           

U.S.

   $ 15,931       $ 3,442       $ 29,335       $ 16,121   

International

     (1,443      2,059         2,691         585   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating income, including inter-segment

     14,488         5,501         32,026         16,706   

Inter-segment operating (loss) income

     (309      (145      (174      28   
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating income

     14,179         5,356         31,852         16,734   

Interest expense, net

     (6,978      (13,876      (13,996      (24,499

Loss on extinguishment of debt

     —           (15,528      —           (15,528

Other income, net

     396         800         454         417   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

   $ 7,597       $ (23,248    $ 18,310       $ (22,876
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Overview (Policies)
6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Consolidation and Presentation

Basis of Consolidation and Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

 

In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s financial statements for interim periods in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this quarterly report should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes for the year ended December 31, 2015 included in the Company’s Form 10-K filed with the SEC on March 2, 2016. The Company’s accounting policies are described in the “Notes to Consolidated Financial Statements” in the Form 10-K and updated, as necessary, in this quarterly report. There were no changes to the Company’s accounting policies since December 31, 2015. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

The Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply, which is currently approved for manufacture by a single manufacturer. The Company has technology transfer activities ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and the Company cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY.

Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company’s ability to maintain and profitably renew those contracts and relationships with those key customers and group purchasing organizations is an important aspect of the Company’s strategy.

Borrowing capacity under the $50.0 million revolving credit facility, or the Revolving Facility, is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted operating results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of June 30, 2016, the aggregate Borrowing Base was approximately $43.3 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $34.4 million. The Company’s $365.0 million senior secured term loan facility, or the Term Facility, contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect the Company’s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity.

Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months.

Use of Estimates

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-09, Compensation – Stock Compensation (Topic 719), Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of accounting for employee share-based payment transactions, including the accounting for income tax consequences, the classification of awards as either equity or liabilities, an accounting policy election for forfeitures, statutory tax withholding requirements and certain classifications on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.

In February 2016, the FASB, issued ASU 2016-02, Leases (Topic 842), or ASU 2016-02. ASU 2016-02 supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 was issued to increase transparency and comparability among organizations by requiring lessees to recognize all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). The accounting for lessors remains largely unchanged. ASU 2016-02 retains a distinction between finance leases and operating leases. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize a lease liability and right-of-use asset. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) or ASU 2014-09. ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

Subsequent to issuing ASU 2014-09, the FASB issued the following amendments concerning the adoption and clarification of ASU 2014-09. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date, which defers the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017 with early adoption permitted as of its original effective date of December 15, 2016. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which further clarifies the implementation guidance on principal versus agent considerations. The new guidance requires either a retrospective or a modified retrospective approach to adoption. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, which clarifies the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients or ASU 2016-12, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for noncash consideration and completed contracts at transition. The Company is currently evaluating the impact these ASUs will have on our financial position, results of operations, cash flows and disclosures.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-4): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern or ASU 2014-15. ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016. Early adoption is permitted. The Company does not anticipate this ASU will have a material impact to the Company’s financial position, results of operations, cash flows and disclosures.

Revenue Recognition

Revenue Recognition

The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.

 

Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement’s consideration is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.

Inventory

Inventory

Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. There was no significant product expensed for the six months ended June 30, 2016 and 2015. At June 30, 2016 and December 31, 2015, the Company had no capitalized inventories associated with product that did not have regulatory approval.

The Company includes within current assets the amount of inventory that is estimated to be utilized within twelve months. Inventory that will be utilized after twelve months is classified within other long-term assets.

Goodwill

Goodwill

Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. There were no events as of June 30, 2016 and December 31, 2015 that triggered an interim impairment test of goodwill.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015, 

(in thousands)

   Total fair
value at
June 30,
2016
     Quoted prices
in active
markets
(Level 1)
     Significant other
observable
inputs
(Level 2)
     Significant
unobservable
inputs
(Level 3)
 

Money market

   $ 2,686       $ 2,686       $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 2,686       $ 2,686       $ —         $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

(in thousands)

   Total fair
value at
December 31,
2015
     Quoted prices
in active
markets
(Level 1)
     Significant other
observable
inputs
(Level 2)
     Significant
unobservable
inputs
(Level 3)
 

Money market

   $ 1,586       $ 1,586       $ —        $ —    

Certificates of deposit—restricted

     74         —          74         —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 1,660       $ 1,586       $ 74       $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Assets Held for Sale (Tables)
6 Months Ended
Jun. 30, 2016
Leases [Abstract]  
Summary of Assets and Liabilities Sold

The following table summarizes the major classes of assets and liabilities sold as of January 12, 2016 (date of the sale) and December 31, 2015:

 

(in thousands)

   January 12,
2016
     December 31,
2015
 

Current Assets:

     

Accounts receivable, net

   $ 2,620       $ 2,512   

Inventory

     730         806   

Other current assets

     15         26   
  

 

 

    

 

 

 

Total current assets

     3,365         3,344   

Non-Current Assets:

     

Property, plant and equipment, net

     760         791   

Intangibles, net

     462         480   

Other long-term assets

     28         29   
  

 

 

    

 

 

 

Total assets held for sale

   $ 4,615       $ 4,644   
  

 

 

    

 

 

 

Current Liabilities:

     

Accounts payable

   $ 435       $ 430   

Accrued expense and other liabilities

     858         1,285   
  

 

 

    

 

 

 

Total liabilities held for sale

   $ 1,293       $ 1,715   
  

 

 

    

 

 

 

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventory (Tables)
6 Months Ended
Jun. 30, 2016
Inventory Disclosure [Abstract]  
Schedule of Inventory, Classified in Inventory or Other Long-Term Assets

Inventory, classified in inventory or other long-term assets, consisted of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Raw materials

   $ 7,062       $ 7,506   

Work in process

     2,712         2,407   

Finished goods

     4,659         5,709   
  

 

 

    

 

 

 

Inventory

     14,433         15,622   

Other long-term assets

     1,156         1,156   
  

 

 

    

 

 

 

Total

   $ 15,589       $ 16,778   
  

 

 

    

 

 

 

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property, Plant and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2016
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment, Net

Property, plant and equipment consisted of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Land

   $ 14,950       $ 14,950   

Buildings

     69,577         68,941   

Machinery, equipment and fixtures

     65,982         60,787   

Construction in progress

     4,882         9,099   

Accumulated depreciation

     (70,969      (67,260
  

 

 

    

 

 

 

Property, plant and equipment, net

   $ 84,422       $ 86,517   
  

 

 

    

 

 

 

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Asset Retirement Obligations (Tables)
6 Months Ended
Jun. 30, 2016
Asset Retirement Obligation Disclosure [Abstract]  
Schedule of Reconciliation of Company's Asset Retirement Obligations

The following is a reconciliation of the Company’s asset retirement obligations for the six months ended June 30, 2016:

 

(in thousands)

      

Balance at December 31, 2015

   $ 8,145   

Net increase due to changes in estimated future cash flows

     39   

Accretion expense

     466   
  

 

 

 

Balance at June 30, 2016

   $ 8,650   
  

 

 

 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles, Net (Tables)
6 Months Ended
Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangibles, Net

Intangibles, net consisted of the following:

 

     June 30, 2016  

(in thousands)

   Cost      Accumulated
amortization
     Net      Amortization
Method
 

Trademarks

   $ 13,540       $ 7,843       $ 5,697         Straight-line   

Customer relationships

     100,997         90,158         10,839         Accelerated   

Patents

     42,780         41,367         1,413         Straight-line   
  

 

 

    

 

 

    

 

 

    
   $ 157,317       $ 139,368       $ 17,949      
  

 

 

    

 

 

    

 

 

    
     December 31, 2015  

(in thousands)

   Cost      Accumulated
amortization
     Net      Amortization
Method
 

Trademarks

   $ 13,540       $ 6,934       $ 6,606         Straight-line   

Customer relationships

     100,737         88,564         12,173         Accelerated   

Patents

     42,780         41,063         1,717         Straight-line   
  

 

 

    

 

 

    

 

 

    
   $ 157,057       $ 136,561       $ 20,496      
  

 

 

    

 

 

    

 

 

    

Schedule of Expected Future Amortization Expense Related to Intangible Assets

Expected future amortization expense related to the intangible assets is as follows:

 

(in thousands)

      

Remainder of 2016

   $ 2,587   

2017

     3,393   

2018

     2,688   

2019

     1,836   

2020

     1,595   

2021 and thereafter

     5,850   
  

 

 

 
   $ 17,949   
  

 

 

 

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses and Other Liabilities (Tables)
6 Months Ended
Jun. 30, 2016
Text Block [Abstract]  
Schedule of Accrued Expenses

Accrued expenses and other liabilities are comprised of the following:

 

(in thousands)

   June 30,
2016
     December 31,
2015
 

Compensation and benefits

   $ 9,118       $ 10,525   

Freight, distribution and operations

     3,282         2,962   

Accrued rebates, discounts and chargebacks

     2,373         2,085   

Accrued professional fees

     1,272         1,493   

Marketing expense

     725         490   

Research and development services

     298         360   

Other

     596         587   
  

 

 

    

 

 

 
   $ 17,664       $ 18,502   
  

 

 

    

 

 

 

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Financing Arrangements (Tables)
6 Months Ended
Jun. 30, 2016
Debt Disclosure [Abstract]  
Schedule of Maturities of Principal Obligations Under Term Facility

The Company’s maturities of principal obligations under the Term Facility are as follows as of June 30, 2016:

 

(in thousands)

      

Remainder of 2016

   $ 1,825   

2017

     3,650   

2018

     3,650   

2019

     3,650   

2020

     3,650   

2021 and thereafter

     344,925   
  

 

 

 

Total debt

     361,350   

Unamortized debt discount

     (3,860

Unamortized debt issuance costs

     (5,002
  

 

 

 

Total

     352,488   

Less current portion

     (3,650
  

 

 

 

Total long-term debt

   $ 348,838   
  

 

 

 

Schedule of Term Facility Financial Covenants

The financial covenants are displayed in the table below:

Term Facility Financial Covenants

 

Period

   Total Net Leverage Ratio  

Q2 2016 to Q4 2016

     6.00 to 1.00   

Q1 2017 to Q2 2017

     5.50 to 1.00   

Thereafter

     5.00 to 1.00   
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2016
Equity [Abstract]  
Schedule of Changes in Stockholders' Deficit

The following table presents the changes in stockholders’ deficit for the six months ended June 30, 2016:

 

     Common Stock                   Accumulated
       
     Shares      Amount      Additional
Paid-In
Capital
     Accumulated
Deficit
    Other
Comprehensive
Loss
    Total
Stockholders’
Deficit
 

Balance at December 31, 2015

     30,364,501       $ 303       $ 175,553       $ (359,160   $ (1,985   $ (185,289

Net income

     —          —          —          17,673        —         17,673   

Other comprehensive income

     —          —          —          —         256        256   

Vesting of restricted stock awards

     20,936         —          —          —         —         —    

Stock-based compensation

     —          —          992         —         —         992   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Balance at June 30, 2016

     30,385,437       $ 303       $ 176,545       $ (341,487   $ (1,729   $ (166,368
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

XML 45 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Stock-Based Compensation Expense Recognized

Stock-based compensation expense for both time based and performance based stock options and restricted stock awards were recognized in the condensed consolidated statements of operations as follows:

 

     Three Months
Ended
June 30,
     Six Months
Ended
June 30,
 

(in thousands)

   2016      2015      2016      2015  

Cost of goods sold

   $ 73       $ 52       $ 139       $ 51   

General and administrative

     345         465         578         679   

Sales and marketing

     80         79         128         115   

Research and development

     87         60         147         88   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total stock-based compensation expense

   $ 585       $ 656       $ 992       $ 933   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 46 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share (Tables)
6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Summary of Net Income (Loss) Per Share

During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 

(in thousands, except share and per share amounts)

   2016      2015      2016      2015  

Net income (loss)

   $ 7,350       $ (24,423    $ 17,673       $ (24,048
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic weighted average common shares outstanding

     30,377,562         18,898,003         30,372,901         18,489,451   

Effect of dilutive restricted stock awards

     165,166         —           80,875         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted weighted average common shares outstanding

     30,542,728         18,898,003         30,453,776         18,489,451   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic and diluted income (loss) per weighted average common share outstanding

   $ 0.24       $ (1.29    $ 0.58       $ (1.30
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 47 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Income, net (Tables)
6 Months Ended
Jun. 30, 2016
Other Income and Expenses [Abstract]  
Schedule of Other Income, Net

     Three Months
Ended
June 30,
     Six Months
Ended
June 30,
 

(in thousands)

   2016      2015      2016      2015  

Foreign currency gains (losses)

   $ 256       $ 18       $ 19       $ (360

Tax indemnification income

     140         781         436         777   

Other income (expense)

     —           1         (1      —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total other income, net

   $ 396       $ 800       $ 454       $ 417   
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 48 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2016
Segment Reporting [Abstract]  
Schedule of Selected Information for Each Business Segment

Selected information for each business segment are as follows (in thousands):

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2016      2015      2016      2015  

Revenues

           

U.S.

   $ 72,244       $ 64,689       $ 143,014       $ 130,477   

International

     12,832         14,936         24,373         29,092   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue, including inter-segment

     85,076         79,625         167,387         159,569   

Less inter-segment revenue

     (7,110      (6,311      (12,947      (11,432
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 77,966       $ 73,314       $ 154,440       $ 148,137   
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues from external customers

           

U.S.

   $ 65,134       $ 58,378       $ 130,067       $ 119,045   

International

     12,832         14,936         24,373         29,092   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 77,966       $ 73,314       $ 154,440       $ 148,137   
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating income

           

U.S.

   $ 15,931       $ 3,442       $ 29,335       $ 16,121   

International

     (1,443      2,059         2,691         585   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating income, including inter-segment

     14,488         5,501         32,026         16,706   

Inter-segment operating (loss) income

     (309      (145      (174      28   
  

 

 

    

 

 

    

 

 

    

 

 

 

Operating income

     14,179         5,356         31,852         16,734   

Interest expense, net

     (6,978      (13,876      (13,996      (24,499

Loss on extinguishment of debt

     —           (15,528      —           (15,528

Other income, net

     396         800         454         417   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

   $ 7,597       $ (23,248    $ 18,310       $ (22,876
  

 

 

    

 

 

    

 

 

    

 

 

 

XML 49 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business Overview - Additional Information (Detail)
6 Months Ended
Jun. 30, 2016
USD ($)
Item
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]  
Number of commercial products | Item 10
Number of radiopharmacies owned | Item 3
Senior Secured Term Loan Facility [Member]  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]  
Debt instrument, face amount $ 365,000,000
Revolving Line of Credit [Member]  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]  
Maximum borrowing capacity 50,000,000
Borrowing base 43,300,000
Unfunded standby letter of credit outstanding 8,800,000
Accrued interest 100,000
Available borrowing capacity $ 34,400,000
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Accounting Policies [Abstract]      
Significant product expenses $ 0 $ 0  
Capitalized inventories $ 0   $ 0
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments - Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Recurring Basis [Member] - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total $ 2,686 $ 1,660
Money Market [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents, fair value 2,686 1,586
Certificates of Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents, restricted investments   74
Quoted Prices in Active Markets (Level 1) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 2,686 1,586
Quoted Prices in Active Markets (Level 1) [Member] | Money Market [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents, fair value $ 2,686 1,586
Significant Other Observable Inputs (Level 2) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total   74
Significant Other Observable Inputs (Level 2) [Member] | Certificates of Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents, restricted investments   $ 74
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Jun. 30, 2015
Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and cash equivalents, carrying value $ 54,851 $ 28,596 $ 22,200 $ 19,739
Certificates of Deposit [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Restricted investments, noncurrent   100    
Money Market [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and cash equivalents, carrying value $ 2,700 $ 1,600    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Income Taxes And Tax Related [Line Items]          
Provision for income taxes $ 247 $ 1,175 $ 637 $ 1,172  
Accounting Standards Update 2015-17 [Member]          
Income Taxes And Tax Related [Line Items]          
Noncurrent deferred tax assets         $ 100
Noncurrent deferred tax liabilities         $ 200
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Assets Held for Sale - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]    
Purchase price for asset sale   $ 9,000
Working capital adjustment   500
Gain on sale of assets $ 117 $ 5,945
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Assets Held for Sale - Summary of Assets and Liabilities Sold (Detail) - USD ($)
$ in Thousands
Jan. 12, 2016
Dec. 31, 2015
Current Assets:    
Total current assets   $ 4,644
Current Liabilities:    
Total liabilities held for sale   1,715
Disposal Group Held-for-sale Not Discontinued Operations [Member]    
Current Assets:    
Accounts receivable, net $ 2,620 2,512
Inventory 730 806
Other current assets 15 26
Total current assets 3,365 3,344
Non-Current Assets:    
Property, plant and equipment, net 760 791
Intangibles, net 462 480
Other long-term assets 28 29
Total assets held for sale 4,615 4,644
Current Liabilities:    
Accounts payable 435 430
Accrued expense and other liabilities 858 1,285
Total liabilities held for sale $ 1,293 $ 1,715
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventory - Schedule of Inventory, Classified in Inventory or Other Long-term Assets (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 7,062 $ 7,506
Work in process 2,712 2,407
Finished goods 4,659 5,709
Inventory 14,433 15,622
Other long-term assets 1,156 1,156
Total $ 15,589 $ 16,778
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventory - Additional Information (Detail) - USD ($)
$ in Millions
Jun. 30, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Non-current raw materials $ 1.2 $ 1.2
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Property, Plant and Equipment [Abstract]    
Accumulated depreciation $ (70,969) $ (67,260)
Property, plant and equipment, net 84,422 86,517
Land [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment, gross 14,950 14,950
Buildings [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment, gross 69,577 68,941
Machinery, Equipment and Fixtures [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment, gross 65,982 60,787
Construction in Progress [Member]    
Property, Plant and Equipment [Abstract]    
Property, plant and equipment, gross $ 4,882 $ 9,099
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property, Plant and Equipment, Net - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Property, Plant and Equipment [Line Items]          
Depreciation expense $ 2,200 $ 2,000 $ 4,100 $ 7,700  
Property, plant and equipment, net 84,422   84,422   $ 86,517
Fixed Assets Dedicated to R&D Activities [Member]          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, net $ 3,900   $ 3,900    
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
Asset Retirement Obligations - Additional Information (Detail)
$ in Millions
6 Months Ended
Jun. 30, 2016
USD ($)
Asset Retirement Obligation Disclosure [Abstract]  
Financial assurance in form of surety bond $ 28.2
Unfunded standby letter of credit 8.8
Asset retirement obligation liabilities expected, present value $ 26.7
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.5.0.2
Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2016
USD ($)
Asset Retirement Obligation Disclosure [Abstract]  
Balance at the beginning of the period $ 8,145
Net increase due to changes in estimated future cash flows 39
Accretion expense 466
Balance at the ending of the period $ 8,650
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles, Net - Schedule of Intangibles, Net (Detail) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]    
Cost $ 157,317 $ 157,057
Accumulated amortization 139,368 136,561
Net 17,949 20,496
Trademarks [Member]    
Finite-Lived Intangible Assets [Line Items]    
Cost 13,540 13,540
Accumulated amortization 7,843 6,934
Net $ 5,697 6,606
Amortization Method Straight-line  
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Cost $ 100,997 100,737
Accumulated amortization 90,158 88,564
Net $ 10,839 12,173
Amortization Method Accelerated  
Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Cost $ 42,780 42,780
Accumulated amortization 41,367 41,063
Net $ 1,413 $ 1,717
Amortization Method Straight-line  
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles, Net - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]        
Amortization expense $ 1.3 $ 1.5 $ 2.6 $ 3.0
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Intangible Liability Disclosure [Abstract]    
Remainder of 2016 $ 2,587  
2017 3,393  
2018 2,688  
2019 1,836  
2020 1,595  
2021 and thereafter 5,850  
Net $ 17,949 $ 20,496
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Payables and Accruals [Abstract]    
Compensation and benefits $ 9,118 $ 10,525
Freight, distribution and operations 3,282 2,962
Accrued rebates, discounts and chargebacks 2,373 2,085
Accrued professional fees 1,272 1,493
Marketing expense 725 490
Research and development services 298 360
Other 596 587
Accrued expenses $ 17,664 $ 18,502
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.5.0.2
Financing Arrangements - Additional Information (Detail) - USD ($)
6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Debt Instrument [Line Items]    
Consolidated fixed charge coverage ratio to be maintained 100.00%  
Deposits to be made in case of default equaling, percentage of greatest amount of letter of credit drawn 105.00%  
Seven Year Term Facility [Member]    
Debt Instrument [Line Items]    
Debt instrument, face amount   $ 365,000,000
Debt instrument discount percentage   1.25%
Debt instrument discount amount   $ 4,600,000
Increase in aggregate amount   37,500,000
Description of variable rate basis The term loans under the Term Facility bear interest, with pricing based from time to time at the Company's election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%.  
Interest rate at end of period 7.00%  
Prepayment terms The Company is permitted to voluntarily prepay the Term Facility, in whole or in part, without premium or penalty.  
Percentage of principal amount required to be paid quarterly (0.25%)  
Maturity date of term facility Jun. 30, 2022  
Percentage of net cash proceeds of all non-ordinary course sales or other dispositions of assets 100.00%  
Percentage of net cash proceeds from issuances or incurrence of debt 100.00%  
Percentage of excess cash flow 50.00%  
Seven Year Term Facility [Member] | Interest Rate Floor [Member]    
Debt Instrument [Line Items]    
Basis spread on variable rate (as a percent) 5.00%  
Revolving Line of Credit [Member]    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 50,000,000  
Unfunded standby letter of credit outstanding $ 8,800,000  
Letter of credit, expiration date Feb. 28, 2017  
Renewal period of unfunded standby letter of credit 1 year  
Period required for non renewal notification of debt instrument 60 days  
Unfunded standby letter of credit payment term The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires in February 2017.  
Borrowing base $ 43,300,000  
Available borrowing capacity 34,400,000  
Accrued interest $ 100,000  
Revolving Line of Credit [Member] | LMI [Member]    
Debt Instrument [Line Items]    
Description of variable rate basis The loans under the Revolving Facility bear interest with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread of 2.00% or (ii) the Reference Rate (as defined in the Revolving Facility) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020.  
Unused line of credit fee (as a percent) 0.375%  
Maximum borrowing capacity $ 50,000,000  
Senior Notes [Member]    
Debt Instrument [Line Items]    
Debt instrument, face amount   $ 400,000,000
Notes interest rate   9.75%
LIBOR [Member] | Seven Year Term Facility [Member]    
Debt Instrument [Line Items]    
Basis spread on variable rate (as a percent) 6.00%  
LIBOR [Member] | Revolving Line of Credit [Member]    
Debt Instrument [Line Items]    
Basis spread on variable rate (as a percent) 2.00%  
LIBOR [Member] | Revolving Line of Credit [Member] | LMI [Member]    
Debt Instrument [Line Items]    
Basis spread on variable rate (as a percent) 2.00%  
Reference Rate [Member] | Seven Year Term Facility [Member]    
Debt Instrument [Line Items]    
Basis spread on variable rate (as a percent) 1.00%  
Reference Rate [Member] | Revolving Line of Credit [Member] | LMI [Member]    
Debt Instrument [Line Items]    
Basis spread on variable rate (as a percent) 1.00%  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.5.0.2
Financing Arrangements - Schedule of Maturities of Principal Obligations Under Term Facility (Detail) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Debt Instrument [Line Items]    
Less current portion $ (3,650) $ (3,650)
Total long-term debt 348,838 $ 349,858
Senior Secured Term Loan Facility [Member]    
Debt Instrument [Line Items]    
Remainder of 2016 1,825  
2017 3,650  
2018 3,650  
2019 3,650  
2020 3,650  
2021 and thereafter 344,925  
Total debt 361,350  
Unamortized debt discount (3,860)  
Unamortized debt issuance costs (5,002)  
Total 352,488  
Total 352,488  
Less current portion (3,650)  
Total long-term debt $ 348,838  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.5.0.2
Financing Arrangements - Schedule of Term Facility Financial Covenants (Detail)
6 Months Ended 9 Months Ended 72 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Jun. 30, 2022
Senior Secured Term Loan Facility [Member] | Scenario, Forecast [Member]      
Debt Instrument [Line Items]      
Total Net Leverage Ratio 5.50% 6.00% 5.00%
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholder's Equity - Additional information (Detail) - $ / shares
6 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Equity [Abstract]    
Common stock, shares authorized 250,000,000 250,000,000
Common stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 25,000,000 25,000,000
Preferred stock, par value $ 0.01 $ 0.01
Voting rights per share One vote per share  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity - Schedule of Changes in Stockholders' Deficit (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Equity [Line Items]        
Beginning balance,amount     $ (185,289)  
Net income $ 7,350 $ (24,423) 17,673 $ (24,048)
Other comprehensive income     256  
Stock-based compensation     992  
Ending balance,amount (166,368)   (166,368)  
Common Stock [Member]        
Equity [Line Items]        
Beginning balance,amount     $ 303  
Beginning balance,shares     30,364,501  
Vesting of restricted stock awards     20,936  
Ending balance,amount $ 303   $ 303  
Ending balance,shares 30,385,437   30,385,437  
Additional Paid-In Capital [Member]        
Equity [Line Items]        
Beginning balance,amount     $ 175,553  
Stock-based compensation     992  
Ending balance,amount $ 176,545   176,545  
Accumulated Deficit [Member]        
Equity [Line Items]        
Beginning balance,amount     (359,160)  
Net income     17,673  
Ending balance,amount (341,487)   (341,487)  
Accumulated Other Comprehensive Loss [Member]        
Equity [Line Items]        
Beginning balance,amount     (1,985)  
Other comprehensive income     256  
Ending balance,amount $ (1,729)   $ (1,729)  
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation - Additional Information (Detail) - shares
6 Months Ended
Jun. 30, 2016
Apr. 26, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Contractual term 10 years  
Time Based Stock Options [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period 4 years  
2015 Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares that may be issued pursuant to awards   4,555,277
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 585 $ 656 $ 992 $ 933
Cost of Goods Sold [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 73 52 139 51
General and Administrative [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 345 465 578 679
Sales and Marketing [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 80 79 128 115
Research and Development [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 87 $ 60 $ 147 $ 88
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Earnings Per Share [Abstract]        
Net income (loss) $ 7,350 $ (24,423) $ 17,673 $ (24,048)
Basic weighted average common shares outstanding 30,377,562 18,898,003 30,372,901 18,489,451
Effect of dilutive restricted stock awards 165,166   80,875  
Diluted weighted average common shares outstanding 30,542,728 18,898,003 30,453,776 18,489,451
Basic and diluted income (loss) per weighted average common share outstanding $ 0.24 $ (1.29) $ 0.58 $ (1.30)
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Income (Loss) Per Share - Additional Information (Detail) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Stock Options [Member] | Unvested Restricted Stock [Member]        
Earnings Per Share [Line Items]        
Weighted average number of common shares excluded from computation of earning per share 2,183,075 2,153,827 2,183,075 2,153,827
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Income, Net - Schedule of Other Income, Net (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Other Income and Expenses [Abstract]        
Foreign currency gains (losses) $ 256 $ 18 $ 19 $ (360)
Tax indemnification income 140 781 436 777
Other income (expense)   1 (1)  
Total other income, net $ 396 $ 800 $ 454 $ 417
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.5.0.2
Legal Proceedings and Contingencies - Additional Information (Detail)
Dec. 16, 2010
Lawsuits
Claim Against Insurance Carriers to Recover Business Interruption Losses [Member]  
Gain Contingencies [Line Items]  
Number of suits filed 1
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 25, 2016
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Avista [Member] | INC [Member]            
Related Party Transaction [Line Items]            
Costs incurred associated with agreement   $ 300,000   $ 500,000    
Agreement term       3 years    
Avista [Member] | INC [Member] | Accrued Expenses and Other Liabilities [Member]            
Related Party Transaction [Line Items]            
Purchases included in accrued expenses and other liabilities   100,000   $ 100,000    
Avista [Member] | Advisory Services and Monitoring Agreement [Member]            
Related Party Transaction [Line Items]            
Annual fee   1,000,000   1,000,000    
Costs incurred associated with agreement   0 $ 6,800,000 $ 0 $ 7,000,000  
Agreement term       7 years    
Aggregate termination fee paid $ 6,500,000          
Due from parent   0   $ 0   $ 0
VWR [Member]            
Related Party Transaction [Line Items]            
Purchases   100,000 $ 44,000.0 200,000 $ 100,000  
VWR [Member] | Accounts Payable and Accrued Expenses [Member]            
Related Party Transaction [Line Items]            
Purchases included in accrued expenses and other liabilities   $ 6,000   $ 6,000   $ 10,000
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information - Additional Information (Detail) - Segment
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Segment Reporting Information [Line Items]        
Number of operating segments     2  
Geographic Concentration Risk [Member] | U.S. [Member] | Revenues [Member]        
Segment Reporting Information [Line Items]        
Concentration risk percentage 83.50% 79.60% 84.20% 80.40%
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information - Schedule of Selected Information for Each Business Segment (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenues        
Revenues $ 77,966 $ 73,314 $ 154,440 $ 148,137
Revenues 77,966 73,314 154,440 148,137
Operating income        
Operating income 14,179 5,356 31,852 16,734
Interest expense, net (6,978) (13,876) (13,996) (24,499)
Loss on extinguishment of debt   (15,528)   (15,528)
Other income, net 396 800 454 417
Income (Loss) before income taxes 7,597 (23,248) 18,310 (22,876)
U.S. [Member]        
Revenues        
Revenues 65,134 58,378 130,067 119,045
Revenues 65,134 58,378 130,067 119,045
International [Member]        
Revenues        
Revenues 12,832 14,936 24,373 29,092
Revenues 12,832 14,936 24,373 29,092
Operating Segments [Member]        
Revenues        
Revenues 85,076 79,625 167,387 159,569
Revenues 85,076 79,625 167,387 159,569
Operating income        
Operating income 14,488 5,501 32,026 16,706
Operating Segments [Member] | U.S. [Member]        
Revenues        
Revenues 72,244 64,689 143,014 130,477
Revenues 72,244 64,689 143,014 130,477
Operating income        
Operating income 15,931 3,442 29,335 16,121
Operating Segments [Member] | International [Member]        
Revenues        
Revenues 12,832 14,936 24,373 29,092
Revenues 12,832 14,936 24,373 29,092
Operating income        
Operating income (1,443) 2,059 2,691 585
Inter-Segment [Member]        
Revenues        
Revenues (7,110) (6,311) (12,947) (11,432)
Revenues (7,110) (6,311) (12,947) (11,432)
Operating income        
Operating income $ (309) $ (145) $ (174) $ 28
EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 143 248 1 false 51 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.lantheus.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.lantheus.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations Statements 2 false false R3.htm 104 - Statement - Consolidated statements of Comprehensive Income (Loss) Sheet http://www.lantheus.com/taxonomy/role/StatementOfOtherComprehensiveIncome Consolidated statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.lantheus.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.lantheus.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.lantheus.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 108 - Disclosure - Business Overview Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Business Overview Notes 7 false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Fair Value of Financial Instruments Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments Notes 9 false false R10.htm 111 - Disclosure - Income Taxes Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 10 false false R11.htm 112 - Disclosure - Assets Held for Sale Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAssetsAndLiabilitiesHeldForSaleNotPartOfDisposalGroupDisclosureTextBlock Assets Held for Sale Notes 11 false false R12.htm 113 - Disclosure - Inventory Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventory Notes 12 false false R13.htm 114 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Property, Plant and Equipment, Net Notes 13 false false R14.htm 115 - Disclosure - Asset Retirement Obligations Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAssetRetirementObligationDisclosureTextBlock Asset Retirement Obligations Notes 14 false false R15.htm 116 - Disclosure - Intangibles, Net Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangibles, Net Notes 15 false false R16.htm 117 - Disclosure - Accrued Expenses and Other Liabilities Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherLiabilitiesDisclosureTextBlock Accrued Expenses and Other Liabilities Notes 16 false false R17.htm 118 - Disclosure - Financing Arrangements Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Financing Arrangements Notes 17 false false R18.htm 119 - Disclosure - Stockholders' Equity Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity Notes 18 false false R19.htm 120 - Disclosure - Stock-Based Compensation Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation Notes 19 false false R20.htm 121 - Disclosure - Net Income (Loss) Per Share Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Income (Loss) Per Share Notes 20 false false R21.htm 122 - Disclosure - Other Income, net Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock Other Income, net Notes 21 false false R22.htm 123 - Disclosure - Legal Proceedings and Contingencies Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock Legal Proceedings and Contingencies Notes 22 false false R23.htm 124 - Disclosure - Related Party Transactions Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 23 false false R24.htm 125 - Disclosure - Segment Information Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment Information Notes 24 false false R25.htm 126 - Disclosure - Business Overview (Policies) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperationsPolicies Business Overview (Policies) Policies http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 25 false false R26.htm 127 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value of Financial Instruments (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 26 false false R27.htm 128 - Disclosure - Assets Held for Sale (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAssetsAndLiabilitiesHeldForSaleNotPartOfDisposalGroupDisclosureTextBlockTables Assets Held for Sale (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAssetsAndLiabilitiesHeldForSaleNotPartOfDisposalGroupDisclosureTextBlock 27 false false R28.htm 129 - Disclosure - Inventory (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventory (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock 28 false false R29.htm 130 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables Property, Plant and Equipment, Net (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock 29 false false R30.htm 131 - Disclosure - Asset Retirement Obligations (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAssetRetirementObligationDisclosureTextBlockTables Asset Retirement Obligations (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAssetRetirementObligationDisclosureTextBlock 30 false false R31.htm 132 - Disclosure - Intangibles, Net (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangibles, Net (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 31 false false R32.htm 133 - Disclosure - Accrued Expenses and Other Liabilities (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherLiabilitiesDisclosureTextBlockTables Accrued Expenses and Other Liabilities (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherLiabilitiesDisclosureTextBlock 32 false false R33.htm 134 - Disclosure - Financing Arrangements (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables Financing Arrangements (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock 33 false false R34.htm 135 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 34 false false R35.htm 136 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 35 false false R36.htm 137 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Income (Loss) Per Share (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 36 false false R37.htm 138 - Disclosure - Other Income, net (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlockTables Other Income, net (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsOtherIncomeAndOtherExpenseDisclosureTextBlock 37 false false R38.htm 139 - Disclosure - Segment Information (Tables) Sheet http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Segment Information (Tables) Tables http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 38 false false R39.htm 140 - Disclosure - Business Overview - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureBusinessOverviewAdditionalInformation Business Overview - Additional Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Fair Value of Financial Instruments - Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfTheInformationAboutTheCompanysAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasis Fair Value of Financial Instruments - Schedule of the Information about the Company's Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Details 41 false false R42.htm 143 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformation Fair Value of Financial Instruments - Additional Information (Detail) Details 42 false false R43.htm 144 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 43 false false R44.htm 145 - Disclosure - Assets Held for Sale - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureAssetsHeldForSaleAdditionalInformation Assets Held for Sale - Additional Information (Detail) Details 44 false false R45.htm 146 - Disclosure - Assets Held for Sale - Summary of Assets and Liabilities Sold (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsAndLiabilitiesSold Assets Held for Sale - Summary of Assets and Liabilities Sold (Detail) Details 45 false false R46.htm 147 - Disclosure - Inventory - Schedule of Inventory, Classified in Inventory or Other Long-term Assets (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureInventoryScheduleOfInventoryClassifiedInInventoryOrOtherLongtermAssets Inventory - Schedule of Inventory, Classified in Inventory or Other Long-term Assets (Detail) Details 46 false false R47.htm 148 - Disclosure - Inventory - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureInventoryAdditionalInformation Inventory - Additional Information (Detail) Details 47 false false R48.htm 149 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipment Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail) Details 48 false false R49.htm 150 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentNetAdditionalInformation Property, Plant and Equipment, Net - Additional Information (Detail) Details 49 false false R50.htm 151 - Disclosure - Asset Retirement Obligations - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureAssetRetirementObligationsAdditionalInformation Asset Retirement Obligations - Additional Information (Detail) Details 50 false false R51.htm 152 - Disclosure - Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureAssetRetirementObligationsScheduleOfReconciliationOfCompanysAssetRetirementObligations Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Detail) Details 51 false false R52.htm 153 - Disclosure - Intangibles, Net - Schedule of Intangibles, Net (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureIntangiblesNetScheduleOfIntangiblesNet Intangibles, Net - Schedule of Intangibles, Net (Detail) Details 52 false false R53.htm 154 - Disclosure - Intangibles, Net - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureIntangiblesNetAdditionalInformation Intangibles, Net - Additional Information (Detail) Details 53 false false R54.htm 155 - Disclosure - Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureIntangiblesNetScheduleOfExpectedFutureAmortizationExpenseRelatedToIntangibleAssets Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Detail) Details 54 false false R55.htm 156 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpenses Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses (Detail) Details 55 false false R56.htm 157 - Disclosure - Financing Arrangements - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureFinancingArrangementsAdditionalInformation Financing Arrangements - Additional Information (Detail) Details 56 false false R57.htm 158 - Disclosure - Financing Arrangements - Schedule of Maturities of Principal Obligations Under Term Facility (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureFinancingArrangementsScheduleOfMaturitiesOfPrincipalObligationsUnderTermFacility Financing Arrangements - Schedule of Maturities of Principal Obligations Under Term Facility (Detail) Details 57 false false R58.htm 159 - Disclosure - Financing Arrangements - Schedule of Term Facility Financial Covenants (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureFinancingArrangementsScheduleOfTermFacilityFinancialCovenants Financing Arrangements - Schedule of Term Facility Financial Covenants (Detail) Details 58 false false R59.htm 160 - Disclosure - Stockholder's Equity - Additional information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholder's Equity - Additional information (Detail) Details 59 false false R60.htm 161 - Disclosure - Stockholders' Equity - Schedule of Changes in Stockholders' Deficit (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureStockholdersEquityScheduleOfChangesInStockholdersDeficit Stockholders' Equity - Schedule of Changes in Stockholders' Deficit (Detail) Details 60 false false R61.htm 162 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) Details 61 false false R62.htm 163 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognized Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) Details 62 false false R63.htm 164 - Disclosure - Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfNetIncomeLossPerShare Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) Details http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables 63 false false R64.htm 165 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformation Net Income (Loss) Per Share - Additional Information (Detail) Details http://www.lantheus.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables 64 false false R65.htm 166 - Disclosure - Other Income, Net - Schedule of Other Income, Net (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureOtherIncomeNetScheduleOfOtherIncomeNet Other Income, Net - Schedule of Other Income, Net (Detail) Details 65 false false R66.htm 167 - Disclosure - Legal Proceedings and Contingencies - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureLegalProceedingsAndContingenciesAdditionalInformation Legal Proceedings and Contingencies - Additional Information (Detail) Details 66 false false R67.htm 168 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 67 false false R68.htm 169 - Disclosure - Segment Information - Additional Information (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureSegmentInformationAdditionalInformation Segment Information - Additional Information (Detail) Details 68 false false R69.htm 170 - Disclosure - Segment Information - Schedule of Selected Information for Each Business Segment (Detail) Sheet http://www.lantheus.com/taxonomy/role/DisclosureSegmentInformationScheduleOfSelectedInformationForEachBusinessSegment Segment Information - Schedule of Selected Information for Each Business Segment (Detail) Details 69 false false All Reports Book All Reports lnth-20160630.xml lnth-20160630.xsd lnth-20160630_cal.xml lnth-20160630_def.xml lnth-20160630_lab.xml lnth-20160630_pre.xml true true ZIP 86 0001193125-16-672020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-672020-xbrl.zip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

SV.=G>='9D'71W,3R;DAF=:9R! .^ M7I)R0VX8Z'HK:G66;U00L0,V,"!G3;%V:3+F$B3JV^RT>NL[H:C(AP6&6^_!TT_M) MJKR N+0921N)_X*0'"K"/*#PB^86PE]-T )L6T7GGQJ?0VF()B,O0/HM)V*] M%EQ-\NWK:RG^"NW;I,C&6ODO$K,L*TS3#;5/"TL@[6H) &45#:5+OH0>*H!0 M?+&#[P0=GQK+-?JTAEPJZ5A.PO(-[+/C895]-R#C$[OOFZZJ@);6Y8<45EICI M^IS:5?//D9F8IS$K1LOE=__M1 ]?_6MRCU@[?O!BS680GMKN\6BO!-,0.QW9 MZ)N\UE=,(%[L\9:B=7C#[!JJBLU.!QW6(C.E>VN"L=%% _XMJWC%9,5%D@K+8"F#CJ3W>*4K@[!T MS0%O] 2!MRS9ZG04I2]W#0;,@8UQVX:@Y(LQEQ-;*K#U(F>,8:KS2&[(* YH M8J;_C!>ZL/QA*SA#,Y0M MHQ@%6-R75(GO#@2PI0**E=K3>-&P)&.@:X9@=!G'0,,D494-2<\5Z1Z"$X>M M?T1^2*)(Y4M4C=TP=4W3 A'M]WC3DE1>$>4!6-QNG^\85K^CB'U#%&3&%:PU M$T%^I=*F6E42>< CLA-3B@DC;MT/02JMS)UW)NY.%[6=P-A6DCJF6D6J+]Q # M0B5VB72/4Y4["O"OR\ -0=0WZJ=2<9.H)^BZV9,@YAN GZ)( F\8XH#O*X+: M,2 ^&/3-#%1,UM-KT[O2>LP#TR" M98<64[A[<>+@KL.)W".5(G-N[A,>CK)CNP,:4J:A6IB"HFY$6J4$?(N#T8.= MB,"AA'^[AO55+>4VZ5@_AUVM; BU';F,66/B?.Q[$;@,U^2>8BMXT5=[NE6& M7TI@95C^KYR$,1306MWD!_V!!H3U$4[(E'E=&BABUY(&AF3=42RQS];7VW_T M?[_A_G'UN7?Y];>;%G?YM=O^^X=E:4CF+PI@O57P5WL#@15E;4^JBU%/2V5%&Q! MTWPY>_Z(XL7PTKPV%#&\;DER MVTM-!4S&2S_:9A)6)JF,H3&,YKWW;H'4CNN/OA]L&?M29S P8$<0+=/B%:T' MYE#"D,@:&)9FF3U5TIFX_*_9EP8O;CDUXLOUO5OEU_Y MSM7M[=67CYPPBW[A_OV/R]L^?_/-ZO8_>KZX]<<#]\+[3@__W\"S>X^GK[D1-A<.YO M]LP/?[EUIK"=?B5/W+4_M3WV(;SCLG?U[QOXY2]<,J_;JV_P3P-G];E_>]N_ MGD\AG1B=Q>777A_?0>?%/Y'A=R?BD.T-K0,>=XD<_9W$^RIK8%;NJX M+I@<&"9$EXY_(7; %5C?XIX>G-$#]V2'G!.&,0SAD8CS)S"(V);4OW)CQ!R, MO0@&@4]_4MI:.FR;N\W- )PB>"; 6C4.YA"0/V.\\FQ[,*<$(2ID OCX1]D M1.G$Q1)_P$A@E M(!-J3G L;A*[+AUWSI09C#=R9AFAZ81_@O"V+< "6HARE36TRX8(%Q+X%!AIB3X"807W#@ MBQ*49/I?.\JK_'SUS%]"CKB$AB?P(QCAO?/S7&4^7W:NKA-UX4)85'N,PJ.U M!1"3]_3=-L=^%*"D35P?!(>*MHB_^1F%^+V3'Q*G@9D3#F'2N/>@^6,47VI_ M.#\NV9B?,VW-O5[%H=MWS27["O(PSY"AQUX0'JW1'DAIIKY;V"C8GXE?P$T%8$IGWYS<'T!QEAK=5 MY4&1YQ%()29VF0I\K,4J:#LN@G"4T"83U07>T(N9*7]PZOS-Y?_K,REBM/ # MZ\OEY__]N(:<18[!/M@#*H!%GZUO-S#FR'==>Q:291@' Q<=UP9J/_ M0@O'\-\S],V3?]/?_GHAPFYUP0W] /8T_#S/HB#_CW'ZA/I7^J,2;Z-Q\<>/ MMNO<>[]>1/XL>Y<$;TH^=LDDR@^#9F3S@<3MIU!^+]*=&EZ,'V@@D(\\;->% MH6"!^!0_"=8Q#L#!"FT7) '],1J&C"DLO,,NK.*#M!*3ND@I1CS'XC 2QBZU MPO"R&/R4(]]FAN% M$NN'9$XE;ERL$A9B'HAO4N=K&(=X(2"D9L7!_2]Z(NXC; F^%SV$%=S^4)"5 M#U2Y&D/4&*+&$.UIB##B1+\WN705,L>7]3H98?8& JT5A,7/^I?4 =?3Y>B#9[WC5">SZIDIY5_+JY M!=LN?,5K1O<^[@8PAS&]9!/.NZ M[/<@S_.41%5NGZ,)M#'$QR/:QDABV4D\5I)I-L)&!E+K:XKR1J@QB'176M6N.%3"*N,H2Z$W [_*<0_X1! MJO/M]B)![?*;QOZ4>1/+\I^9\4CA_F\ MZ*E%0<4Z&]LL\\5JLCS_*;!GOUZP_UYLJH*[SH8*S.T_P#P9;5J-D0A<.OA< M*\$_C+C0=YWQ@K(M%*N\IRZ!'X=@]L.?5U2KK%OEDC^_F6>?LA)4!836PQ9H M6\0%U6_>12RV4W]0E7N8L0^Z\E_=;K\_&"R1% Q<=A"+;8U1,MSG_@!-,9E6 MF-B"(>'A-^F\KNEI%W/WZ(9RTH7'+W_:2$*2?](:');O:1F2NM&C%7JZV7P/ M+SAG*R;8\?+DDK&E$5D0$;FEJ<*YB<@/9%M :(Q&:!J[LEI$S$9$&KNRI=!( M0B,TC5U9+2(BS63A>1ZQ)Q#@GI_$*$K+K(./6[SCL(38$S!T$WE+@F(J(H6( M^'E=1+P\:71._EEJ'M+#@_-\;F4!*4%B=Q(X2$/C\Y4EN"(+V:'#5.ROG,[?1.RME: M">J2G)TMD%6II1C&N7DC/]#N\IF6M;%6T-R,]=(Z.S%ZOU?2I-E2FBVEV5*6 M1;FN[]WS]&K0J/@ M7^_PKCUUX/#^HS?F&):*0QN0),RGM=L4H&&$R!6+EYQAD/GE1SH*XL %, C. M)GH(2(@MO!/XF.)NFT]I( N\XO_(_C*=3"%T>*FQ YIE3+B=G!1 M8#LNNXT]P9N1Z97^H1TZR4LKR*)UL'@MU+5?&*0%*Y9E19Q#XOI/-2E_W57: M).6@NEJJZ$RUL4)O!QFW:ZO!34GQVRHIUI7M2XK%%<\^AB;AL)E])E(.A2FX?SC^YQCL>)08T M9=9]ZRV50'G?XYR\P/9I-OS+3U#!,/7D* SS[RXDUG^!9GS^XW_P)O>LR]B Z:8C8E/\'IY'^#6'%CY]$9$P_! MJKP6IEJ2)@@X(0IL.,8V LXP9BREN11@\HS>DT<(JIF#Z?00>WIGSS 8F70M MR#C#1&13R#.$_CZ=)P.;8K_$W^5_R*#M@ L,1RNB,!>%A9@%"(L+:DOO:X^S MN_N_,-S/Q^)*4#>7@BJ_FX-;1;D^)PR[E7)X,@'Y@3'/'ACWN+G1.>X/-MI" M\6"MMNJ66JE3$BKG0 MEG7UKRF$-F:+<>]96-=W[.[&N1N18VSSU@J,API-P%68H(R.N1M$.J58()]) ME.#D,K.#R#,IU+S1-HK8]IL\GZ;^*2ZOYZ&W 0O>RA!NL]1_ O6+@@+>!(E0 MJI=@Q)L\(70XD&2##'5NXHAE@T0T?,3M"*>YSR2($1GBGDIL>?B[EIH M28!*'*9FA0V,F,H(^4%/.1CB(Z<),,9+?F>.1P^,< H"TFA"M<-;88@6H'7^ MX;N8@@Y7X.HP!S?,(>; TL]<,KZG5JO2HTP<9H:9D^*>)WXS;@T4+-NA8INA MDHY&K#]#0$;$>4358"#;C^!C(=H3.W ;@420Y%^H6#/T\]IH,:L2'*+RIB:>8V/.'$+P]1=IVYM#R>:ALFY&;P:!"Z.90@/>* M>1=G_>XOR^8-QL1#S?9HR$$"\%O;RXP8T^K$C,UWZ2(-M$V'/9L%_C-M4@4K M\I,BM^74:N$H\WX>L)KQ*%E1+X_W7+!T&QDY).LGH2UF#V&\,!H%,6LYDO0Q M8*"S^ (: =@48[)$@?UH.VXNU"I1(RMMY5W6S.+<5?]U/.GZ'E?6R:=>8D(/ M7G4 BOB$83;US1=_@48LQEXQ$%8Z]_32PO@NY[A_T(4 M'MP3NJ/G6]S@[W'?3?9DT'[QHR!\Q/_3YGZ?^;2) '8$BAB '3C"-F@N,SXN MH6X]NE#XSZRCSYB,7#N!DV?^/P5DPR@>ALB#=N5-C3.=@DPR[1[')&TSPYIG M,+0U.GT$DV;0??DGF'6G!/M!:M!:Z:75=*I3FS9LH&G$Q'MX3%$ ,]*6H.&S M] 6AJ-IAXI1DN0O<1KP"5#Z\$DTC'7K$M"W?D@%K2-*F#**@9F"[]S3A@PUT M6*R%#A8SU'2Z;FIOD15L5(3;'L+, ONIP@Q^2%JTS1O/+>D@5VJX-_XC3E(G MM[Z5I:J^V<[XTNNR+ UMBSLLM\6]1NX!B\@-;&/.B+#3RVLR\N\].LJ_;#<^ M;9^^SJ"C=@5#X/NJI?&*WNOREMI5^8%L#/J=KJ#(/1'[]&EWV 12T"X^F:46 MKL=FQV(/2?:[OC?N[=4V<[=FDM+%)QR$%S1>%HHM)0OS*LI,UPX?+&^,_^D# MT8^VB_QB#Y3;HI]T_65%40VK8_$]31_P2M^2>%.']3=[ABSJ74TUU %0+2M MMB:IQ1:WVU!5Y$??#K#Q"?XV[2#MC&"HGN/&:*<.RH([V SN0GQ-F.>&M, , M0X+_"$:?-P8#BU>LOLQ; TV'OW082^@*LBCB?O%):*O&G!%KR"G)0K8# M82=<^&OTE4+7T T32(%U56%=M0'?Z5M]OB,)4L?JFX8XD,^K5V7A@$QF MH,>OXC'B'P[^@:M,][#"BM)]]1N&*N #99=AG,Q_;#S)I9XDAHG4IV ]D6P( M>J,T-G*FK/&&%S+SD'?B$G<0DY@8C#,/Z,%^Q-)-XC$(9-;7D;XB&-/+KRR? MRR)3EDM)LKG8+.2>0"3*HO41EK-F"4[N=X].Z@;?1%??FL+L1G;2<.GW]DV; M^\VROK'D5_5,\_-,$IYI.B"-E)<%]Y\P6L^?ID%,3)U RJQ1^E0Z M&O7U\B9O8L4$A/R\M/@8*^273$7_F>,G)PU) ?)B@ MS;K])NF:G/+#2'/U7Z?V5(+1 EV/)<$+N$F9^ W,>NG35=8N;N!OG/T*OQ-_UGB,6]>\K8J1.&%"W> M9Z=C-_TN,ZDY'LS/BQ+S#/OQ_)8 RRMPX8,?NV., ^G) /P.9OY'[(V2$;*N MM)6KN5[FDC@Z,=[9_N71IK&39/;T"(#0#"%XQ.7.A"+K3+A SI(Y#3"; =[@ M_X4)(6A_1@'PB+4__&('HX?Y"R1VO-->#B,^WP>Y&;JD=$4"0M,:X2APAO,I MS1_L_L(ZX\):=_-L&N1D[29CU/RYWB_I6'-*D(OQC#Y/TSV9%K;8ME2YMFU6 M^L3: 'L^QZ0G3(6OBM+Y'EN@-710[)S4<"1'2E1" IK[0H\C#K#\)*2IYC%8A<>T:6UJ_:I$KL4-8QCSTN'QG!OT].0QT<\<:>P4#RS#O5LD.2W@ MR,][/LG**::TP%2_/=BXI/$(#]E0U!-%R[^9JAN=#,1L#W4RQFF1X$M3P_P#'(-73JW1 MO47=^QWV&+? ?E@Z-(AHW# Q#7L!S'&,J6ZF6.-4AN?!*.TN3(4X+%9G@ @_ MQBY&JST$G;2_7>C<>\X$3#L8$7N,!0TDVX=90$E+1O&$ MP7D&"0Y\<,* = ]#E%YX9W+4D3*' M>>R]$DTZ>)R1'R0U/=2\C@DN#SWQ\[COY"63[3"I8;@/_'C&)96]--0,[FW/ M^4_)IYK:?_A!KDPZ:5 [250?C^Y&6/P\M>^IEYH8@%7^>U(,0"VUXR7A(CTG M#/R)@]7N:5T2ZRF+B>; 'D5I<):$9@_.+$SC"?@9C+% YCHB'5K%!3J"YH>> MYME9$?/2D"81TZ;[5X5<5M3MS(M&:8EI5E$29&?Q[ 04W8OD4#X+I!?/ZUO4 M'[+=$0;HBU5 - TT!4#ZQN;0$:'4!$)7F>0E01DVQ,J9L M^Y$P<'AP-\RV7I;J>' (Y8'#P@XR@OT$4QGEF*15[%Q6&37GB6*9VHRN49)[ MP$ M*7E CW,RH1WS"L;8KB*JLAX*Z5E?$56L2EV2&_A)UM2:.$NT$+ZJJ1-^C1+&H6 MC)^)364A>HX@Z@DQN5TNA+E=B$)TO&2IJ:2ZAJ%M)&Y6X;)1*U?F6'10U\S3>:M^7T M9>(QCQVRDP#, KC@RD=)#_%G^ ,\>@CB67JM*%'L_U<7+*VJ)2A7'4QA\!N\ M//8O'YEXC25IX<$*#@:F*(J"T>7[D*MJ-'/+.883(/RR7R]%3.JKBQ:<)!/"$S;4PE?D,NTP;YQ0Q:TL"0+,97&%GB99%-=]F\BK+]&SNLM[RQ-09GT:'! M!&RL_20D/V5!U88U1.K%)]'05;%03[6&CE()%=V+KR;IF1E>R+KRJDNRNLQL M@3Y=S2UB'5BZLB/BT^FK!H%AJP@ M83FM1R1.731,NF'U>H;.2[@!*%*GQYN"(N!?BJ4JIFIU!Z "PL4G!>5_&7$E M:K)CK:M)L8B4QJQ=1+)/:^_(^%MR"_KPA75@=45)LS2^8_9 JR71Y$U)D7B] MKUL==: ,)*-;P\(Z<$W^C/UHT3=,OWBM:CI1SIU*THV?9\YC?I'K63BW.T^/ MTW\ 9;W'OR^?]].?X M7?XP_^=:14![2/I)&[<3B(_]%\+J+.97Y>@M3TPF0?SY9 ?C)"Y/4C\9_UD2 M(_LG3;HF/@,)YAF9C@]#L%BH!Q'(*/*3'.X,[X1$87*OPO;23%Z"+C%+#S#P MGYA>F>7V$GJ9A67@;JQK%G.E\!/T@<5/:$&7DR2;4R",7."6C,F]SPM;KW]= M*!KYF>4B,\;!## V(P'\-2Y0A]E)B +MQ4+*].@V94R.+7@!!B.S[+![?C+3 M8CSB<$8TI?'N+^7K+72QDI/1T0/^$M4DAHY4>RL.U$..;)(5:B MCG>)'_R =FNAIX%ILY9YP)HM.RL8HO7U]&!*::FJVI)T'4-O:Q8X.1PY24N+ M@*[82> J\:(R26E.RXOPKM,S"48(FH(0!&1^1X>F:VP'!WFD%UA6)?I'-,)+ MY"Q!*L#2&7R(OI#R!6$,D@NFAYDE9S04\16+1L)6>OB1 M.]S<8+P'DG\""XW/+GSX&C.D^1-%/ 68P34'9ZB)%"8V^+*((E) M>3.KDDGJDDNOHF]:9%?R*H=E>Y.9)EB[P +,[R8O8.]NE;@9^,-Y5I8> Z2) M]Q*SN0@OX:&^/B92'J37@[B0W0]*",B53.!F%:3ZQ,!]L50SDT)VI3JW/(P0 MG/"4W8?S%@60B^FAELUU7!N\D9O1@X^GV6#=)@&IZL)8;=HX8%)"DBBS)IF/$YAD ML!9D7*U8E$'I[U&B"+L4F5C[^4O"='$0L "5F:*+/-A1]M/$-"2E7J4YY&[Z M)25F3OB=GV 9609E@G:0G@R&\30I3&!OI?7SMP$%=7[AF+DL$I-I7U;-,T7Y MQ>B N.R$:#K$%8MRY'*N,\D5GE$JZE3S2P:VH+CE9S)%WVHU!9CL6O1&B=;TI*2U%RIP)O#FTLF6^14@N3+BVNO,"ENK/I_&%'B;2;P/N0S*;/M9DE#Y;J.,OY=L.C@-; M-\;=.,]<7;CU.L)_I'X F^WDV!= ,=K:P=H"O*<>D1^'X$>%/Z_('M=/4"O; M V2$97CS/Y1RKJ59?8,T-^O\:HTLUMO2UP"/W\"6[@,BCR>H-%?DX\UD6,KQ M<:WEX5HUZO)&S^V,'%\;0M6=FYZ?&:&B;+X12E7QN(0>SP2>O<%+JJU896BA MWNKDAF_?+AJRHIZ;ONQ+LJ*].9)5_2-H7,0M+.:-G8*Y3.W@ M.\%3W[,SE<:1VPS5C^)CJU#]*!:E-V]+Z#P!+S=WYR_)"B7.:V_8RUZQ*LRK-JC2K4I>YK5N5)NNQ37=E/VN[NJ+8\^3._JX' M#L;9Y4UWI%13M3="J6F^E8-!4S[R6>\;\>5EV&W&?CQT20VWPL-.[JP\E&9= MFG5IUJ59E[U]^@_T9DKN@V' C5P[#'^]L&8SE_"L3PR%5.$]\H2W1R^R$N=T MD,4&>?NA<"S#<6(MPUX%R4FY^/1/J0K'*3>G!22M64 >@'3GD5QZ".+\E417 MDUO[^:08,NI T3M #6_T-8E7#$G@.Z8A\#W)4!2E;W2Z:N=.QH9UHFY*9K%S MVW(:YFO4]R(G>ADX+@FZ",[*\"Q/B@<%J_/5]WCLP>3BO37:7 +^8@M6,<%2 MJ\8<.,[5Y-*+0-P19<%B39=/"8ICF@-3E'L6WU-DG5<$I<,;LJKSIBST3%,U M>CW59* X% "IT&%Q)15EX0QA&7_#&LX;WSUP([W#0%^)%Y]@\0VC))"%>1>) M&MA.\"^\TSTW/T= ]I$514 ]X;L=38050CBF;E_A9<.R+*FO]:S^8"=DG]7Y MBU+68A%\)[\-#?'O/&(.LH;[5WK?/6N\PEUZ813$K.\*6O)A%I1L?,=SCVEK M"PD5Y:]9.@5[BMCT@O:0N/Y3VA^EV-MHZ,?+<4;?96W3&3HN0QAPZ)5O.Z)7 MTJ?T CF["9_'!&#MRN=MGQA@@EW=3ISB9=!W5#:&>?>7!%R'0?[2]B8D0\-( MWOC@@-V"C3;#^G[,X0C0IA'.GS',G*&1LCOT64-VAB4R'PVQ6]/6=*T"YD98 MZN+^&8^AY[,587ZS.,I>PV%>#&$'$,D#^?D^]EBW+#+^F:'P4A@@5N>3P% @ M\#G%)4][U@=YWB-NQR";Z9KY2.7YL$XY/G@E.!O6 :.3W856%6VOPILO-ZEV.;51WGU3KX)'A-0U.VJ]I1Z>/*2[FY M[\_D0MWA./E/NB/.)\&VQA)7LHV^]'FRYY8^?5]V*LIB]V-S],;)&AW-9T); MTI7X-'<.%MB-;L0:KDIOEZM%QN2]K%T8*1^8D;L=FI?WHM,?D"^+U'8Z#/_B M>^0EL0_'W6H.=V@HM33CK1P%GQVM5?/8C/;2@XN\F$='L/LK!YUAPY_=^?,C M'['/]\6:59H=96*GU83:D%W;B37K4:^)->M1KXF=QL,_*W^>)5P:1[ZA]GTYVARL-P?KZ_;FYF#] MF-[EKC"]+?6\QY!>3B7V"&!01#!!W_J>",W'A,$7.)HC4#N MMRDND4[$=O%"4"$99 M< C F9DG%[V?D#Q2FB<(OP)4%(F^C!058LP" EH%!5@%$M!#:" M+T-"A_/\B(L">TSI24CT9\1+SHRW@1=Z+@H-_KLD%<\;R/BQA'(QH"O(9#5* MUZ(\1K38:62'K"\3_@$#D#]C!_B,N&C(^Y]4I6TNR&PJFIFLV;-9X#\[4UAF M%P&B?I+:^L)3.-XT=XK/36)O'+;7Z!&,ML',2_.F4S#:VI8SYWX2VQHWGRX, M4S'ADRWT2NN#,'$DC.C,QSG]"%.5J0*&XR8I -X[K&7)(/!:"4,0\;$C?&E:$X3^I+)#,G(CD-&>@%XC7-"+HR'?Y!1A(0R MN%EJ#=^EM7 EI+9%Z5L$H5T)!UE"CO0# AY!-PX"XHU>;@/;"[$PS_=^LQWO MLQ^&'0([#CDY=JNABK(VT/F!T9=XI=\1^$[7-/F^H _ZEFK(W:[!T$#%(G#K M%@05.8'0FD^@^98W+B.(IE]]@QUR=#B(UX&HBX:H"[R@PV/*0)9YLR>:O*5U M!I9EF))DU -/,Z6?2EMUF>]K &6FTT(EPLW?9C"P9-SBAG&$GZ(M(;AAD)": M!P1I!'O@!&A>0/%A$'2?X$\/_!L7-@#J13T0#]R0@(/_XS$8QY$3C.)I&*%; M%.:A+.D8#GT9O)UPKO,=]Q'XPF,."8(RPO=3^P6L0/)V=(QN"WL:8CH2EXPB MAF\Y(P%"?3*H1#HU2@(EX#ZC.D=)LN==C2*_9*30$!(;=KP78@?TM3#+)T+] MI93 ]/&=[!\C,0J<^WM"\42]=PFZI#/-SY$2 )-)Y[^)(=M8)XNJW+<##XQO M^(T$%&O[\%"XO8XD&(JF\*:B&;PB23IO6:;%=ZR.IG9[8K\_Z.VDNO_^Q^5M MG[_Y9G5!63R$>W7A0PB_Z&>77W]+W%.J$K?7UM>;P=7U%_RI!W%8]^KSU74> M8IVI&E,[<%7!]UYL H0?TAL"5_^^@5\NVH-?N,_]VUN(_[(II!,K*":=%_]$ MAM^=B$+;7,]QZ0Q(HIET@ND0R3QI%+IRINLG"&-43W'U!%O; M^1'B^(+-'>.L$6*73";HH<&8+*(.$1Z9 2H[Z&?ZX-O-/X,QJ($%8P/SPWF" MV2;/)!@Y(9K^'GL]>S7N)DE,DO-7J0F%\4)*/:X.>-O43:6 S"/623=A*GY= M6''J@+JCV+7+O,17I",NY2;C8&E1\8499]R7.6]RO,"WD^# M057.%09?/6'LDQ^[8]P?;1@^'7G+..M8JB[MJ.K"40SG\FS#%F#&J\E99-E2 MK.-EW,RQY& <.!FLLKH]K++V>@##S:N/\NJ=+GZNT*L-SDY/?9.JT%MS_64J M;?7-R8> $+RC$SV$7-\;LV+R$OXPE\ .U_R*V4$9<^,\GYXMIY7>HUQA7K?E MXG5F45?;2L5]YJH%W/)*C^9AV5/:;V)WE%8YK' ]8A=B2U;=2 M7?I>4EJ*M'.OX)_/@DA1;VGZD?LAUX987%%!,8ZRHC]R?6C3++6>%7#-NC3K M4I_)->M2S\F=WE,_6[^^X+'A LM"2=;VE:M*Y MN7S[4BX:+<,T6H)P=L[N0=9<:IF"^-8HAS57#+.EJ$>FO,EUK+"I_:PP(#L/ MG\/I))4']I,=C,.SLZ:BIK9$[:QNH/XX*"IG98D,H67HZCE1_28$Y8TD;6J' M97&LN9U5"-JL2K,JS:HTJ](D:W8++-*"Z1\[7:,J4DN7=CZS.E>'^4VG:Q15 M;NGZ6<65/UJZY@?P^ILCCF9=FG5IUJ59E[.9W.F]_Q_HH*&S<.MO\<+GRECA MW5]>-5C8L:A-:$MG!0VY!ZGOQ;9D[DKK>=1C"FWU[&*]W5=3WKF6N*G%;#;& M9EU>?7+-NM1S-"5XV7H;H-';&%)TJ04'DI)9HR"U!5SE_AB@="/Z!(\;> M(T/.6BAJPK=36"F&8I+!>C#8/2>@ \RQ/!*@#XK8B2 O=L" KA8(*$S_W?Q^ M= *UQX!2*J:ORBU#TM/I%R8/HZR;_B985$M!I8K84Q2=ZII$3D 0]NIJ"/I* MD4_F6'R'AZ-21^$'&N/GK&9Q<[@FFAC#*'&(.!\^]:!;XXYCB(N8G2L'J@%=^0!$H.X[K M@H*,[!;W!5X/"@,Z'D5,OVY@3O\=VUZ+^Q:3 !AP[8Q\T.%*D,I7@TA-&> @ M*O&?L9,8'B#_$9:3+N;O[9LV]S4>N<0.0##O$:K(#UX8]Y+EHA07>= C8,8B MMA(3X &LQHC[!['=Z*$ LPH/Q0'%4QX3L&Y@B6"1$BRF2GA2>\B 26&:"#B; MK&2%\. (=*F6+]1\F><2^<+D,;%&8)-=A#VX+P!0@5M PL3(1@0GX<, ^ A) M\)C94 M ABEG<=I.N(01#D-GIAB'0(=-P7JE#'@7IP6S'/K>.,/KC4+B(KP7 MXIE1;,_(?6'84PSB"H3Q)Z-M9&/$'O(.OKO!E!?\X#/P(\4(Z\)#3I2;:KH3 M.<&8PU5%>0ECMNWB-SB5&@EU$>?6YEPGE1F*#K[<4(0,'2P 6;KW$"HS78ID M&R]@DIH MA"Q*WN91#'5J)$8(%I4@=,+?,%G0%H:!5F;LR \C"GN&NF'/G B\W06;/&8Z0A+[.B; J)%#?^,C'"E% \7OB^8"-'T2N\#R MR;:0:4<54=]U_2>*)PWD4+9Z:#+8 J]"9Z8D4B&M%.#4[RT[BXOR"&.@1'[< MG2F4R.T#HRV@V!:8O!1K;6, -,W8#P#-,&L(@+83HM%FG9M7)&*WE)>U,\B0 MBQ2CK54 %\W;X.V&6G0R1*(R[W)(+'MG9W;*>*_5K'/OT]=)>G+8JYHEG'31 M]S@=,5JBXN1W6L?S[NAG9L M8+>W8 CJ=Y19RUZ$BT='VYP)%4^3KK%#"[;'.F7O)4."_PA&GS<& XM7K+[, M6P--A[]T&$'H"K(H)+V75$51A$+_I73&13HNDQY6WVQG?%):9$51#:MC\3U- M'_!*WY)X4^^JO-DS9%'O:JJA8H\EV0!B)-TLTI*?=9&>;X$_(F0<#@)_>F.[ MY&IRG1TQ7M)S1]; K(:DBN;%)UTIT+DA->4EQ>9!?O!RS(--19 D038D7N\H M0),A6[PIBRH_Z/=D7; LI2_N=K!9NWJ"X_;9T7)M=K*%6Y$L.BO>':.I3L:D M5KY-*4313OH%-G6I[J^*B6=Z7$P/(-(&IFD^?,MT=-/6I&EK@AEV7=LOJZ^O M2-&_6E;_W X4SJ]%PI*#A@-T2/B1NA\LA+?TFWF7CK>(FE]YRK#(EP99_W27 MP*[M)PXS^($#,<"Y)%_TEG!^@)P[TZH*-<@XOQ&,E'_[P7=TR6<8OH;G=X@E MM73Q[#1C?Z(503\W%?F!]I"!XSGA \2EV(?Y_'1&:6GJD<]^ZT>TVM*%&AQX MG^OY10.UUJQ*/>9V^NBG/OO4EL4GQ2SU.6U1HM)2Y#>'[":J+4TZLC?;.'8K M%.:J\BSB_+2G):IO#QSP^$0W#M[;MWYDNR??GG;M)*JV M5./L\@Z[$JNU=/W(0%UO9#NJ7\ED@\K3K,LVU:QG50EV%%0>*^)@71^68>G@ M5>WE-_):6<&80]C-^YD?1.R*>'7U6(IJ,^9^$MO2?,04V(#>O0_R)\&;H->L MJM8LUG72./*K[R5H(M[])04:[;,K0'4L1!:EBT^*6BQI74U%D>*;T0,9QUCV M.K"=X%]X1Y]6;(>6-_Z< !G ZGU)8 RNO&N$G0A@4$1E#6]18PY?^FHI6M\P MC [?TRR55[2>Q)MF5^.[^'7?L(R!(IX:TV<=6 XU'B$W)*[_E,$\.![B?+![ M__;0CZ.E5__?%? /W#GKX0D[0IR% I9$'@4#AJ;:E2P,-\25H4HVV5IQW['" MEM9AJA*/<,/?E/:K!525[6L!C=>K!6Q>79\*R 92X5C!:G5)W\+T=Z[G8_%V M-@34?,Z5V5/KX!RF./!PG_QG[X,'-)S$+G!$)2UP!&6)(:Z7/IW;P M/@/?.!-G9'O1?";4/2[QR1^&)'BD(4J9W;-X M+5>EM\O5(F-B;S]&R@=FY(\)M[#E =X7"(I?$OMPW*WF<*E"J:499W=:]U9H MK9K'9K37I+EQPY\M^?,C9]4;.))F/9KU:-:C68\Z3NPT'OY9^?-G5>!P=L[M M6Z+U[!W5AE.-2]\ BYV1T]*L2+,BS8HT*W(HU[YXR@K4/M V9[]>B-KRW2GW MF_F1AW(FOV].U]_>Z3JW^:'ZZZ#KU)R)S<%Z<[!^;EQUFX/UNB?BSO%@76RI MYY6C>DNT_GA9IH8_S?%%R6IV21#132XBM(I^3&9^Z$1Y[L_;*I_^EAC_68Y,>M9<]0Y>(3+YJ&)!3;HZZG9J$-K.W=.\ @QM%C MM@XU=5-1!:7'2Z9H\(JNBKREB3JO&1W5-)5.1^QUF]:AZUN'FH76H>GZA2W. M2T[3JZNWSHJ%Q^D@6N15TQ)T._E;O@,T+4$/ P.FB=O#@,FO!XC5O/HHKSYM M(]0C^\\'Z8L)WLY6S4*/@(#5=*=MNM-FA'7]L.QI';P,HFXT0R013V/73FJ+ MPQP3KJ MLVD^+,HM57DKYWYZRU#.KN_8CK2J+EIJ&4",CHNXD" M&Q_B7<>CUU ^X%,;1QXUZL]VMJ:R&X? 2Q)P 7'IWA4^.+,S[,8F""WS[2F: M*;1$]<@=<.I'M2BT#/GLFASM2S5$&L3%)A')+88SLHX_D&OY#?COG6&[2D5J MZ<;9.9A[4RVV9.W-[0IB2Q'/SK_>E^A%7_)5#>2YUI(US3";5:G'W)I5J>/< M3K\JQ__=J=,!I^#:SOUC]98LGIW'M'/6U03_\.SBYUVIU5NF=W^-Q4KAV%K7NN:GO10_&OEL&+4XC-P6%H:ADT'* M9T!DP+T0.TC&L7%D&(>1'[87%&>YU#P?3VI U7<4FN>3 G6>E4IMCF*ZN4;U MGU$X01@G<10'I%H3Z#DK%5@J@W.%@ $2E7!"%&V&%QLV:+$-6NP.:+&:L1]: MK&%LCQ:K_5C@I4VU\<%B !L2<0X)Z=Q*@M M0SUR2>8;.=MLRF]JLZW4.*(\!73/&U&XYG!TTX/&8<"-7#L,?[VP9C.7\ [F M8D(\\8;7R!;LI3!]?Z$^Y01/%8M?%;X$_(T'T\LVUO5*P.WU441=)E4^\->DW[Q?7M%_5<^\5T M(5L<74KJ[62+V31D7,/2.?=F&?=(RKVF.V-SWG;8\S9=V^^\35]Q>/9JYVW- M45]SU+?6L3P!MLI"!5+B6*4 *X?OR%A_GE0B?"WRY?1X7V\W;?D9].[D2:A= M8V&E91X[^?2FB&URLYD>=&+'1?_H_&[):V9+U<_N]M/>5!LM4SGR+:AFXUBA M,%_LT8/CD0""U7F(B@'KQ'G&2M(S5"2U91K2FU,DH:4W-4NGPZ[R/0C8XQ&M MKX;89Q;X]Z LYZ\IBM@2S!H% MEJGM+$H_GY?:O-?TEJ3M',RLI/:-'%XVU0+-JM1X51H/;XZVM^H0;WX$>@;Y M-D-I*=+9^7B[$JNUU&,CT+V1O:HIM&G6I>;KLC/20G-G_KS*=(YQ9WY?% H8 M(A^\5EVSGZVL!'JR0QCC)ZDM%9$CE+8X?]W& !126R@.H[?UA6&. D!10WDY M#FR)\XP@(PPI 03#&:7K#&L#G!P]4,:/"2R1G_B)P.1KN@KXOSV4&1O7T(D< M$K:XIP<''GHB >$<6 2*X#!\H0OTA8X'@B;G!X U0!CN>V<$(X4/S@1>\6 _ M@OAR(SL(7ASO'@UZ3+"X[">Y;("'$B MB*"2I_L)QH,?<''DN,Y_$''"#V 0XN!M"(Z6F'JVZ[YPDY@JC^_=^SBK/!%S M%I3X4V!/.@(PQ)[3S8&L1AX)VMPE*Y]+)^V$L+X1LB4>C4@83F(7,[,3Q\,# MP:HAYI!I?[U("4!FX.,1),(4IL8%"T&#)"WD!_8G=,;(DC(=_@(;" M*" 2N)Y.0/69S\,K[P;VR7AU815[L(8 M](_+;%+=!SNX)^'N5;BQY["GG-!7)%&_^_VF=P&R/W) Q<)?+WAYH5+7D. _ M@M'GC<' XA6K+_/60-/A+QU&$+J"+ IW\+.+3ZJIJ/#F.4>VI:O$E0 >!:9. MG*B.!$L7GS0@6"I2/)]SD9A+#PPVN;6?CUE4/;"D3E_LP\Q53>(5F"YOZH;) M6XHQL%1)5[JFL%-1]>IHOF3D%^N?%PK/E%S5,N,,!ZQ)CBUWJ$_>8W[:0CY! M^6LZW[QU!:?@T1DGIL5A?LY+6IY9\OD^UY,2Q"QB08A-&'#@4,-G4\LHJ[Q5DE M#J30EA8=/>H""FV-*WM^%>XNCK(:<*WH?.8\3Z"U,"<8"3T/L6I*JV; W@]/ M5\Y W=(=W@$3ACY+O_E!=7E!IX?#JD+V?ERTT)A@BW"**/?^4/4!I0M MNA((N#+UG DZIU0.[H'9+-S Z<)(:8#"_)1$F^BS_M!U[EDK)I!XF#S,D 4* MB5(LTC2?2(NN+U. O%_V8(=IQ#&U0===<@\:,']5.S&/59,'E2/.(ZWS!PU! M!;SWJ-.)M,"D??3>X'D((T9Q$-#:%>H8,!5*E3]1PTKVX,]1O5$3J\=/;?3[ M),#[F69_TT%!'L;X*;(3KW9@JIZJ.K4VE/' *?3G&&/;*$3V"$T)-5"I$,T9 M618C\"^]B"X%C#UZ:;'7%@P,4N8Z]A!<\N@%O5C0+9@K.+-.8ONHJ0([A 3[ M&+$F1":^;7[EWP-U3(VI>$TFP"'Z_@D9 Q4N"B0SI4/B$?!/?JY<'!2OLAUM MX]$O4 ZC)4$L>SW&3P$&'(PL&B;E3#):7U@$-YY;W[(E?'!<0C^?S[ 1N,72] M)*;+-(4%'31BH;+$]@/]_[6GT$TIRO"SQ^YCNU2?;IY(,"3+MY[S+2<27./@!>":S-W$.F8 MR'8;^ UA?[K)H9?EA#G7\O8!%@N$WAO;P9B:"C"$ :X#1,/C=.#$BX.ER2U5 MBW[ <$I3NUOAJ6!(R80HF3J--=&R\:EI\U._8YC0&B*MN5E:R,',-N=FC H6 MNU'>=P$!+?"(;MM"6\S\!?AW^N(\@6D>@":=)#R*M&C-QX_*R#7Q8 M-G#^9]7L0"-,Z4 M%44UK([%]S1]P"M]"Z.UKLJ;/4,6]:ZF&NH HC41 DU>-N5"G+D),47RV?>@ MN@%Y *L)ZL)8A_'Y5Q)=38"'WQ!^U/>L* J<84SS\K?^-SM(+D">C#.=04?M M"H; ]U5+@SBVU^4M%3@SD(U!O],5%+DGWJF"H-V9\%I!N?@DJ5J!/WM26Q6[ MXZ,#V$.Z;/L 0WF5N0<= EX4R621A/WG*+#IE@G.TR5X%.%7T UX,O!!I[S[ MRW1CKV%B0Y0O/HD@@D)9XH[%A#*W,9R%^/(;=9P.GR615-GLFTH/+YS+O"(/ M.KS1[>J\T1D >P:"VM,&M8*L[GMZGG#ULE/#ED MWAU#4 ;9FY( )N-B'CB-X-()T0IY^D,,G4&>_"EX(HD_'*:_IML@352O&A2S M*LFP+(>=S27),CMKN!3&HX?<($A\XM".N?'<$4NR%"QH">=N-5KZ<1*%P2=/ ME,T0FM^S,,F+LI&S4=-(?M/X7:,,HSLQ9T4K?H.N8]7M0OILT6E\L*D'7%CF MA%'@';S[RVIA&CMCRFIZ>%(A0C7QH_-YPR1\"=/@M!CQ,H&;8JR(W(>;!8*LGC+];U[ M'M-<:9B^D5]6;<7_?_;>M;EQ)$<7_CX1]1\8WIX(5P3IX4T4U;W=$;(L==>^ MU56UY>HSYWRJH*24Q2F*U/#BR_SZ%T F;[K9DBU9M'(VMLN6Q60B@40"2.!! M7=?#4=P#/^@+CZV.+Q_^ CG]$.+#"3J#W>)::=6!60N MH+5X#^1>?YYM*)[I!J.<#TL XP)H[8:&RA88PG\,_93=A7=A<=( M(5B?KN$NV$J+$W\BXL[+&SN]RRN[9X-U8UWJ5V#IN6VM8[D=S7+=?LNXLOH= M=["DG)2Q,I" M+@D)T]#B? D)(R%A)"3,2U M(6$D)(R$A)&0,$W8/1(21D+"G&:9O00?D5PY M8JY("T]"PAR)C2H/_DBH$N+^M*OI9E M14>8D63H9[^9NMYYI&)@F9BE+*418V/*]\;Z_<^3+SP7T[]E1UPNT3[[C:H" M:BEGCY+R5,Y_\1Z.ENV8MV^W[2>R75"RE)!9)OIW;ST_X&41O6@VB\+K%/;( M- K&+$XNO<0?'67Y0@N6H>VTK<44S&T(6UR5NVY1T F2$T98STY)C#R]=5^E M"NVNVQL8NJ&YK4M'LZ\0VL&U;,UVV^TKQS%L_=)I5O9>S9*W.*37(;/0 I'Z M@#]0'2%J/_ *2OXJ=0;34>(75MX.51BGD"GY(2RACT29Z, /O9"*)BIK>RU* M&Q/E,H)_J$R>%U,,NM>7JN(G22:*27$D3>^H=;.!.(&Y]2Q,> 5D67AM_:+0 M1G['B[*+;^05IT;GO:I\F&&I "M0(_JS>1 ],"Q!]6*F77J\*%PD*5?F7@I" MM7:SG*B2^# 4)M G2L)NJ>;:H])4+&O NNQR&; 2@^4O3NC%'"%D+EZ;QA[, M?L0A,M[]3501Y#4A"R.5:"24DPK.+1.EJ;2RRQ6CWAVQP$MR "CTA],'9,9" M">R[ORV7LBLL$% *^'+X_PF,@C>,:@4;!"8#SV(A :I5?%@4WXK:<'#"!BCRH*@8YG,4(H"5V7PZUHHIR8JQS M0H$LZ@O4RMIR*+2BE%8"RJW6=0,VC#.$Q:BHN]7ZRUREOSZB)594PKNV^;Y4 M+J@2\6:E'.&B^HN29, X4!6\#DYA]SZ5D"@WF<^A*5#T WQ!;>\^91IZ91KT MTG=_*UZ+]66".(1)$U8EUU.(*A."7J!-S6$).:8%5C;1!HKB&R_T_R,V^/!! M* .<=\# _N;EXP48!=7GYS145:%RSM$O8.\0/@B[1\PX5 ^&*4J9WN:#EJ ;O,A?H:B3%DTT+._CV"+G'F+[3!"BY7V.=;*@=G'F48R8 M#S-08XD2((89;%8P'<@S'=<81WHHI2]ZN,-@&*Y$ARR]8RP4.Y;Q*?*-*/8H MK1)^B!,9Y.SE:@CQ8[ R"TL0:A5=8H(J$8U+#.Q[][=2[>""S[P?J+\VJ7C@ M%>EGKC00V@]4&2E.6B8LQJMS;M42(^U+2UP7ZR7M70&^PGFOT]BE6 O5[594 M]Z+B%B=2H;JK[[A0^AS/8@Z'N#@JJVJ:'RF$R04ZF0[(.@4EN 2P8,P+Z>KP M%%2EZ%'5IQ@LYV2QBST./DFYNE0:B5A-2#!7,HA1PSGA@_^$VKTR754(!!P M\QPCC/B(/^"R5R"X<$_Y JPG\-FDCB2YX>P1)P^.(<^>5SE[_O3HV+'+8V?A MU+'76,U?$2,%U#3!L@12B*0]IQXQ-@CJY?7Y%(% M;:F[*+I&;;,TD_HB\M,&U<>$0\PE M*9LC'73$H1X83;'^G6^\A=6!K4-08V-";4TB^"45"C\"XQHC5C-\XE_9^*;( M#,PKBQ,X"+"\/E=A96FQP)Q99EXQ+3CIRL* _)P_"5)[@ MAD QJ()9E2A=)*3H 8G)%BY043-]Z\5^'I*K8(#5W-S"@B6-544<5;K9#6SY"C[!@AY]E\-8V1LT M*9[CR[ITI29]KPH@*P1BR_$C^H7!=VL(^JB)[T2XH;" .1TU8&6#0P3$?+,_LW2HPB-ROOE@9*5JU]F!3 MN2^V]E]RD%+E%OZ6@=UR ^+TCJ=_%CH#'OI:K%Y^6A*BKW@,'OC$TO=J)298 M3)!8AK/*8@JI"&D4;AJ&ABB4X=7//JYC:G-#@;\IZHO')0(A'HHA;.7BX<+B M%%$"?/!U[%(Y8F'ARN5J*$?] M*\[CI'+L>^@IU[6/,.&H&<'Z]5T9.MAA?7]6/GEQ'-UIUR,PO.L!4"3]"PXA M$$[[8,>,?8I[UV]KZ>7UR 1,4"Q]@8V\H((Y4&>2E'$K++\&^ M6O-\MH^[57T?Q+^$E4BD]W-8[Z<\N#XI:&<@P&3TEXR]99FPVXJD08Y/__*L:TYQ.T*N0>5 M*Y!>&,6E8)3:6U<=,%4'C!"9RE^XO\.W8/5H 3;!48)4U:>!N-"X9<1L*"10 M$75PH>@\*?!.$[#A4B^D@ /FA*0YE;2C5\'?EG2.JG0JO*N$L.*XXHW*V1>* M=!)%:1@1"'FY(7@,KK0%P:ROKP%!:*VX EAA$S'17@(-HD<,EG[=&*J%[JM1 M$U1,$>-08+A6>*:G;%68!(YD#]4>S"R/XT>;P(0W:Y0E?8)&R-,TRG**S+8W MW8^E37PHL;V.,F7"./M-:YFM1U(F*E0L@&KF =HRM^ 84R(Z9[]9AKO0JF+% MW)\$SB6T9A/!N2R$4C7M;U!V1<=Z(E"GW[#?384/5T M>-V]K,D:0>MS6,M+CMYYC&K7L,]^: M4@;&8FD_$@L5D7=*K0'0&JMQ4N:3;6C:1TV'_!GO)P3_UE%D??0EL!\]1PKV);-7$3L*^^PM A;6UQ*S#WP/X>, MA;Q% %Z=U%K%T66UFK>5X_<0A/.9AYN&#^ &W8+_0P&F@$8IL6QQ"EDZ!6.S MVFR0W<\QEN33>#=@EF(@%TC[L80K_ X[3N0O4ZL@N> /<3S7ROJHW"WCW@2N M1A[&K!)?M,HK+GJP22;0744;YI=7%"$J>IAP_P@\1-&%/7@*3.##Y,Z1-9(U$-9KSVRYPC7!1Q[P_ MU<2[C;#QQP/W2"OT\]XOA5A@3@$%L="SS%N%TF 97J5%X%*&Y.#::'I+6F(^1AX_+G+F,@DE;&&"W&=!./=R'! MH'SI*&)_&]'P)Z9PY0IO$3NFK.PNN:+7!X=MAI$*SS7O$%FRM.RD57WRC@0, MKS+",0YP)9, ML*V+O0$4BBLHNE1.LI@WC/-B\,YCS+QE/RA<&^7-?,IN790-%&<\CA-$&)I^ MMPPXCF+PZ>M?\#BH#[RMGV;I&+&'\VL",-OH#O,FB(9TWOP9P39,LOD<_P&Y M2KT;)EI9H2*B7 6Z)E&-,2#;<$ #X/:PWQ "<7]8)"LLCKAWJNM.AKB[/ R&7^ M)?%.'FJ<1>*FGRY!&#;FY?EF#"\P-*Z:,)9(^1.4[\ [X8FLL?J":D7R!:YN%E26%H/9&,=<#"B*X909@[?#K#-*](.CCIIAS?-P('6# MS.=0CQWR:8B,LU43X=)1X7*K.I55E,4,!7WEE/++3]P,L _RR^)R+3"'8L4D MKMD\71V A7F@IQ13(SSYK-PM^;0HF(P31T\VJ34^K-/)OX49 M!31.T3N9IH)VA-+SXQ'HX(O5*KLVN25Y(9.:M(PRC-'L$3T)5W?-HQEPHXZ$ M=L4!X6Y8"R&:U1>AN*SF!)\5$47WW4N*SEDA%<6J+J_7PFHI4X8MO"(J XEO M,GYGL=A^L3A4RH7SG]ZM$M>6)B&D&]1^:^W4G\[H_#K-4ZZ%B'Y&$&JT-'WL M=B$' $TK.O6U[L- M%<)/"KPL1,D]=/H^3UXB\KT0F''ZU@#^YVB6U;[4[$NCI[E6_TKKM8Q6S^YW M^OJ@+0,S3PC,5*3F,C<&/]]B%B:[.[THS"Y+>+JK]72'Y@]>Z$8E%U=@7=Y1 M/ZLH!DM(A#R$(S#/0_VB%? $G1WJGAHDT9J'I0>YO.#5$V#,;ED0S3%7"/R6 M"1CS62R\B[)]E_\?\O?#Z-83;;S'OG<3@E?AC_(VST639TK"XR.('E0)#P5@ MM6*2TNGBASZ,6R8LB^%\D5.&<;JR?C$>^_#B9)0%7BS2V7B0 ^Q97MZSOH-X MI059,1F4D SC1D-T%?CX070#R,2(0I_3**$N89C70$/"#S=QE,T+;TV0<1.+#JUC M%OCD&(0LQ?EQ/HAG,D0,H6!PK1QMT>=:,3WNZ8O(&X:"RR!:SGEN^^2)1#"O MGA=Z8T]5OF3@O$3@QX\B>KP+WA;8A+Z7^['\PHL[:>24XK!3?TY#]S,,,*I* M-X$'OL"Z3$!2\<&/>'6O=$$H8*6EX%?1+O7Y?!LTBIYG0*WHH^LBY CFP@UJHF0 MH>M_WZYM4.OOVX"*(N)?_J19]BL*V"2M#F/JIOGT@8SMI[#XWJO^X,.G#]_^ M7VYDP>E',< L '6;1!F=MSP9.$GKVS$_1>MGJ+A:*@]!5 F\+R=]SQM5QN95 MFZ-IQ(>@1Q")_=Z;)0J'=A *GJ=OX]A90G'BZL0]O$3Y%R5(8U$730YM#K6L M8:HYV612^B$:+GF)*A9Z(HXUG ^D:42OT2&F+\XH7%V;YHR7EI%)DY]EMWZ2 MH;%4),KR]9R@S8.)<'#DB"ZG"E8^P\DZF].R3#T"41!/8 DY:,A*'@\_1U?(,?B_SR2AA"F62BKGK-O"^V!A^36E=J M7:EU5VO=;^@2L(^@DOB5*1C/$PVUK(?("6A-/R0IFY%Z!&V&5G,4J[0WZK 3Z(4*U5X.3L.XM^#,Y#%8'L'>-$U >V3Z^P%KX%2 M$V(LTV1Y7@@,D'M#=2M,J@*I"J0J>"E5\'\9K+WR?YEB6);RNY?0GJ]%*IA++CO-K M^! DZ M4GN\E/;H\;C*KNI#Y8<\IGP2(!G&YLF9\$=*Z,T(*X!]IG#^_?%!YXNF8[I#R2Q^\-:YHDVKHOLP9YD&/ M1FB/XXK7?PB74U;J23[\8J:((*73.,INIB0-!!9 DN3-1+ZNAU\&S@!#@G0Z M\@@NB2K\XN+29C$"A8($NYA15OP=O [_W7Q[1#;HYCNH#==ZJPSB_%K@'2]H MGL<@F[$?/)0"1_DSG/C*Y<6B(PR;A>8#$DUA3T1>((\9CLEX3-43=&D!"[_V MCBJ'D,U9 &,F(OUQ\744+2VNSN"+J^W]I+:V=/\)'XW]&/0!Y=YC:3;NX3@O MR,@OTIYV%583&7@:WLJO?8O5HT._>LU&0(CQ#P9Z)J%Y5>_E"&RU8EVPT-[=$,^&F'^ZKA^+Y[G!&+R8;Y/*1FX1/T3F'^K9EJ=9_VN5,PGSZNL M957BKKV;@M9[T$@54K:Z#R=_S*$[*5N=-Q+)G\I'X\D;%=C9+Y\1* 7/KAX3X59PSJV!E M!&W!0[X:I+K6:,E-NG%Y*J7:X(I"\ 6+VP2>'EB52>:%.0",$F=!41)#Y6J\ M?#%/L+[&]>=5:_B=_CT'FL:%%8&4O*&"MW;X(F.US6%FR_I,1 M&([EE,H'>[]\(B(Y^%.Y3*MAJ,KGKG[)QRHIH0CYG)XG@[K8A2H_EE;RE@@" MEP)+OF#!%2X]R::2C'?+_1^HOX6/8K^>-7SID(L:RQ,O5FDE@=$N$-KA,R]7 M'"*;0<#)BVQ-V"Y8*9M0W0\XQXPF;"F\ HK:J]FB8H MRIO!25JE6+X517RBHTS&ME%)O>W N>:2N%OQ=&1 MXEQYYQB8:24X)YQ<4BE"@YQL [!&+3R M1.$VKR;.J\1S9(\2@:\*_#U9"#9QD *5DK84;L=L'?GOHC7Y@K(\0&XICE?9IBF'<&W_T+F^Q@4=P M8Z)^KW56HDH'BQ,A$D<>WZT,:_R1/:+$^P=[J+19X.4OCX362U7_+P3K>"B@ M$P@:N$"!6"S<*4*U&^SW$I\4,UB%NRB2\B=^2C@P<-[!^G(0YPJ*<(X=4,2/ MA3\14;>B)3(?(U)'0)M$H'.FOQ7<&Q9_0'O("+.1* M11(B(O63(4 7@1[>\8I)8/+W0C3%PU,$NTYZO)0DQ\0 57>#K3JJ@6&O$984U)2+@XT.%W4_$@8&#YZ& MQ='+0QW8>83T+'<[V C.$S9>]DD6+HQ6>LU5HL3U64Y7CC2%CAK!A]R6"$?H MZ:;3+.%'1EZ%7B>(AL,#0X2HUVZ@X9*05-&0E!H($J[ES4V,\UEZ'Z$;H4%\ M3YU48+(_V=:%E4M8#M_%45KR7),ASUOYR;UP"U',PDE&7B)UR(1O?&18A4[W M)22;0F7^I%\8Q4,\"A5G>=2?)6F.#%Q4YH7@6-R,L;J6D+1X^I@+$5F^T>+RHJK05R2"I%AYTJ4()CIL#W5CN3#C:"OQ M6!:_2,UUP+)4U65*6''" 2;D-U!08]QG\LA:/K)$@="&N*H %"L5[CR@*MVZ MY3[$2,4MXW?P11\F:C) E=#X YX4MV!!T2Y9TYB 9]96&;I"W$MA%]XOG1NP M94>^Z/938+^3OU5WKNOT%>)1^@[%30!& ;!/'M])(:QDO=5A4R3J^*[D_^(( MF/V\#YB\>W^JX\,O@@JO=+M+-^Z?8QB!;Y[5ET=%=Y_RZJ_HV5EV'R8_$]C'K$HAUVV;Q(K73_I@.[PL,*RIT/1,_"LC5/U:V@-F-DK]$0ZR0" MQ4L8FSG#T(1(>8,-?HR0_5ZQI2AK;8+!7;JEX;YTR;$HKDILP[,G7)D]L=4A MMY\D]*4S[BM#3ULINYHH];8F\LQ[ M&%.NIU[,-#*U\?J&M[>HS+T4A,I)7)DHG#LP%.\PEY /%8A0G;@-7F@/SO(7 M)_1B#@(P%Z^M9I?5,4OSY)[*2*6&IS.+;G-'K(BU4'_N6JL[1(\:(S)XWAD0 M38F4PND5E:X*=,;US;\G_#9Y J/@!;E*)V-&QQ,_*]!VF7+8J[K93MZ&.#/K M\TN$GU--K.'X2'DGM#7+O]0AG#=WHF/WJ2TO%:/ 1RQ6?$6B4:U)^+H>4I5I M4HLHRJ!:U21JZSYS[_Y6](62/;9?I1)AP(8Q@A]7U=UJ_;6R2>-'WM5=Z"77 M-M^7RD4DOE9&J+>1+WMI\Q*%W(DO^KJAZ%/;^-K>?."X@>I7&A001V5 ^/ ,[$FVT*T;[^IR M&FJ)MN<\ @9[A^)>&*1+R&4P3.'MO\_C)")WB*YN,7N(<.9IT$+)":A\)?9O MIJD6333$(>'6]#EE$&'3@O'[O./X@MK%F4U8QJ?(-V(9S>$?XD0&.7O%Q9+'PZCHA%6#'HJ8 MH$I$XQ*+=M]%K][<5_3"32H>46]0/W.E05&>@!+R^#)A^D.=6U,E8+"'W^THZ[(4BF$O!**0R@?M TH6D_.8,0)5JO^=G'Y'%2GJPJ! M0.3O'/6;WV'##[CL952@['(JNDW4,X>>V.-4GCVO0MN.(E[=QFM( M%EJ:$XI75>\4(2-,PJ)\GVCFHT6-81;2AGC3B9"0E$Z9)Y6)%)3R1A[OQ,CJ MI6@4#Y*)P%&2A[DJO81S9 J,>(R$5A4)+AA $6J#:YNEF=07D9\VJ#XF/)LU M2=F:>=>RI2H=MT6 +L^J M4,LX7N$"I2K[81' M==F:B4N-M:RQKLO\8F1)PGNC5%75DAZC"\L%4"!5V'F%U_-0^Z5%7Q'P!1K>QD_V71J"_M(8?66QJ4-Y.5I5:#& M?!@5$_469_9N<[OD59&B56L/-I7[8FO_IZ7NU$A,L)ICG0N0W\9(P-C MJ[X-ISK 2B?1^#NO]E ?W)@<(CIL5>^?+@HBM+JS3?B<; MNL4<#)B4]I*IMS0;=M-5P23.S[_"O-\DW8,.HPS-:Z6/48*%R^5NF='5 MRW-?1"I4[:VK#IBJ X85=)5?N+_#MV#U:"DS Q9@15@RQRTC9L,3!4I1!Q>* MSI.4J@%A0U3ZN(&' >N14TD[^K',M0J="B_;$58<5[Q1.?M"D:XJQ.4'8,46 M1%"/VAJ@8[?J"F"%323* L@@>L1@Z=>-H5KH?J$U -804D@,UPK/])2M"I-X M97O(/(Z?]Z)ZI 1ZE499TB=HA#Q-HRPW.%KN5K30S8BE/7C%%\ZO\>7#7^!C M?P@_YX'*;E%()>0;/GN)SD=[;&[?.OO--&RC56O#_3PZ5S2(YWV]N^&8?A/- MO4M-\O)=NQVGVVEU^GW-;8$?8QN]@>8Z/4MSVJTKQ^JUK]RKEFP.]83F4*V* MH4#,4S@O,>,X/;:< %,B_C4*\:]3@>$;4=1_._R_=@X N ES;QBEX!44[[36 M/_)2G\M7'_35=?# -%ZQL=QM]M791K*V0'M<_<3F9\7@RAF,%<1 M_!T]*#>4JW4._GG"A-+Q/3[(PQ:^4746/F2WG20^N.->>,]M7H-1P M3X70SHD0>FXY^JZDOC^LXFNLFOOFW2\5>_'Z@8-KN.V>6+$O[)VEY;4VQG-) M;KO&J9%L6XT[T)[-Y79[OR1+0W"#AN0Q?E%3=2Y*60]K_SW"V1U&6!:R,CZ/ M%ZC[FFJC]MW)Z=;SG2G>:&[)S?#$J3Y%#]>O)-]G)-X9( :[20W05^R,YX+A\]OE0ALE4UPXI" MB$^\9H^/()X\QKH0]^PWS3#<6E7(6@+J='X06.NB5E-\YQ-+#TJG:\(_NMO7 MW,&@J]G=OJ5U!TX;?FK#"'I/MPS]N_7=T)%0J]-Q:J2NI:%.*N'M(<(;BY,^ M@X8-?QKT.K*NY0EU+6:E MKJ7*QC(0WOE%X3PE35"FH;UZE>-DE%KL&'/\& MF(>#1!PFA3]-DZ$*2/XK^W=&Z+]8KEWYUI!Z@!,&#]53^EA]AU6,#"O+R]88 M!!Y*O=RH,7P44W>HHH<#?WHNNJY0V2JYCD4?Z'SJB(6)G1"S%.M;Q[P[D%B3 M=W_C9,I"[-40YP5"B\*+N40!OT!)*EJ6U62EJEN0OPR; :1%(Z_^6W/=\0*,(R9=#E<++RZJLN]JHQI[*=%_JR-F5-D/MN*VW29G;4DUWYSKRDRVNMK8[O/"*_Q6*J=]P MA91<*+E0Q[Q0+V$<&FW5:;^V 2&%XA4BJZ\B"J?E?FYY@O/B_U$U;B)/]"/6 MOW*AY$+)A6K8*??Z&'5OA5#I>Q&&GL4SM&GFC+^YT?] 1_ M$?'1U4ZST*].67G*A9(+=?#C6"[/J2Z/=.,W& -TO:\-O83Q5H#@R1/4J73B MI8YO\$*]A%'9Z9C2HFR&;,CE.08G?N\;YD2@9B2&FN2*Y(KDBN3*T<_M4$?S ML=![S'.3O#B>N3VVLF_Y.F;W//[5( X["<)K.LZ8P^^V5-O:,_+DRU,N<_@? M3;MRU):]<^IWPZ@]MVQ#M=V=Q?BX,]W5MKF?//=7I\QQ5,O9N>G=LW/XWT ( M0J)$2KY(ODB^2+XT9G(-<'\E-R0WCI(;>T:"?C+V;QTR^*^$?9[TD]2?>2E+ M7@X7V.ZU=--V---Q+C6[:[6UKNVVM&[;ZCJ7[E7/N6PU"Q>XG@!#[W@=J&#\ MP<$T(P@J7.8S;W8MYNF5!\PS'B:8\)\A?# MDPA?HTS\T M'/@$$PP4^[\=*K\=7%=@6_^O=O]HL0, M]B "^P*5W@T]C%BX,^\'4T8L3CT:B!4;#Q%Y8?=GLSG."F%;O53Q)A/"T(4I MPXRC&&?E$?@2@N7"\_ $2_G#@>\-_\&;785I;@)A- D99 MXGY(8P@8YC+9H?-+LAT96"L69.-BP95_9>,;_I>8W7@Q(0P+:F"(F(TBF!NN MOZK<1-$8$9)5)045["-F*ZX):.7B5UQ[/)$R$B051O!#&"N-XH?*Q^)[,4M! M'$@,HB$<8O1'6&C1V3;U[N'Y&@_A;3$C(*6E%N$P4^;?X@&B(FHO!XWF0ZR3 M"!2OT2C.X(LYPRZ4[BC-$(V9)5F0XN)F :XE,B3V"1%Z[(,(QLHDCF; E @T M3LFQ**Y*[#; S/?[4S5PI.\([WY_4!C@Y0.\?A(O /N/IFRRZLEHJ=8\"^_5*D\170MK8_GE?L"[MQ3>:? M2W+;;1R:]7-)MIL%Q_(B7&[O.=]9&H*/XA&**YMS<8]R6/OO[908-VK?G9QN M/=^9XN>E;9_H9MA)#[^!''!9K":Y(KDBN2*YXD3ZU0B*=CC3(DJWH*J MA"P]>!AEUU+33N/\ZATI=?7&Q8EVI-1NV:="J7$$(9(W8)K+T@W)%\D7R1?) ME\9,;CL3_1DE:/! /LAR(=I.N>KU?/=_,CS.V;A["T_>L$\9=I[]/+GR@PP^ MY5W7/V=IDGHA%7'LG.B>A3Y_*J$QSY0Q&_DS+T@H$WLA#=XUX1_=[6ON8-#5 M[&[?TKH#IPT_M6W3T'NZ9>C?+1C_[#=+MUM6N^V4R[(E20OY__AG E#N5?"3 MNW&,O,&BDLN'\BM?O ?\J(MM%F"M?5[H](4*<5ZL)*#3=RS+M%N::QHMS>[W M3>W2Z+4T_=*R.^VN;?;T :[%V6]?#/W_5:3CI2A95R#1]^(0UB^!;]% EU[B MC[KA6"STGBHDW(%CM?6KGM9SKBXU&Y9"ZW1M0QM8+6=@=72SU>XUJ][Q@"5Y M5[QPC)>*8=66M\+0K50$-/%6&R%X8 PNE:OF(, ;\"3^Y$SM5\?A6Y<,D2E11./BZ M>92"<.9U4O!J_Q;+R!(&,Q555_!V=D\U:..\AHH5D\'\BB$;>5G"\',_5AC5 M^\$8=UB)!7^$]Z1^/O8V%59[E!QS1\G1]U(5N_YPE'5$+U-'U-JACLAYO8H: M^>J]O%K6$>U>1[2V%D8YZ8*A R[+B50&&>W6A;V?TB 5#1F&#Y--1?9/86$) M< !9/G3L6U.6#TD^R_*A ]\&?P(/,\\914^S,05#;=5JGGT'D(1K:'PVQR%'=E@B]1W,[<=23V_.I?LRD'_7D)%^.[)'2;JLMIU$]1E^"CG)H,U3W8L1/KV&P_7M&Q3;9N-0R^4X9IG\-QN66J[W2B_\JV%:]Z U2^O M."1?)%\D7R1?&C.YPUO_;^BB@5_>5JO^:BF6E)R^T5> ,5[36=@QJ4V_,$\% MQ^7MUT-PEP9^DR8G#9;CG)SDRW%.3O+E.">W MG8&_=SB>K9!1UL*KS.9!],#8-8MO_1'+!UJ WJRK4,T[0'?;?_)@!8G@ZC\70 MEFO,R]((<@=]I(*/>:MH91+%'&XEA;DJ_(N\^S?X6=@*W0M'^><\R2L2?6%NBUO0.!8>T%C-\AS+SX!TN;6-;A-@Y"[[D4[WO+'!_%Q@G6 M[!A[/OZDH5BHP:\L85X\FO)\5W;+@FB.]Z#-TX5[;LUW?!0[)Z?]#?ODF.SN M6?N?2(JKK/N67)%+0]?/)(TN7!C?M=+PSW MM,MVW]3T7L\VG4N[Y5PY.Y6F;79?%AR7NL1@?=)2N5CAGTR9J*;"5M=^HGA4 MHQ6._,#G+DHTJ3;G%D($2]#Y!;Z,R_L.R[KR%5:B8HD3*B7#9Q/_7IGQ/J , M<]:7L]1A#%S5+0NZJHM"1&Z_4;:HB5I:Y+5%3T^N1'+\4XW MPN)NMI'W4A>PQ-[-M0#_I=/_CK\08$,"]+-/ZQ>*!2TR__#QGW4*=$>\HH!J M9+U4N6(C-ANRN*+L#%4IDLL;$/)Q56/?^7XO(S2O*R+63GU"8P:FCS+.F))& M"K>G$BR,9DGJSZ@.>I*E68E"FTVIW M^GU#:]M]1[/MP:76-5I=K66U7%._:G=[+?U-P",Y>X!'*GF4J$H(5CJB$OD) MFN(B$%9$RR3ZD$0?>@7T(<>0Z$/RU1)]:#&<:=@; 1TVF,7#IW+W!1P/B8Y3 MSO(5@^('0!#!B\J7%:_CI[D[&F6S+,#()7U6XE)YLRA._?^0X7QJJ_*)G9X@ M++"[(@E_,MCNXX,KWA-.08Z],<.:ZL/?'>R,P**V[,85T^T*(*2"CW\BM+94 MIW-R%8/XO4D4IKEJ6 @$%/1=I[&'#VF83D6OPJ>>['G(XNL7@"'+$EA+%BLQ M"W@.T]2?-^_*U=!UM7-Z&ZVCJT;SFNP\G]FJVSS$LN=2#9X&"Q 4GGL:3=*. M;\BT_ +K'Z;-4Y#8>OGTL'IL0[6V.>PWV8>/\YUVI;:L=NWEN M\U%L_S=@SAU?@J2LR99\D7PY@LF=JE%73\Z!D:<,3\M?SPQG_=LKWZFD8JU[ M0&:M;9FU]DC]Z"$3*&3F6CE+6G>9N=:HG28SU[9?%9FY)C/79.;:5C&4$\I< M<]2.99\,K8[>.$10F;DF,]>:E9B!F6MMJW$1]^>2[;IJRVF<*GTVLTW5:%[[ M5)FY]A9,2YFYUJ0]8QNJ[IRKF;XQ:%T9 M76&"6E^;+!PSZFR# P&7E8&'_7+2!\6+F>(E B,4^^/@(*NAYR1\J(0/ MW0$^]-DM@]K;PX>VWA::I4P_?3$;X!B["9W(#>97-O-\.HC@B&D2Q+^ANN91 M=A1ZDXE!(!GM@TO&/H G&RN@6$QI5"(_7*9A'I2!&1>F5+H3%U*312 MKVP6$4,!EP;#*S'S)N#@-D]B;%OM'(.-^P:NNV1&ACQ8GE I%J5>H(S9,&V> MLG ,U9('S,%$Y:]05/2R,0F,,O:3492%S9.<-T@=4R5=O=,PB@/%TVR,U' MEB3**(MC%J;*',\9@3O2)#$Z?U;01!XI\DB11\HZ+S>(PALMQ;2C5_%W=[SU MM6Q7=:TC.%C>@&Z0*:UK./Z,]%!X(!]D0Y+HTW(\ZQFB_R2(1#;NWK+8NV&? M,@3T^SRYGGHQ#).E2>J%F.5UZ27^:/?TT"ST^5,)#7P&VF'DS[P@H>RQA>11 MUX1_=+>ON8-!5[.[?4OK#IPV_-2V34/OZ9:A?[>^&YVSWRS=:IL=W2B78RN" M%K)E0=#\B3_RPK0[HJ@+?.\+'"4C6-*7SY'M.7VW>VEW-P,+ME+BMQ'S)_@-3BL4JWDU9J+!; M?\PP'@H\&?@4,$ [-Y/TD154C\-F#+U$F4.!P0;JWCCJ,1^\B.A M^\>8W7GQF!*XH[N0Q0BH!%^_Q:3O% 9,)@Q\M+&21O3@2 P\6$2%@2X%>:Q M#]/P$V7BW\-W85QX>LS0>O-#/#-4>AKPDPF\\*#"[#%YT MH0RB.'^W-^*9Z),H!I+]T;18@+@4(V4$1Q6+?8^F#0N?*@\,EV#(8)%F+!4D MLV0.+_?A*]X,]W!":>PX4#S&22 N,@7L]4)(,7CV/X%A5,!T5I(,O M1OYB' A>)!:4SQ#4!
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̏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end

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